

CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity Report

January 29, 2021

Contents

Table 1. Demographic	2
Table 2. Responder rates	4
Table 3. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs)	58
Table 4. GMTRs or GMCRs between post-vaccinations vs. pre-vaccination	100
Table 5. Ratios of GMTs/GMCs between the vaccine arm vs. placebo arm, by baseline status	142
Table 6. Ratios of GMTs/GMCs between baseline positive participants vs. negative participants, among the vaccinees	144
Table 7. Ratios of GMTs/GMCs between demographic subgroups among the vaccine recipients	145
Table 8. Differences of responder rates between the vaccine arm and the placebo arm	149

Table 1. Demographic

Table 1. Demographic

Characteristics	Placebo (N = 425)	Vaccine (N = 1180)	Total (N = 1605)
Age			
Age < 65	228 (53.6)	579 (49.1)	807 (50.3)
Age ≥ 65	197 (46.4)	601 (50.9)	798 (49.7)
Mean (range)	56.6 (18, 85)	58.2 (18, 85)	57.8 (18, 85)
BMI			
Mean +/- SD	29.8 +/- 7.5	29.9 +/- 7.1	29.9 +/- 7.2
Sex			
Female	234 (55.1)	661 (56.0)	895 (55.8)
Male	191 (44.9)	519 (44.0)	710 (44.2)
Hispanic or Latino ethnicity			
Hispanic or Latino	62 (14.6)	140 (11.9)	202 (12.6)
Not Hispanic or Latino	317 (74.6)	933 (79.1)	1250 (77.9)
Not reported and unknown	46 (10.8)	107 (9.1)	153 (9.5)
Race			
American Indian or Alaska Native	13 (3.2)	31 (2.7)	44 (2.8)
Asian	33 (8.0)	97 (8.5)	130 (8.3)
Black or African American	84 (20.4)	223 (19.5)	307 (19.7)
Multiracial	24 (5.8)	66 (5.8)	90 (5.8)
Native Hawaiian or Other Pacific Islander	7 (1.7)	20 (1.7)	27 (1.7)
Not reported and unknown	35 (8.5)	111 (9.7)	146 (9.4)
Other	14 (3.4)	38 (3.3)	52 (3.3)
White	24 (5.8)	57 (5.0)	81 (5.2)
White Non-Hispanic	178 (43.2)	502 (43.8)	680 (43.7)
Risk for Severe Covid-19			
At-risk	198 (46.6)	589 (49.9)	787 (49.0)
Not at-risk	227 (53.4)	591 (50.1)	818 (51.0)

This table summarises the case-cohort, which measures antibody markers at (Day 1, Day 29, and Day 57).

Table 2. Responder rates

Table 2a. Responder rates by All participants

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
All participants							
All participants	Negative	Day 29	1062	Binding Antibody to RBD	51.4% (50.7%, 52.1%)	51.4% (50.7%, 52.1%)	51.4% (50.7%, 52.1%)
				Binding Antibody to Spike	51.4% (50.7%, 52.1%)	51.4% (50.7%, 52.1%)	51.4% (50.7%, 52.1%)
				PsV Neutralization 50% Titer	33.8% (28.6%, 39.0%)	33.8% (28.6%, 39.0%)	26.5% (20.2%, 32.9%)
				PsV Neutralization 80% Titer	41.0% (37.8%, 44.2%)	41.0% (37.8%, 44.2%)	35.3% (31.8%, 38.8%)
				WT LV Neutralization 50% Titer	35.9% (32.4%, 39.4%)	35.9% (32.4%, 39.4%)	27.7% (22.8%, 32.6%)
		Day 57	1062	Binding Antibody to RBD	51.4% (50.7%, 52.1%)	51.4% (50.7%, 52.1%)	51.4% (50.7%, 52.1%)
				Binding Antibody to Spike	51.4% (50.7%, 52.1%)	51.4% (50.7%, 52.1%)	51.4% (50.7%, 52.1%)
				PsV Neutralization 50% Titer	49.0% (48.0%, 50.0%)	49.0% (48.0%, 50.0%)	46.2% (45.0%, 47.4%)
				PsV Neutralization 80% Titer	50.0% (49.5%, 50.5%)	50.0% (49.5%, 50.5%)	48.6% (47.9%, 49.2%)
				WT LV Neutralization 50% Titer	48.6% (48.4%, 48.8%)	48.6% (48.4%, 48.8%)	46.9% (46.3%, 47.6%)
	Positive	Day 29	543	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	99.9% (99.6%, 100.2%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	64.0% (51.6%, 76.4%)	64.0% (51.6%, 76.4%)	46.2% (32.2%, 60.2%)
				PsV Neutralization 80% Titer	82.1% (77.3%, 87.0%)	82.1% (77.3%, 87.0%)	68.6% (58.5%, 78.6%)
				WT LV Neutralization 50% Titer	66.4% (57.2%, 75.6%)	66.4% (57.2%, 75.6%)	51.4% (40.1%, 62.7%)
		Day 57	543	Binding Antibody to RBD	100.0%	100.0%	100.0%

Table 2a. Responder rates by All participants (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
				Binding Antibody to Spike	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 100.0%
				PsV Neutralization 50% Titer	(100.0%, 100.0%) 90.2%	(100.0%, 100.0%) 90.2%	(100.0%, 100.0%) 85.9%
				PsV Neutralization 80% Titer	(85.2%, 95.2%) 98.1%	(85.2%, 95.2%) 98.1%	(80.0%, 91.8%) 95.7%
				WT LV Neutralization 50% Titer	(97.8%, 98.4%) 94.0%	(97.8%, 98.4%) 94.0%	(93.6%, 97.7%) 88.0%
					(91.8%, 96.2%)	(91.8%, 96.2%)	(82.2%, 93.8%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of quantification (LLOQ) with detectable ID50 neutralization titer above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in ID50.

Binding Antibody Responders are defined as participants who had baseline values below the LLOQ with detectable antibody concentration above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in antibody concentration.

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 2b. Responder rates by Age

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Age Age < 65	Negative	Day 29	513	Binding Antibody to RBD	51.6% (51.5%, 51.8%)	51.6% (51.5%, 51.8%)	51.6% (51.5%, 51.8%)
				Binding Antibody to Spike	51.6% (51.5%, 51.8%)	51.6% (51.5%, 51.8%)	51.6% (51.5%, 51.8%)
				PsV Neutralization 50% Titer	31.5% (29.5%, 33.6%)	31.5% (29.5%, 33.6%)	23.8% (21.4%, 26.2%)
				PsV Neutralization 80% Titer	39.6% (38.0%, 41.2%)	39.6% (38.0%, 41.2%)	33.8% (31.9%, 35.7%)
				WT LV Neutralization 50% Titer	34.3% (32.7%, 36.0%)	34.3% (32.7%, 36.0%)	25.6% (25.1%, 26.2%)
		Day 57	513	Binding Antibody to RBD	51.6% (51.5%, 51.8%)	51.6% (51.5%, 51.8%)	51.6% (51.5%, 51.8%)
				Binding Antibody to Spike	51.6% (51.5%, 51.8%)	51.6% (51.5%, 51.8%)	51.6% (51.5%, 51.8%)
				PsV Neutralization 50% Titer	49.1% (47.9%, 50.3%)	49.1% (47.9%, 50.3%)	45.7% (44.9%, 46.5%)
				PsV Neutralization 80% Titer	50.0% (49.4%, 50.7%)	50.0% (49.4%, 50.7%)	48.3% (47.6%, 49.1%)
				WT LV Neutralization 50% Titer	48.5% (48.3%, 48.7%)	48.5% (48.3%, 48.7%)	46.8% (45.9%, 47.7%)
	Positive	Day 29	294	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	99.9% (99.5%, 100.2%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	59.3% (57.2%, 61.4%)	59.3% (57.2%, 61.4%)	40.9% (38.3%, 43.5%)
				PsV Neutralization 80% Titer	80.2% (76.4%, 83.9%)	80.2% (76.4%, 83.9%)	64.6% (64.4%, 64.7%)
				WT LV Neutralization 50% Titer	62.8% (62.3%, 63.2%)	62.8% (62.3%, 63.2%)	47.2% (44.5%, 49.9%)
		Day 57	294	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%

Table 2b. Responder rates by Age (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Age >= 65	Negative	Day 29	549		(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	88.5%	88.5%	83.8%
					(86.8%, 90.2%)	(86.8%, 90.2%)	(82.0%, 85.5%)
				PsV Neutralization 80% Titer	98.0%	98.0%	95.1%
					(97.9%, 98.0%)	(97.9%, 98.0%)	(93.6%, 96.7%)
				WT LV Neutralization 50% Titer	93.1%	93.1%	86.0%
					(92.6%, 93.6%)	(92.6%, 93.6%)	(83.8%, 88.2%)
				Binding Antibody to RBD	50.4%	50.4%	50.4%
					(50.4%, 50.4%)	(50.4%, 50.4%)	(50.4%, 50.4%)
				Binding Antibody to Spike	50.4%	50.4%	50.4%
					(50.4%, 50.4%)	(50.4%, 50.4%)	(50.4%, 50.4%)
				PsV Neutralization 50% Titer	41.9%	41.9%	36.5%
					(41.9%, 41.9%)	(41.9%, 41.9%)	(36.5%, 36.5%)
				PsV Neutralization 80% Titer	46.1%	46.1%	40.8%
					(46.1%, 46.1%)	(46.1%, 46.1%)	(40.8%, 40.8%)
				WT LV Neutralization 50% Titer	41.4%	41.4%	35.1%
					(41.4%, 41.4%)	(41.4%, 41.4%)	(35.1%, 35.1%)
		Day 57	549	Binding Antibody to RBD	50.4%	50.4%	50.4%
					(50.4%, 50.4%)	(50.4%, 50.4%)	(50.4%, 50.4%)
				Binding Antibody to Spike	50.4%	50.4%	50.4%
					(50.4%, 50.4%)	(50.4%, 50.4%)	(50.4%, 50.4%)
				PsV Neutralization 50% Titer	48.6%	48.6%	48.1%
					(48.6%, 48.6%)	(48.6%, 48.6%)	(48.1%, 48.1%)
				PsV Neutralization 80% Titer	49.8%	49.8%	49.4%
					(49.8%, 49.8%)	(49.8%, 49.8%)	(49.4%, 49.4%)
				WT LV Neutralization 50% Titer	48.9%	48.9%	47.2%
					(48.9%, 48.9%)	(48.9%, 48.9%)	(47.2%, 47.2%)
	Positive	Day 29	249	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	83.1%	83.1%	67.7%
					(83.1%, 83.1%)	(83.1%, 83.1%)	(67.7%, 67.7%)
				PsV Neutralization 80% Titer	90.1%	90.1%	84.9%
					(90.1%, 90.1%)	(90.1%, 90.1%)	(84.9%, 84.9%)

Table 2b. Responder rates by Age (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
				WT LV Neutralization 50% Titer	81.2% (81.2%, 81.2%)	81.2% (81.2%, 81.2%)	68.3% (68.3%, 68.3%)
		Day 57	249	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	97.4% (97.4%, 97.4%)	97.4% (97.4%, 97.4%)	94.6% (94.6%, 94.6%)
				PsV Neutralization 80% Titer	98.6% (98.6%, 98.6%)	98.6% (98.6%, 98.6%)	97.8% (97.8%, 97.8%)
				WT LV Neutralization 50% Titer	97.8% (97.8%, 97.8%)	97.8% (97.8%, 97.8%)	96.2% (96.2%, 96.2%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of quantification (LLOQ) with detectable ID50 neutralization titer above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in ID50.

Binding Antibody Responders are defined as participants who had baseline values below the LLOQ with detectable antibody concentration above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in antibody concentration.

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 2c. Responder rates by Risk for Severe Covid-19

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Risk for Severe Covid-19 At-risk	Negative	Day 29	541	Binding Antibody to RBD	51.9% (50.8%, 53.1%)	51.9% (50.8%, 53.1%)	51.9% (50.8%, 53.1%)
				Binding Antibody to Spike	51.9% (50.8%, 53.1%)	51.9% (50.8%, 53.1%)	51.9% (50.8%, 53.1%)
				PsV Neutralization 50% Titer	33.8% (23.1%, 44.5%)	33.8% (23.1%, 44.5%)	26.4% (14.1%, 38.7%)
				PsV Neutralization 80% Titer	40.9% (33.6%, 48.1%)	40.9% (33.6%, 48.1%)	34.9% (27.0%, 42.8%)
				WT LV Neutralization 50% Titer	35.8% (28.1%, 43.6%)	35.8% (28.1%, 43.6%)	28.6% (20.8%, 36.5%)
		Day 57	541	Binding Antibody to RBD	51.9% (50.8%, 53.1%)	51.9% (50.8%, 53.1%)	51.9% (50.8%, 53.1%)
				Binding Antibody to Spike	51.9% (50.8%, 53.1%)	51.9% (50.8%, 53.1%)	51.9% (50.8%, 53.1%)
				PsV Neutralization 50% Titer	48.6% (46.3%, 50.9%)	48.6% (46.3%, 50.9%)	46.5% (42.6%, 50.4%)
				PsV Neutralization 80% Titer	50.6% (47.7%, 53.5%)	50.6% (47.7%, 53.5%)	49.1% (45.3%, 52.8%)
				WT LV Neutralization 50% Titer	49.4% (47.0%, 51.8%)	49.4% (47.0%, 51.8%)	47.0% (44.1%, 49.9%)
	Positive	Day 29	246	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	99.6% (99.1%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	68.7% (54.1%, 83.4%)	68.7% (54.1%, 83.4%)	50.8% (36.7%, 64.8%)
				PsV Neutralization 80% Titer	78.3% (70.2%, 86.3%)	78.3% (70.2%, 86.3%)	70.8% (56.9%, 84.8%)
				WT LV Neutralization 50% Titer	67.3% (58.4%, 76.1%)	67.3% (58.4%, 76.1%)	55.7% (45.3%, 66.0%)
		Day 57	246	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%

Table 2c. Responder rates by Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Not at-risk	Negative	Day 29	521		(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	92.2%	92.2%	87.7%
					(89.3%, 95.1%)	(89.3%, 95.1%)	(84.4%, 91.1%)
				PsV Neutralization 80% Titer	97.7%	97.7%	96.9%
					(96.8%, 98.5%)	(96.8%, 98.5%)	(95.8%, 98.0%)
				WT LV Neutralization 50% Titer	94.5%	94.5%	91.4%
					(89.7%, 99.4%)	(89.7%, 99.4%)	(86.4%, 96.3%)
				Binding Antibody to RBD	51.2%	51.2%	51.2%
					(49.6%, 52.8%)	(49.6%, 52.8%)	(49.6%, 52.8%)
				Binding Antibody to Spike	51.2%	51.2%	51.2%
					(49.6%, 52.8%)	(49.6%, 52.8%)	(49.6%, 52.8%)
				PsV Neutralization 50% Titer	33.8%	33.8%	26.6%
					(29.6%, 38.0%)	(29.6%, 38.0%)	(21.0%, 32.1%)
				PsV Neutralization 80% Titer	41.1%	41.1%	35.4%
					(38.6%, 43.5%)	(38.6%, 43.5%)	(32.7%, 38.2%)
				WT LV Neutralization 50% Titer	35.9%	35.9%	27.3%
					(33.2%, 38.6%)	(33.2%, 38.6%)	(23.1%, 31.6%)
		Day 57	521	Binding Antibody to RBD	51.2%	51.2%	51.2%
					(49.6%, 52.8%)	(49.6%, 52.8%)	(49.6%, 52.8%)
				Binding Antibody to Spike	51.2%	51.2%	51.2%
					(49.6%, 52.8%)	(49.6%, 52.8%)	(49.6%, 52.8%)
				PsV Neutralization 50% Titer	49.2%	49.2%	46.1%
					(48.1%, 50.3%)	(48.1%, 50.3%)	(45.7%, 46.5%)
				PsV Neutralization 80% Titer	49.8%	49.8%	48.4%
					(48.4%, 51.2%)	(48.4%, 51.2%)	(47.7%, 49.1%)
				WT LV Neutralization 50% Titer	48.3%	48.3%	46.9%
					(47.4%, 49.2%)	(47.4%, 49.2%)	(46.1%, 47.7%)
	Positive	Day 29	297	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	62.5%	62.5%	44.7%
					(51.1%, 73.9%)	(51.1%, 73.9%)	(31.0%, 58.5%)
				PsV Neutralization 80% Titer	83.4%	83.4%	67.9%
					(78.2%, 88.6%)	(78.2%, 88.6%)	(58.3%, 77.4%)

Table 2c. Responder rates by Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
				WT LV Neutralization 50% Titer	66.2% (56.0%, 76.3%)	66.2% (56.0%, 76.3%)	50.0% (39.1%, 61.0%)
		Day 57	297	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	89.6% (84.6%, 94.6%)	89.6% (84.6%, 94.6%)	85.3% (79.0%, 91.6%)
				PsV Neutralization 80% Titer	98.2% (97.5%, 99.0%)	98.2% (97.5%, 99.0%)	95.3% (93.3%, 97.3%)
				WT LV Neutralization 50% Titer	93.9% (92.2%, 95.6%)	93.9% (92.2%, 95.6%)	86.9% (81.9%, 92.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of quantification (LLOQ) with detectable ID50 neutralization titer above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in ID50.

Binding Antibody Responders are defined as participants who had baseline values below the LLOQ with detectable antibody concentration above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in antibody concentration.

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 2d. Responder rates by Age, Risk for Severe Covid-19

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Age, Risk for Severe Covid-19							
Age < 65 At-risk	Negative	Day 29	257	Binding Antibody to RBD	51.4%	51.4%	51.4%
					(51.4%, 51.4%)	(51.4%, 51.4%)	(51.4%, 51.4%)
				Binding Antibody to Spike	51.4%	51.4%	51.4%
					(51.4%, 51.4%)	(51.4%, 51.4%)	(51.4%, 51.4%)
				PsV Neutralization 50% Titer	28.6%	28.6%	20.5%
					(28.6%, 28.6%)	(28.6%, 28.6%)	(20.5%, 20.5%)
				PsV Neutralization 80% Titer	37.4%	37.4%	31.1%
					(37.4%, 37.4%)	(37.4%, 37.4%)	(31.1%, 31.1%)
				WT LV Neutralization 50% Titer	32.1%	32.1%	24.8%
					(32.1%, 32.1%)	(32.1%, 32.1%)	(24.8%, 24.8%)
	Positive	Day 29	148	Binding Antibody to RBD	100.0%	100.0%	99.4%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(99.4%, 99.4%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	62.4%	62.4%	44.7%
					(62.4%, 62.4%)	(62.4%, 62.4%)	(44.7%, 44.7%)
				PsV Neutralization 80% Titer	74.7%	74.7%	64.8%
					(74.7%, 74.7%)	(74.7%, 74.7%)	(64.8%, 64.8%)
				WT LV Neutralization 50% Titer	63.4%	63.4%	51.2%
					(63.4%, 63.4%)	(63.4%, 63.4%)	(51.2%, 51.2%)
		Day 57	148	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%

Table 2d. Responder rates by Age, Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Age < 65 Not at-risk	Negative	Day 29	256	PsV Neutralization 50% Titer	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					91.0%	91.0%	86.3%
				PsV Neutralization 80% Titer	(91.0%, 91.0%)	(91.0%, 91.0%)	(86.3%, 86.3%)
					98.0%	98.0%	97.4%
				WT LV Neutralization 50% Titer	(98.0%, 98.0%)	(98.0%, 98.0%)	(97.4%, 97.4%)
					92.4%	92.4%	89.2%
				Binding Antibody to RBD	(92.4%, 92.4%)	(92.4%, 92.4%)	(89.2%, 89.2%)
					51.7%	51.7%	51.7%
				Binding Antibody to Spike	(51.7%, 51.7%)	(51.7%, 51.7%)	(51.7%, 51.7%)
					51.7%	51.7%	51.7%
		Day 57	256	PsV Neutralization 50% Titer	(51.7%, 51.7%)	(51.7%, 51.7%)	(51.7%, 51.7%)
					32.3%	32.3%	24.7%
				PsV Neutralization 80% Titer	(32.3%, 32.3%)	(32.3%, 32.3%)	(24.7%, 24.7%)
					40.2%	40.2%	34.5%
				WT LV Neutralization 50% Titer	(40.2%, 40.2%)	(40.2%, 40.2%)	(34.5%, 34.5%)
					35.0%	35.0%	25.9%
				Binding Antibody to RBD	(35.0%, 35.0%)	(35.0%, 35.0%)	(25.9%, 25.9%)
					51.7%	51.7%	51.7%
				Binding Antibody to Spike	(51.7%, 51.7%)	(51.7%, 51.7%)	(51.7%, 51.7%)
					51.7%	51.7%	51.7%
				PsV Neutralization 50% Titer	(51.7%, 51.7%)	(51.7%, 51.7%)	(51.7%, 51.7%)
					49.6%	49.6%	46.0%
				PsV Neutralization 80% Titer	(49.6%, 49.6%)	(49.6%, 49.6%)	(46.0%, 46.0%)
					50.3%	50.3%	48.6%
				WT LV Neutralization 50% Titer	(50.3%, 50.3%)	(50.3%, 50.3%)	(48.6%, 48.6%)
					48.6%	48.6%	47.2%
		Positive	146	Binding Antibody to RBD	(48.6%, 48.6%)	(48.6%, 48.6%)	(47.2%, 47.2%)
					100.0%	100.0%	100.0%
				Binding Antibody to Spike	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
				PsV Neutralization 50% Titer	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					58.5%	58.5%	39.9%
				PsV Neutralization 80% Titer	(58.5%, 58.5%)	(58.5%, 58.5%)	(39.9%, 39.9%)
					81.6%	81.6%	64.5%
				PsV Neutralization 80% Titer	(81.6%, 81.6%)	(81.6%, 81.6%)	(64.5%, 64.5%)
					81.6%	81.6%	64.5%

Table 2d. Responder rates by Age, Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Age >= 65 At-risk	Negative	Day 57	146	WT LV Neutralization 50% Titer	62.6% (62.6%, 62.6%)	62.6% (62.6%, 62.6%)	46.2% (46.2%, 46.2%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	87.8% (87.8%, 87.8%)	87.8% (87.8%, 87.8%)	83.1% (83.1%, 83.1%)
				PsV Neutralization 80% Titer	98.0% (98.0%, 98.0%)	98.0% (98.0%, 98.0%)	94.6% (94.6%, 94.6%)
				WT LV Neutralization 50% Titer	93.3% (93.3%, 93.3%)	93.3% (93.3%, 93.3%)	85.2% (85.2%, 85.2%)
				Binding Antibody to RBD	52.8% (52.8%, 52.8%)	52.8% (52.8%, 52.8%)	52.8% (52.8%, 52.8%)
				Binding Antibody to Spike	52.8% (52.8%, 52.8%)	52.8% (52.8%, 52.8%)	52.8% (52.8%, 52.8%)
				PsV Neutralization 50% Titer	41.9% (41.9%, 41.9%)	41.9% (41.9%, 41.9%)	35.7% (35.7%, 35.7%)
				PsV Neutralization 80% Titer	46.4% (46.4%, 46.4%)	46.4% (46.4%, 46.4%)	40.9% (40.9%, 40.9%)
	Positive	Day 29	98	WT LV Neutralization 50% Titer	41.7% (41.7%, 41.7%)	41.7% (41.7%, 41.7%)	34.6% (34.6%, 34.6%)
				Binding Antibody to RBD	52.8% (52.8%, 52.8%)	52.8% (52.8%, 52.8%)	52.8% (52.8%, 52.8%)
				Binding Antibody to Spike	52.8% (52.8%, 52.8%)	52.8% (52.8%, 52.8%)	52.8% (52.8%, 52.8%)
				PsV Neutralization 50% Titer	50.3% (50.3%, 50.3%)	50.3% (50.3%, 50.3%)	49.4% (49.4%, 49.4%)
				PsV Neutralization 80% Titer	52.8% (52.8%, 52.8%)	52.8% (52.8%, 52.8%)	51.9% (51.9%, 51.9%)
				WT LV Neutralization 50% Titer	51.2% (51.2%, 51.2%)	51.2% (51.2%, 51.2%)	49.2% (49.2%, 49.2%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%

Table 2d. Responder rates by Age, Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Age >= 65 Not at-risk	Negative	Day 57	98	PsV Neutralization 50% Titer	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					82.1%	82.1%	63.6%
				PsV Neutralization 80% Titer	(82.1%, 82.1%)	(82.1%, 82.1%)	(63.6%, 63.6%)
					85.6%	85.6%	83.6%
				WT LV Neutralization 50% Titer	(85.6%, 85.6%)	(85.6%, 85.6%)	(83.6%, 83.6%)
					75.4%	75.4%	65.1%
				Binding Antibody to RBD	(75.4%, 75.4%)	(75.4%, 75.4%)	(65.1%, 65.1%)
					100.0%	100.0%	100.0%
				Binding Antibody to Spike	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
		Day 29	265	PsV Neutralization 50% Titer	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					94.9%	94.9%	90.8%
				PsV Neutralization 80% Titer	(94.9%, 94.9%)	(94.9%, 94.9%)	(90.8%, 90.8%)
					96.9%	96.9%	95.9%
				WT LV Neutralization 50% Titer	(96.9%, 96.9%)	(96.9%, 96.9%)	(95.9%, 95.9%)
					99.0%	99.0%	95.9%
				Binding Antibody to RBD	(99.0%, 99.0%)	(99.0%, 99.0%)	(95.9%, 95.9%)
					48.1%	48.1%	48.1%
				Binding Antibody to Spike	(48.1%, 48.1%)	(48.1%, 48.1%)	(48.1%, 48.1%)
					48.1%	48.1%	48.1%
				PsV Neutralization 50% Titer	(48.1%, 48.1%)	(48.1%, 48.1%)	(48.1%, 48.1%)
					42.0%	42.0%	37.3%
				PsV Neutralization 80% Titer	(42.0%, 42.0%)	(42.0%, 42.0%)	(37.3%, 37.3%)
					45.8%	45.8%	40.7%
				WT LV Neutralization 50% Titer	(45.8%, 45.8%)	(45.8%, 45.8%)	(40.7%, 40.7%)
					41.1%	41.1%	35.7%
		Day 57	265	Binding Antibody to RBD	(41.1%, 41.1%)	(41.1%, 41.1%)	(35.7%, 35.7%)
					48.1%	48.1%	48.1%
				Binding Antibody to Spike	(48.1%, 48.1%)	(48.1%, 48.1%)	(48.1%, 48.1%)
					48.1%	48.1%	48.1%
				PsV Neutralization 50% Titer	(48.1%, 48.1%)	(48.1%, 48.1%)	(48.1%, 48.1%)
					47.0%	47.0%	46.8%
				PsV Neutralization 80% Titer	(47.0%, 47.0%)	(47.0%, 47.0%)	(46.8%, 46.8%)
					47.0%	47.0%	47.0%
				PsV Neutralization 80% Titer	(47.0%, 47.0%)	(47.0%, 47.0%)	(47.0%, 47.0%)
					47.0%	47.0%	47.0%

Table 2d. Responder rates by Age, Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Positive	Day 29	151	WT LV Neutralization 50% Titer	46.6% (46.6%, 46.6%)	46.6% (46.6%, 46.6%)	45.4% (45.4%, 45.4%)	
			Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	
			Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	
			PsV Neutralization 50% Titer	83.7% (83.7%, 83.7%)	83.7% (83.7%, 83.7%)	70.4% (70.4%, 70.4%)	
			PsV Neutralization 80% Titer	93.0% (93.0%, 93.0%)	93.0% (93.0%, 93.0%)	85.7% (85.7%, 85.7%)	
			WT LV Neutralization 50% Titer	85.1% (85.1%, 85.1%)	85.1% (85.1%, 85.1%)	70.4% (70.4%, 70.4%)	
	Day 57	151	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	
			Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	
			PsV Neutralization 50% Titer	99.0% (99.0%, 99.0%)	99.0% (99.0%, 99.0%)	97.0% (97.0%, 97.0%)	
			PsV Neutralization 80% Titer	99.7% (99.7%, 99.7%)	99.7% (99.7%, 99.7%)	99.0% (99.0%, 99.0%)	
			WT LV Neutralization 50% Titer	97.0% (97.0%, 97.0%)	97.0% (97.0%, 97.0%)	96.4% (96.4%, 96.4%)	

Neutralization Responders are defined as participants who had baseline values below the lower limit of quantification (LLOQ) with detectable ID50 neutralization titer above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in ID50.

Binding Antibody Responders are defined as participants who had baseline values below the LLOQ with detectable antibody concentration above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in antibody concentration.

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 2e. Responder rates by Sex

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Sex							
Female	Negative	Day 29	597	Binding Antibody to RBD	51.9%	51.9%	51.9%
					(50.4%, 53.3%)	(50.4%, 53.3%)	(50.4%, 53.3%)
				Binding Antibody to Spike	51.9%	51.9%	51.9%
					(50.4%, 53.3%)	(50.4%, 53.3%)	(50.4%, 53.3%)
				PsV Neutralization 50% Titer	34.0%	34.0%	26.9%
					(27.6%, 40.4%)	(27.6%, 40.4%)	(19.6%, 34.2%)
		Day 57	597	PsV Neutralization 80% Titer	40.9%	40.9%	35.5%
					(35.4%, 46.4%)	(35.4%, 46.4%)	(30.8%, 40.1%)
				WT LV Neutralization 50% Titer	35.7%	35.7%	28.3%
					(30.1%, 41.3%)	(30.1%, 41.3%)	(23.2%, 33.5%)
				Binding Antibody to RBD	51.9%	51.9%	51.9%
					(50.4%, 53.3%)	(50.4%, 53.3%)	(50.4%, 53.3%)
				Binding Antibody to Spike	51.9%	51.9%	51.9%
					(50.4%, 53.3%)	(50.4%, 53.3%)	(50.4%, 53.3%)
				PsV Neutralization 50% Titer	49.3%	49.3%	47.3%
					(47.2%, 51.4%)	(47.2%, 51.4%)	(44.3%, 50.2%)
	Positive	Day 29	298	PsV Neutralization 80% Titer	51.1%	51.1%	49.2%
					(49.6%, 52.6%)	(49.6%, 52.6%)	(46.9%, 51.5%)
				WT LV Neutralization 50% Titer	48.8%	48.8%	47.0%
					(46.9%, 50.6%)	(46.9%, 50.6%)	(45.3%, 48.8%)
				Binding Antibody to RBD	100.0%	100.0%	99.8%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(99.4%, 100.3%)
		Day 57	298	Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	61.3%	61.3%	45.8%
					(48.9%, 73.7%)	(48.9%, 73.7%)	(34.4%, 57.3%)
				PsV Neutralization 80% Titer	82.4%	82.4%	67.4%
					(78.9%, 85.9%)	(78.9%, 85.9%)	(58.4%, 76.4%)
				WT LV Neutralization 50% Titer	66.0%	66.0%	47.5%
					(57.6%, 74.4%)	(57.6%, 74.4%)	(35.6%, 59.4%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%

Table 2e. Responder rates by Sex (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Male	Negative	Day 29	465		(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	89.2%	89.2%	84.8%
					(84.7%, 93.8%)	(84.7%, 93.8%)	(78.9%, 90.7%)
				PsV Neutralization 80% Titer	97.6%	97.6%	94.6%
					(97.0%, 98.3%)	(97.0%, 98.3%)	(91.6%, 97.6%)
				WT LV Neutralization 50% Titer	92.9%	92.9%	86.3%
					(89.5%, 96.4%)	(89.5%, 96.4%)	(79.0%, 93.5%)
				Binding Antibody to RBD	50.7%	50.7%	50.7%
					(48.0%, 53.5%)	(48.0%, 53.5%)	(48.0%, 53.5%)
				Binding Antibody to Spike	50.7%	50.7%	50.7%
					(48.0%, 53.5%)	(48.0%, 53.5%)	(48.0%, 53.5%)
				PsV Neutralization 50% Titer	33.5%	33.5%	26.0%
					(28.9%, 38.1%)	(28.9%, 38.1%)	(19.9%, 32.1%)
				PsV Neutralization 80% Titer	41.2%	41.2%	35.1%
					(40.8%, 41.5%)	(40.8%, 41.5%)	(32.6%, 37.6%)
				WT LV Neutralization 50% Titer	36.1%	36.1%	26.9%
					(34.9%, 37.2%)	(34.9%, 37.2%)	(22.2%, 31.6%)
		Day 57	465	Binding Antibody to RBD	50.7%	50.7%	50.7%
					(48.0%, 53.5%)	(48.0%, 53.5%)	(48.0%, 53.5%)
				Binding Antibody to Spike	50.7%	50.7%	50.7%
					(48.0%, 53.5%)	(48.0%, 53.5%)	(48.0%, 53.5%)
				PsV Neutralization 50% Titer	48.7%	48.7%	44.9%
					(46.1%, 51.3%)	(46.1%, 51.3%)	(43.4%, 46.3%)
				PsV Neutralization 80% Titer	48.7%	48.7%	47.8%
					(47.1%, 50.3%)	(47.1%, 50.3%)	(46.4%, 49.2%)
				WT LV Neutralization 50% Titer	48.4%	48.4%	46.8%
					(46.5%, 50.4%)	(46.5%, 50.4%)	(45.1%, 48.5%)
	Positive	Day 29	245	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	67.5%	67.5%	46.7%
					(55.6%, 79.4%)	(55.6%, 79.4%)	(28.1%, 65.3%)
				PsV Neutralization 80% Titer	81.8%	81.8%	70.1%
					(74.9%, 88.7%)	(74.9%, 88.7%)	(58.8%, 81.4%)

Table 2e. Responder rates by Sex (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
				WT LV Neutralization 50% Titer	67.0% (56.6%, 77.4%)	67.0% (56.6%, 77.4%)	56.5% (46.8%, 66.3%)
		Day 57	245	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	91.5% (85.8%, 97.3%)	91.5% (85.8%, 97.3%)	87.4% (80.5%, 94.2%)
				PsV Neutralization 80% Titer	98.7% (97.9%, 99.5%)	98.7% (97.9%, 99.5%)	97.1% (96.2%, 98.0%)
				WT LV Neutralization 50% Titer	95.5% (94.8%, 96.2%)	95.5% (94.8%, 96.2%)	90.3% (86.6%, 93.9%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of quantification (LLOQ) with detectable ID50 neutralization titer above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in ID50.

Binding Antibody Responders are defined as participants who had baseline values below the LLOQ with detectable antibody concentration above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in antibody concentration.

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 2f. Responder rates by Age, sex

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Age, sex							
Age < 65 Female	Negative	Day 29	291	Binding Antibody to RBD	51.4%	51.4%	51.4%
					(49.8%, 53.1%)	(49.8%, 53.1%)	(49.8%, 53.1%)
				Binding Antibody to Spike	51.4%	51.4%	51.4%
					(49.8%, 53.1%)	(49.8%, 53.1%)	(49.8%, 53.1%)
				PsV Neutralization 50% Titer	31.4%	31.4%	23.9%
					(26.8%, 36.0%)	(26.8%, 36.0%)	(18.9%, 28.9%)
				PsV Neutralization 80% Titer	38.6%	38.6%	33.6%
					(35.9%, 41.2%)	(35.9%, 41.2%)	(30.1%, 37.0%)
				WT LV Neutralization 50% Titer	33.3%	33.3%	26.1%
					(31.6%, 35.1%)	(31.6%, 35.1%)	(24.7%, 27.6%)
	Positive	Day 57	291	Binding Antibody to RBD	51.4%	51.4%	51.4%
					(49.8%, 53.1%)	(49.8%, 53.1%)	(49.8%, 53.1%)
				Binding Antibody to Spike	51.4%	51.4%	51.4%
					(49.8%, 53.1%)	(49.8%, 53.1%)	(49.8%, 53.1%)
				PsV Neutralization 50% Titer	48.6%	48.6%	46.2%
					(46.3%, 50.9%)	(46.3%, 50.9%)	(43.2%, 49.2%)
				PsV Neutralization 80% Titer	50.6%	50.6%	48.3%
					(48.9%, 52.2%)	(48.9%, 52.2%)	(46.2%, 50.3%)
				WT LV Neutralization 50% Titer	48.0%	48.0%	46.3%
					(47.4%, 48.5%)	(47.4%, 48.5%)	(44.8%, 47.8%)
	Positive	Day 29	166	Binding Antibody to RBD	100.0%	100.0%	99.8%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(99.2%, 100.4%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	56.7%	56.7%	41.1%
					(54.9%, 58.4%)	(54.9%, 58.4%)	(38.5%, 43.7%)
				PsV Neutralization 80% Titer	81.2%	81.2%	63.8%
					(77.5%, 84.8%)	(77.5%, 84.8%)	(63.1%, 64.5%)
				WT LV Neutralization 50% Titer	62.6%	62.6%	43.2%
					(61.3%, 63.8%)	(61.3%, 63.8%)	(40.5%, 45.8%)
		Day 57	166	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%

Table 2f. Responder rates by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Age < 65 Male	Negative	Day 29	222		(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	87.5%	87.5%	82.4%
					(87.3%, 87.7%)	(87.3%, 87.7%)	(81.2%, 83.6%)
				PsV Neutralization 80% Titer	97.5%	97.5%	93.7%
					(96.7%, 98.2%)	(96.7%, 98.2%)	(92.0%, 95.4%)
				WT LV Neutralization 50% Titer	91.5%	91.5%	83.9%
					(90.2%, 92.9%)	(90.2%, 92.9%)	(81.1%, 86.7%)
				Binding Antibody to RBD	51.9%	51.9%	51.9%
					(50.2%, 53.7%)	(50.2%, 53.7%)	(50.2%, 53.7%)
				Binding Antibody to Spike	51.9%	51.9%	51.9%
					(50.2%, 53.7%)	(50.2%, 53.7%)	(50.2%, 53.7%)
				PsV Neutralization 50% Titer	31.7%	31.7%	23.6%
					(30.6%, 32.9%)	(30.6%, 32.9%)	(22.6%, 24.6%)
				PsV Neutralization 80% Titer	41.0%	41.0%	34.0%
					(40.8%, 41.1%)	(40.8%, 41.1%)	(34.0%, 34.1%)
				WT LV Neutralization 50% Titer	35.7%	35.7%	25.0%
					(34.3%, 37.1%)	(34.3%, 37.1%)	(24.5%, 25.5%)
		Day 57	222	Binding Antibody to RBD	51.9%	51.9%	51.9%
					(50.2%, 53.7%)	(50.2%, 53.7%)	(50.2%, 53.7%)
				Binding Antibody to Spike	51.9%	51.9%	51.9%
					(50.2%, 53.7%)	(50.2%, 53.7%)	(50.2%, 53.7%)
				PsV Neutralization 50% Titer	49.8%	49.8%	45.0%
					(49.4%, 50.2%)	(49.4%, 50.2%)	(43.0%, 47.0%)
				PsV Neutralization 80% Titer	49.4%	49.4%	48.4%
					(48.7%, 50.1%)	(48.7%, 50.1%)	(47.5%, 49.3%)
				WT LV Neutralization 50% Titer	49.3%	49.3%	47.5%
					(48.9%, 49.6%)	(48.9%, 49.6%)	(47.4%, 47.6%)
	Positive	Day 29	128	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	62.9%	62.9%	40.6%
					(60.7%, 65.1%)	(60.7%, 65.1%)	(30.8%, 50.4%)
				PsV Neutralization 80% Titer	78.8%	78.8%	65.6%
					(75.1%, 82.5%)	(75.1%, 82.5%)	(64.4%, 66.8%)

Table 2f. Responder rates by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Age >= 65 Female	Negative	Day 57	128	WT LV Neutralization 50% Titer	63.1% (60.3%, 65.8%)	63.1% (60.3%, 65.8%)	52.8% (50.6%, 55.0%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	89.8% (86.2%, 93.4%)	89.8% (86.2%, 93.4%)	85.7% (80.1%, 91.2%)
				PsV Neutralization 80% Titer	98.7% (97.7%, 99.7%)	98.7% (97.7%, 99.7%)	97.1% (95.9%, 98.3%)
				WT LV Neutralization 50% Titer	95.3% (94.8%, 95.8%)	95.3% (94.8%, 95.8%)	88.9% (87.9%, 90.0%)
				Binding Antibody to RBD	53.6% (53.6%, 53.6%)	53.6% (53.6%, 53.6%)	53.6% (53.6%, 53.6%)
				Binding Antibody to Spike	53.6% (53.6%, 53.6%)	53.6% (53.6%, 53.6%)	53.6% (53.6%, 53.6%)
				PsV Neutralization 50% Titer	44.2% (44.2%, 44.2%)	44.2% (44.2%, 44.2%)	38.7% (38.7%, 38.7%)
				PsV Neutralization 80% Titer	50.0% (50.0%, 50.0%)	50.0% (50.0%, 50.0%)	42.8% (42.8%, 42.8%)
	Positive	Day 29	132	WT LV Neutralization 50% Titer	45.0% (45.0%, 45.0%)	45.0% (45.0%, 45.0%)	36.8% (36.8%, 36.8%)
				Binding Antibody to RBD	53.6% (53.6%, 53.6%)	53.6% (53.6%, 53.6%)	53.6% (53.6%, 53.6%)
				Binding Antibody to Spike	53.6% (53.6%, 53.6%)	53.6% (53.6%, 53.6%)	53.6% (53.6%, 53.6%)
				PsV Neutralization 50% Titer	52.0% (52.0%, 52.0%)	52.0% (52.0%, 52.0%)	51.3% (51.3%, 51.3%)
				PsV Neutralization 80% Titer	53.0% (53.0%, 53.0%)	53.0% (53.0%, 53.0%)	52.6% (52.6%, 52.6%)
				WT LV Neutralization 50% Titer	51.8% (51.8%, 51.8%)	51.8% (51.8%, 51.8%)	49.8% (49.8%, 49.8%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%

Table 2f. Responder rates by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Age >= 65 Male	Negative	Day 57	132	PsV Neutralization 50% Titer	(100.0%, 100.0%) 81.8% (81.8%, 81.8%)	(100.0%, 100.0%) 81.8% (81.8%, 81.8%)	(100.0%, 100.0%) 66.7% (66.7%, 66.7%)
				PsV Neutralization 80% Titer	87.9% (87.9%, 87.9%)	87.9% (87.9%, 87.9%)	83.3% (83.3%, 83.3%)
				WT LV Neutralization 50% Titer	81.0% (81.0%, 81.0%)	81.0% (81.0%, 81.0%)	66.6% (66.6%, 66.6%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	97.0% (97.0%, 97.0%)	97.0% (97.0%, 97.0%)	95.5% (95.5%, 95.5%)
				PsV Neutralization 80% Titer	98.5% (98.5%, 98.5%)	98.5% (98.5%, 98.5%)	98.5% (98.5%, 98.5%)
				WT LV Neutralization 50% Titer	99.2% (99.2%, 99.2%)	99.2% (99.2%, 99.2%)	97.0% (97.0%, 97.0%)
				Binding Antibody to RBD	46.8% (46.8%, 46.8%)	46.8% (46.8%, 46.8%)	46.8% (46.8%, 46.8%)
				Binding Antibody to Spike	46.8% (46.8%, 46.8%)	46.8% (46.8%, 46.8%)	46.8% (46.8%, 46.8%)
		Day 29	243	PsV Neutralization 50% Titer	39.4% (39.4%, 39.4%)	39.4% (39.4%, 39.4%)	34.1% (34.1%, 34.1%)
				PsV Neutralization 80% Titer	41.7% (41.7%, 41.7%)	41.7% (41.7%, 41.7%)	38.5% (38.5%, 38.5%)
				WT LV Neutralization 50% Titer	37.4% (37.4%, 37.4%)	37.4% (37.4%, 37.4%)	33.3% (33.3%, 33.3%)
				Binding Antibody to RBD	46.8% (46.8%, 46.8%)	46.8% (46.8%, 46.8%)	46.8% (46.8%, 46.8%)
				Binding Antibody to Spike	46.8% (46.8%, 46.8%)	46.8% (46.8%, 46.8%)	46.8% (46.8%, 46.8%)
				PsV Neutralization 50% Titer	44.9% (44.9%, 44.9%)	44.9% (44.9%, 44.9%)	44.5% (44.5%, 44.5%)
				PsV Neutralization 80% Titer	46.3% (46.3%, 46.3%)	46.3% (46.3%, 46.3%)	45.8% (45.8%, 45.8%)
				Binding Antibody to RBD	46.8% (46.8%, 46.8%)	46.8% (46.8%, 46.8%)	46.8% (46.8%, 46.8%)
				Binding Antibody to Spike	46.8% (46.8%, 46.8%)	46.8% (46.8%, 46.8%)	46.8% (46.8%, 46.8%)
				PsV Neutralization 50% Titer	44.9% (44.9%, 44.9%)	44.9% (44.9%, 44.9%)	44.5% (44.5%, 44.5%)
				PsV Neutralization 80% Titer	46.3% (46.3%, 46.3%)	46.3% (46.3%, 46.3%)	45.8% (45.8%, 45.8%)

Table 2f. Responder rates by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Positive	Day 29	117	WT LV Neutralization 50% Titer	45.6% (45.6%, 45.6%)	45.6% (45.6%, 45.6%)	44.4% (44.4%, 44.4%)	
			Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	
			Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	
			PsV Neutralization 50% Titer	84.5% (84.5%, 84.5%)	84.5% (84.5%, 84.5%)	69.0% (69.0%, 69.0%)	
			PsV Neutralization 80% Titer	92.7% (92.7%, 92.7%)	92.7% (92.7%, 92.7%)	86.7% (86.7%, 86.7%)	
			WT LV Neutralization 50% Titer	81.5% (81.5%, 81.5%)	81.5% (81.5%, 81.5%)	70.3% (70.3%, 70.3%)	
	Day 57	117	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	
			Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	
			PsV Neutralization 50% Titer	97.9% (97.9%, 97.9%)	97.9% (97.9%, 97.9%)	93.6% (93.6%, 93.6%)	
			PsV Neutralization 80% Titer	98.7% (98.7%, 98.7%)	98.7% (98.7%, 98.7%)	97.0% (97.0%, 97.0%)	
			WT LV Neutralization 50% Titer	96.1% (96.1%, 96.1%)	96.1% (96.1%, 96.1%)	95.3% (95.3%, 95.3%)	

Neutralization Responders are defined as participants who had baseline values below the lower limit of quantification (LLOQ) with detectable ID50 neutralization titer above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in ID50.

Binding Antibody Responders are defined as participants who had baseline values below the LLOQ with detectable antibody concentration above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in antibody concentration.

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 2g. Responder rates by Hispanic or Latino ethnicity

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Hispanic or Latino ethnicity							
Hispanic or Latino	Negative	Day 29	125	Binding Antibody to RBD	46.2%	46.2%	46.2%
					(35.5%, 56.8%)	(35.5%, 56.8%)	(35.5%, 56.8%)
				Binding Antibody to Spike	46.2%	46.2%	46.2%
					(35.5%, 56.8%)	(35.5%, 56.8%)	(35.5%, 56.8%)
				PsV Neutralization 50% Titer	26.1%	26.1%	20.5%
					(10.9%, 41.3%)	(10.9%, 41.3%)	(6.5%, 34.5%)
				PsV Neutralization 80% Titer	37.1%	37.1%	32.1%
					(27.0%, 47.3%)	(27.0%, 47.3%)	(22.6%, 41.6%)
				WT LV Neutralization 50% Titer	30.6%	30.6%	21.2%
					(19.4%, 41.8%)	(19.4%, 41.8%)	(6.7%, 35.8%)
	Positive	Day 29	77	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	61.0%	61.0%	46.4%
					(53.7%, 68.3%)	(53.7%, 68.3%)	(39.4%, 53.4%)
				PsV Neutralization 80% Titer	81.2%	81.2%	62.7%
					(74.3%, 88.1%)	(74.3%, 88.1%)	(54.1%, 71.4%)
				WT LV Neutralization 50% Titer	63.0%	63.0%	49.1%
					(55.2%, 70.7%)	(55.2%, 70.7%)	(39.6%, 58.5%)
		Day 57	77	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%

Table 2g. Responder rates by Hispanic or Latino ethnicity (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Not Hispanic or Latino	Negative	Day 29	844		(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	89.2%	89.2%	88.6%
					(86.4%, 91.9%)	(86.4%, 91.9%)	(84.7%, 92.4%)
				PsV Neutralization 80% Titer	96.3%	96.3%	93.7%
					(94.5%, 98.2%)	(94.5%, 98.2%)	(90.6%, 96.8%)
				WT LV Neutralization 50% Titer	94.2%	94.2%	91.0%
					(91.1%, 97.3%)	(91.1%, 97.3%)	(86.8%, 95.2%)
				Binding Antibody to RBD	53.4%	53.4%	53.4%
					(49.1%, 57.6%)	(49.1%, 57.6%)	(49.1%, 57.6%)
				Binding Antibody to Spike	53.4%	53.4%	53.4%
					(49.1%, 57.6%)	(49.1%, 57.6%)	(49.1%, 57.6%)
				PsV Neutralization 50% Titer	35.6%	35.6%	27.4%
					(29.9%, 41.3%)	(29.9%, 41.3%)	(20.7%, 34.2%)
				PsV Neutralization 80% Titer	42.8%	42.8%	36.4%
					(38.0%, 47.6%)	(38.0%, 47.6%)	(31.7%, 41.2%)
				WT LV Neutralization 50% Titer	37.4%	37.4%	29.3%
					(32.9%, 41.8%)	(32.9%, 41.8%)	(24.9%, 33.8%)
	Positive	Day 57	844	Binding Antibody to RBD	53.4%	53.4%	53.4%
					(49.1%, 57.6%)	(49.1%, 57.6%)	(49.1%, 57.6%)
				Binding Antibody to Spike	53.4%	53.4%	53.4%
					(49.1%, 57.6%)	(49.1%, 57.6%)	(49.1%, 57.6%)
				PsV Neutralization 50% Titer	50.7%	50.7%	47.9%
					(45.8%, 55.6%)	(45.8%, 55.6%)	(43.9%, 51.8%)
				PsV Neutralization 80% Titer	52.1%	52.1%	50.8%
					(47.7%, 56.5%)	(47.7%, 56.5%)	(47.0%, 54.5%)
				WT LV Neutralization 50% Titer	50.6%	50.6%	48.7%
					(46.5%, 54.6%)	(46.5%, 54.6%)	(44.1%, 53.4%)
				Binding Antibody to RBD	100.0%	100.0%	99.9%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(99.5%, 100.2%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	64.9%	64.9%	47.2%
					(51.8%, 78.1%)	(51.8%, 78.1%)	(31.2%, 63.2%)
				PsV Neutralization 80% Titer	80.5%	80.5%	68.0%
					(74.9%, 86.0%)	(74.9%, 86.0%)	(57.4%, 78.6%)

Table 2g. Responder rates by Hispanic or Latino ethnicity (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Not reported and unknown	Negative	Day 57	406	WT LV Neutralization 50% Titer	66.3% (56.7%, 76.0%)	66.3% (56.7%, 76.0%)	51.6% (40.3%, 62.9%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	91.7% (87.3%, 96.2%)	91.7% (87.3%, 96.2%)	87.3% (81.9%, 92.8%)
				PsV Neutralization 80% Titer	98.9% (98.1%, 99.6%)	98.9% (98.1%, 99.6%)	96.7% (95.5%, 97.9%)
				WT LV Neutralization 50% Titer	94.5% (92.6%, 96.4%)	94.5% (92.6%, 96.4%)	87.7% (81.8%, 93.5%)
		Day 29	93	Binding Antibody to RBD	42.0% (28.6%, 55.5%)	42.0% (28.6%, 55.5%)	42.0% (28.6%, 55.5%)
				Binding Antibody to Spike	42.0% (28.6%, 55.5%)	42.0% (28.6%, 55.5%)	42.0% (28.6%, 55.5%)
				PsV Neutralization 50% Titer	28.4% (17.7%, 39.1%)	28.4% (17.7%, 39.1%)	26.2% (20.0%, 32.4%)
				PsV Neutralization 80% Titer	32.1% (17.3%, 46.8%)	32.1% (17.3%, 46.8%)	30.2% (18.9%, 41.5%)
				WT LV Neutralization 50% Titer	30.4% (18.8%, 41.9%)	30.4% (18.8%, 41.9%)	22.6% (12.1%, 33.1%)
				Binding Antibody to RBD	42.0% (28.6%, 55.5%)	42.0% (28.6%, 55.5%)	42.0% (28.6%, 55.5%)
	Positive	Day 57	93	Binding Antibody to Spike	42.0% (28.6%, 55.5%)	42.0% (28.6%, 55.5%)	42.0% (28.6%, 55.5%)
				PsV Neutralization 50% Titer	40.6% (26.5%, 54.7%)	40.6% (26.5%, 54.7%)	38.4% (25.7%, 51.1%)
				PsV Neutralization 80% Titer	42.0% (28.6%, 55.5%)	42.0% (28.6%, 55.5%)	39.3% (28.5%, 50.0%)
				WT LV Neutralization 50% Titer	38.6% (25.0%, 52.3%)	38.6% (25.0%, 52.3%)	38.6% (25.0%, 52.3%)
		Day 29	60	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%

Table 2g. Responder rates by Hispanic or Latino ethnicity (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	62.1%	62.1%	38.9%
					(45.7%, 78.5%)	(45.7%, 78.5%)	(24.9%, 53.0%)
				PsV Neutralization 80% Titer	95.3%	95.3%	81.8%
					(86.7%, 103.9%)	(86.7%, 103.9%)	(76.9%, 86.6%)
				WT LV Neutralization 50% Titer	72.5%	72.5%	53.9%
					(61.9%, 83.1%)	(61.9%, 83.1%)	(40.3%, 67.4%)
		Day 57	60	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	81.5%	81.5%	71.8%
					(66.8%, 96.2%)	(66.8%, 96.2%)	(51.1%, 92.6%)
				PsV Neutralization 80% Titer	95.6%	95.6%	91.5%
					(91.7%, 99.5%)	(91.7%, 99.5%)	(83.1%, 99.9%)
				WT LV Neutralization 50% Titer	90.6%	90.6%	85.7%
					(83.5%, 97.6%)	(83.5%, 97.6%)	(75.8%, 95.7%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of quantification (LLOQ) with detectable ID50 neutralization titer above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in ID50.

Binding Antibody Responders are defined as participants who had baseline values below the LLOQ with detectable antibody concentration above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in antibody concentration.

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 2h. Responder rates by Race

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Race							
Not reported and unknown	Negative	Day 29	98	Binding Antibody to RBD	49.0%	49.0%	49.0%
					(43.2%, 54.9%)	(43.2%, 54.9%)	(43.2%, 54.9%)
				Binding Antibody to Spike	49.0%	49.0%	49.0%
					(43.2%, 54.9%)	(43.2%, 54.9%)	(43.2%, 54.9%)
				PsV Neutralization 50% Titer	31.3%	31.3%	24.8%
					(24.5%, 38.0%)	(24.5%, 38.0%)	(19.2%, 30.3%)
				PsV Neutralization 80% Titer	38.3%	38.3%	35.5%
					(30.8%, 45.8%)	(30.8%, 45.8%)	(31.5%, 39.4%)
				WT LV Neutralization 50% Titer	32.6%	32.6%	26.0%
					(28.0%, 37.3%)	(28.0%, 37.3%)	(20.8%, 31.2%)
	Positive	Day 57	98	Binding Antibody to RBD	49.0%	49.0%	49.0%
					(43.2%, 54.9%)	(43.2%, 54.9%)	(43.2%, 54.9%)
				Binding Antibody to Spike	49.0%	49.0%	49.0%
					(43.2%, 54.9%)	(43.2%, 54.9%)	(43.2%, 54.9%)
				PsV Neutralization 50% Titer	48.0%	48.0%	46.1%
					(41.0%, 55.1%)	(41.0%, 55.1%)	(40.8%, 51.4%)
				PsV Neutralization 80% Titer	48.6%	48.6%	47.6%
					(41.7%, 55.4%)	(41.7%, 55.4%)	(39.7%, 55.6%)
				WT LV Neutralization 50% Titer	48.1%	48.1%	48.1%
					(40.2%, 56.0%)	(40.2%, 56.0%)	(40.2%, 56.0%)
	Positive	Day 29	48	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	63.6%	63.6%	47.9%
					(39.8%, 87.4%)	(39.8%, 87.4%)	(18.0%, 77.9%)
				PsV Neutralization 80% Titer	81.8%	81.8%	69.7%
					(77.6%, 86.1%)	(77.6%, 86.1%)	(54.1%, 85.2%)
				WT LV Neutralization 50% Titer	62.8%	62.8%	48.2%
					(42.2%, 83.5%)	(42.2%, 83.5%)	(18.9%, 77.5%)
		Day 57	48	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%

Table 2h. Responder rates by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
American Indian or Alaska Native	Negative	Day 29	27		(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	97.5%	97.5%	92.2%
					(93.5%, 101.5%)	(93.5%, 101.5%)	(89.0%, 95.4%)
				PsV Neutralization 80% Titer	100.0%	100.0%	89.3%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(74.9%, 103.7%)
				WT LV Neutralization 50% Titer	100.0%	100.0%	88.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(75.7%, 100.4%)
				Binding Antibody to RBD	49.4%	49.4%	49.4%
					(41.4%, 57.4%)	(41.4%, 57.4%)	(41.4%, 57.4%)
				Binding Antibody to Spike	49.4%	49.4%	49.4%
	Positive	Day 29	17		(41.4%, 57.4%)	(41.4%, 57.4%)	(41.4%, 57.4%)
				PsV Neutralization 50% Titer	31.0%	31.0%	24.4%
					(21.8%, 40.2%)	(21.8%, 40.2%)	(11.6%, 37.2%)
				PsV Neutralization 80% Titer	37.4%	37.4%	25.4%
					(31.5%, 43.3%)	(31.5%, 43.3%)	(10.3%, 40.6%)
				WT LV Neutralization 50% Titer	25.4%	25.4%	17.2%
					(10.3%, 40.6%)	(10.3%, 40.6%)	(1.6%, 32.8%)
		Day 57	27	Binding Antibody to RBD	49.4%	49.4%	49.4%
					(41.4%, 57.4%)	(41.4%, 57.4%)	(41.4%, 57.4%)
				Binding Antibody to Spike	49.4%	49.4%	49.4%
					(41.4%, 57.4%)	(41.4%, 57.4%)	(41.4%, 57.4%)
				PsV Neutralization 50% Titer	48.5%	48.5%	48.5%
					(39.7%, 57.4%)	(39.7%, 57.4%)	(39.7%, 57.4%)
		Day 57	27	PsV Neutralization 80% Titer	48.5%	48.5%	48.5%
					(39.7%, 57.4%)	(39.7%, 57.4%)	(39.7%, 57.4%)
				WT LV Neutralization 50% Titer	49.4%	49.4%	49.2%
					(41.4%, 57.4%)	(41.4%, 57.4%)	(41.2%, 57.3%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
		Day 57	27	Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	78.5%	78.5%	44.7%
					(70.5%, 86.4%)	(70.5%, 86.4%)	(24.2%, 65.1%)
		Day 57	27	PsV Neutralization 80% Titer	90.3%	90.3%	63.7%

Table 2h. Responder rates by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Asian	Negative	Day 57	17	WT LV Neutralization 50% Titer	(64.8%, 115.7%) 93.9%	(64.8%, 115.7%) 93.9%	(45.4%, 82.0%) 61.3%
				Binding Antibody to RBD	(77.8%, 109.9%) 100.0%	(77.8%, 109.9%) 100.0%	(48.1%, 74.5%) 100.0%
				Binding Antibody to Spike	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 100.0%
				PsV Neutralization 50% Titer	(100.0%, 100.0%) 96.9%	(100.0%, 100.0%) 96.9%	(100.0%, 100.0%) 96.9%
				PsV Neutralization 80% Titer	(88.9%, 105.0%) 100.0%	(88.9%, 105.0%) 100.0%	(88.9%, 105.0%) 100.0%
				WT LV Neutralization 50% Titer	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 100.0%
				Binding Antibody to RBD	(100.0%, 100.0%) 58.4%	(100.0%, 100.0%) 58.4%	(100.0%, 100.0%) 58.4%
				Binding Antibody to Spike	(47.2%, 69.6%) 58.4%	(47.2%, 69.6%) 58.4%	(47.2%, 69.6%) 58.4%
				PsV Neutralization 50% Titer	(47.2%, 69.6%) 37.9%	(47.2%, 69.6%) 37.9%	(47.2%, 69.6%) 26.5%
				PsV Neutralization 80% Titer	(34.5%, 41.3%) 52.1%	(34.5%, 41.3%) 52.1%	(19.4%, 33.5%) 40.7%
				WT LV Neutralization 50% Titer	(40.6%, 63.6%) 39.1%	(40.6%, 63.6%) 39.1%	(35.9%, 45.5%) 33.7%
				Binding Antibody to RBD	(33.4%, 44.7%) 58.4%	(33.4%, 44.7%) 58.4%	(31.7%, 35.6%) 58.4%
	Positive	Day 29	46	Binding Antibody to Spike	(47.2%, 69.6%) 58.4%	(47.2%, 69.6%) 58.4%	(47.2%, 69.6%) 58.4%
				PsV Neutralization 50% Titer	(47.2%, 69.6%) 57.4%	(47.2%, 69.6%) 57.4%	(47.2%, 69.6%) 53.8%
				PsV Neutralization 80% Titer	(44.1%, 70.7%) 57.5%	(44.1%, 70.7%) 57.5%	(42.4%, 65.2%) 56.0%
				WT LV Neutralization 50% Titer	(46.0%, 69.0%) 56.7%	(46.0%, 69.0%) 56.7%	(43.9%, 68.1%) 56.0%
				Binding Antibody to RBD	(46.1%, 67.2%) 100.0%	(46.1%, 67.2%) 100.0%	(43.9%, 68.1%) 100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)

Table 2h. Responder rates by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Black or African American	Negative	Day 57	46	Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	56.3% (26.7%, 85.9%)	56.3% (26.7%, 85.9%)	34.4% (3.0%, 65.8%)
				PsV Neutralization 80% Titer	73.1% (53.7%, 92.6%)	73.1% (53.7%, 92.6%)	60.2% (37.2%, 83.2%)
				WT LV Neutralization 50% Titer	58.6% (39.9%, 77.4%)	58.6% (39.9%, 77.4%)	43.8% (25.6%, 62.1%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	84.2% (72.1%, 96.4%)	84.2% (72.1%, 96.4%)	82.0% (73.0%, 91.1%)
				PsV Neutralization 80% Titer	95.0% (90.3%, 99.7%)	95.0% (90.3%, 99.7%)	90.2% (81.0%, 99.4%)
				WT LV Neutralization 50% Titer	88.4% (82.9%, 93.8%)	88.4% (82.9%, 93.8%)	82.5% (74.6%, 90.3%)
				Binding Antibody to RBD	51.4% (50.3%, 52.6%)	51.4% (50.3%, 52.6%)	51.4% (50.3%, 52.6%)
		Day 29	216	Binding Antibody to Spike	51.4% (50.3%, 52.6%)	51.4% (50.3%, 52.6%)	51.4% (50.3%, 52.6%)
				PsV Neutralization 50% Titer	32.9% (27.1%, 38.7%)	32.9% (27.1%, 38.7%)	26.6% (19.3%, 34.0%)
				PsV Neutralization 80% Titer	39.5% (33.8%, 45.1%)	39.5% (33.8%, 45.1%)	32.4% (26.3%, 38.6%)
				WT LV Neutralization 50% Titer	35.0% (28.6%, 41.4%)	35.0% (28.6%, 41.4%)	24.7% (15.9%, 33.5%)
				Binding Antibody to RBD	51.4% (50.3%, 52.6%)	51.4% (50.3%, 52.6%)	51.4% (50.3%, 52.6%)
				Binding Antibody to Spike	51.4% (50.3%, 52.6%)	51.4% (50.3%, 52.6%)	51.4% (50.3%, 52.6%)
				PsV Neutralization 50% Titer	46.1% (42.1%, 50.1%)	46.1% (42.1%, 50.1%)	42.7% (37.0%, 48.4%)
				PsV Neutralization 80% Titer	49.5%	49.5%	47.8%

Table 2h. Responder rates by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Multiracial	Positive	Day 29	91	WT LV Neutralization 50% Titer	(48.3%, 50.7%) 47.1%	(48.3%, 50.7%) 47.1%	(45.7%, 49.8%) 45.5%
				Binding Antibody to RBD	(42.4%, 51.7%) 100.0%	(42.4%, 51.7%) 100.0%	(42.9%, 48.2%) 100.0%
				Binding Antibody to Spike	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 100.0%
				PsV Neutralization 50% Titer	(100.0%, 100.0%) 57.5%	(100.0%, 100.0%) 57.5%	(100.0%, 100.0%) 40.1%
				PsV Neutralization 80% Titer	(45.2%, 69.7%) 81.2%	(45.2%, 69.7%) 81.2%	(23.2%, 57.1%) 65.6%
				WT LV Neutralization 50% Titer	(69.8%, 92.7%) 67.7%	(69.8%, 92.7%) 67.7%	(52.8%, 78.3%) 54.2%
		Day 57	91	Binding Antibody to RBD	(56.7%, 78.7%) 100.0%	(56.7%, 78.7%) 100.0%	(48.2%, 60.2%) 100.0%
				Binding Antibody to Spike	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 100.0%
				PsV Neutralization 50% Titer	(100.0%, 100.0%) 93.2%	(100.0%, 100.0%) 93.2%	(100.0%, 100.0%) 86.2%
				PsV Neutralization 80% Titer	(89.9%, 96.6%) 98.7%	(89.9%, 96.6%) 98.7%	(80.2%, 92.2%) 98.7%
				WT LV Neutralization 50% Titer	(96.2%, 101.2%) 96.1%	(96.2%, 101.2%) 96.1%	(96.2%, 101.2%) 84.3%
				Binding Antibody to RBD	(95.7%, 96.4%) 37.1%	(95.7%, 96.4%) 37.1%	(75.0%, 93.6%) 37.1%
	Negative	Day 29	62	Binding Antibody to Spike	(24.0%, 50.1%) 37.1%	(24.0%, 50.1%) 37.1%	(24.0%, 50.1%) 37.1%
				PsV Neutralization 50% Titer	(24.0%, 50.1%) 17.7%	(24.0%, 50.1%) 17.7%	(24.0%, 50.1%) 12.5%
				PsV Neutralization 80% Titer	(0.7%, 34.8%) 28.5%	(0.7%, 34.8%) 28.5%	(-5.2%, 30.2%) 24.9%
				WT LV Neutralization 50% Titer	(16.4%, 40.7%) 26.1%	(16.4%, 40.7%) 26.1%	(15.2%, 34.5%) 17.7%
		Day 57	62	Binding Antibody to RBD	(13.2%, 39.0%) 37.1%	(13.2%, 39.0%) 37.1%	(5.8%, 29.6%) 37.1%
					(24.0%, 50.1%)	(24.0%, 50.1%)	(24.0%, 50.1%)

Table 2h. Responder rates by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Native Hawaiian or Other Pacific Islander	Positive	Day 29	28	Binding Antibody to Spike	37.1% (24.0%, 50.1%)	37.1% (24.0%, 50.1%)	37.1% (24.0%, 50.1%)
				PsV Neutralization 50% Titer	37.1% (24.0%, 50.1%)	37.1% (24.0%, 50.1%)	32.1% (18.2%, 46.1%)
				PsV Neutralization 80% Titer	37.1% (24.0%, 50.1%)	37.1% (24.0%, 50.1%)	36.0% (25.0%, 47.0%)
				WT LV Neutralization 50% Titer	34.8% (21.0%, 48.6%)	34.8% (21.0%, 48.6%)	32.4% (18.2%, 46.5%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	71.6% (63.3%, 79.9%)	71.6% (63.3%, 79.9%)	52.6% (44.1%, 61.1%)
				PsV Neutralization 80% Titer	89.3% (82.6%, 96.0%)	89.3% (82.6%, 96.0%)	65.2% (55.1%, 75.3%)
				WT LV Neutralization 50% Titer	65.2% (55.1%, 75.3%)	65.2% (55.1%, 75.3%)	50.8% (29.1%, 72.4%)
		Day 57	28	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	85.9% (74.4%, 97.3%)	85.9% (74.4%, 97.3%)	85.9% (74.4%, 97.3%)
				PsV Neutralization 80% Titer	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				WT LV Neutralization 50% Titer	91.3% (87.6%, 95.0%)	91.3% (87.6%, 95.0%)	91.3% (87.6%, 95.0%)
	Negative	Day 29	20	Binding Antibody to RBD	65.8% (20.3%, 111.4%)	65.8% (20.3%, 111.4%)	65.8% (20.3%, 111.4%)
				Binding Antibody to Spike	65.8% (20.3%, 111.4%)	65.8% (20.3%, 111.4%)	65.8% (20.3%, 111.4%)
				PsV Neutralization 50% Titer	45.4% (26.1%, 64.8%)	45.4% (26.1%, 64.8%)	41.6% (17.3%, 65.9%)

Table 2h. Responder rates by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Other	Positive	Day 57	20	PsV Neutralization 80% Titer	61.0% (9.4%, 112.6%)	61.0% (9.4%, 112.6%)	59.6% (6.1%, 113.0%)
				WT LV Neutralization 50% Titer	61.0% (9.4%, 112.6%)	61.0% (9.4%, 112.6%)	41.6% (17.3%, 65.9%)
				Binding Antibody to RBD	65.8% (20.3%, 111.4%)	65.8% (20.3%, 111.4%)	65.8% (20.3%, 111.4%)
				Binding Antibody to Spike	65.8% (20.3%, 111.4%)	65.8% (20.3%, 111.4%)	65.8% (20.3%, 111.4%)
				PsV Neutralization 50% Titer	65.8% (20.3%, 111.4%)	65.8% (20.3%, 111.4%)	63.4% (15.0%, 111.8%)
				PsV Neutralization 80% Titer	65.8% (20.3%, 111.4%)	65.8% (20.3%, 111.4%)	65.8% (20.3%, 111.4%)
				WT LV Neutralization 50% Titer	64.4% (16.7%, 112.2%)	64.4% (16.7%, 112.2%)	64.4% (16.7%, 112.2%)
		Day 29	7	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	91.4% (76.1%, 106.7%)	91.4% (76.1%, 106.7%)	34.3% (-26.9%, 95.4%)
				PsV Neutralization 80% Titer	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	89.1% (60.6%, 117.6%)
				WT LV Neutralization 50% Titer	80.5% (50.3%, 110.7%)	80.5% (50.3%, 110.7%)	80.5% (50.3%, 110.7%)
		Day 57	7	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	89.1% (60.6%, 117.6%)	89.1% (60.6%, 117.6%)	89.1% (60.6%, 117.6%)
				PsV Neutralization 80% Titer	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				WT LV Neutralization 50% Titer	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	89.1% (60.6%, 117.6%)
		Day 29	28	Binding Antibody to RBD	79.7% (100.0%, 100.0%)	79.7% (100.0%, 100.0%)	79.7% (60.6%, 117.6%)
	Negative	Day 29	28				

Table 2h. Responder rates by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Positive	Day 57	28		Binding Antibody to Spike	(45.1%, 114.3%) 79.7%	(45.1%, 114.3%) 79.7%	(45.1%, 114.3%) 79.7%
				PsV Neutralization 50% Titer	(45.1%, 114.3%) 59.2%	(45.1%, 114.3%) 59.2%	(45.1%, 114.3%) 52.0%
				PsV Neutralization 80% Titer	(39.1%, 79.3%) 53.7%	(39.1%, 79.3%) 53.7%	(24.3%, 79.7%) 51.1%
				WT LV Neutralization 50% Titer	(44.1%, 63.2%) 49.6%	(44.1%, 63.2%) 49.6%	(47.8%, 54.4%) 36.9%
				Binding Antibody to RBD	(44.5%, 54.6%) 79.7%	(44.5%, 54.6%) 79.7%	(22.6%, 51.1%) 79.7%
				Binding Antibody to Spike	(45.1%, 114.3%) 79.7%	(45.1%, 114.3%) 79.7%	(45.1%, 114.3%) 79.7%
				PsV Neutralization 50% Titer	(45.1%, 114.3%) 77.1%	(45.1%, 114.3%) 77.1%	(45.1%, 114.3%) 77.1%
				PsV Neutralization 80% Titer	(44.1%, 110.1%) 67.5%	(44.1%, 110.1%) 67.5%	(44.1%, 110.1%) 67.5%
				WT LV Neutralization 50% Titer	(49.1%, 85.8%) 78.2%	(49.1%, 85.8%) 78.2%	(49.1%, 85.8%) 78.2%
				Binding Antibody to RBD	(41.0%, 115.4%) 100.0%	(41.0%, 115.4%) 100.0%	(41.0%, 115.4%) 100.0%
				Binding Antibody to Spike	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 100.0%
				PsV Neutralization 50% Titer	(100.0%, 100.0%) 55.8%	(100.0%, 100.0%) 55.8%	(100.0%, 100.0%) 35.6%
	Day 57	24		PsV Neutralization 80% Titer	(44.0%, 67.7%) 82.9%	(44.0%, 67.7%) 82.9%	(23.6%, 47.7%) 57.2%
				WT LV Neutralization 50% Titer	(76.1%, 89.7%) 49.7%	(76.1%, 89.7%) 49.7%	(42.3%, 72.1%) 46.6%
				Binding Antibody to RBD	(29.7%, 69.8%) 100.0%	(29.7%, 69.8%) 100.0%	(33.6%, 59.5%) 100.0%
				Binding Antibody to Spike	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 100.0%
				PsV Neutralization 50% Titer	(100.0%, 100.0%) 90.4%	(100.0%, 100.0%) 90.4%	(100.0%, 100.0%) 88.6%
					(87.7%, 93.2%)	(87.7%, 93.2%)	(82.8%, 94.5%)

Table 2h. Responder rates by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
White	Negative	Day 29	43	PsV Neutralization 80% Titer	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	92.5% (87.3%, 97.7%)
				WT LV Neutralization 50% Titer	83.2% (76.6%, 89.8%)	83.2% (76.6%, 89.8%)	75.4% (63.6%, 87.2%)
				Binding Antibody to RBD	46.9% (31.9%, 61.8%)	46.9% (31.9%, 61.8%)	46.9% (31.9%, 61.8%)
				Binding Antibody to Spike	46.9% (31.9%, 61.8%)	46.9% (31.9%, 61.8%)	46.9% (31.9%, 61.8%)
				PsV Neutralization 50% Titer	35.1% (25.2%, 44.9%)	35.1% (25.2%, 44.9%)	32.0% (25.9%, 38.1%)
				PsV Neutralization 80% Titer	38.6% (20.8%, 56.5%)	38.6% (20.8%, 56.5%)	35.6% (23.0%, 48.1%)
				WT LV Neutralization 50% Titer	32.5% (18.2%, 46.7%)	32.5% (18.2%, 46.7%)	25.8% (15.3%, 36.3%)
		Day 57	43	Binding Antibody to RBD	46.9% (31.9%, 61.8%)	46.9% (31.9%, 61.8%)	46.9% (31.9%, 61.8%)
				Binding Antibody to Spike	46.9% (31.9%, 61.8%)	46.9% (31.9%, 61.8%)	46.9% (31.9%, 61.8%)
				PsV Neutralization 50% Titer	43.2% (26.9%, 59.6%)	43.2% (26.9%, 59.6%)	39.7% (21.3%, 58.0%)
				PsV Neutralization 80% Titer	46.9% (31.9%, 61.8%)	46.9% (31.9%, 61.8%)	43.3% (26.9%, 59.7%)
				WT LV Neutralization 50% Titer	41.8% (28.1%, 55.5%)	41.8% (28.1%, 55.5%)	41.8% (28.1%, 55.5%)
	Positive	Day 29	38	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	68.1% (52.8%, 83.4%)	68.1% (52.8%, 83.4%)	50.0% (47.7%, 52.2%)
				PsV Neutralization 80% Titer	96.2% (89.1%, 103.3%)	96.2% (89.1%, 103.3%)	83.5% (76.7%, 90.2%)
				WT LV Neutralization 50% Titer	67.5% (54.2%, 80.7%)	67.5% (54.2%, 80.7%)	52.4% (29.9%, 74.9%)
		Day 57	38	Binding Antibody to RBD	100.0%	100.0%	100.0%

Table 2h. Responder rates by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
White Non-Hispanic	Negative	Day 29	456		(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	78.4%	78.4%	70.9%
					(62.2%, 94.5%)	(62.2%, 94.5%)	(50.6%, 91.3%)
				PsV Neutralization 80% Titer	93.8%	93.8%	93.8%
					(87.0%, 100.5%)	(87.0%, 100.5%)	(87.0%, 100.5%)
				WT LV Neutralization 50% Titer	92.3%	92.3%	92.3%
					(86.6%, 98.0%)	(86.6%, 98.0%)	(86.6%, 98.0%)
				Binding Antibody to RBD	52.3%	52.3%	52.3%
					(49.0%, 55.6%)	(49.0%, 55.6%)	(49.0%, 55.6%)
				Binding Antibody to Spike	52.3%	52.3%	52.3%
					(49.0%, 55.6%)	(49.0%, 55.6%)	(49.0%, 55.6%)
				PsV Neutralization 50% Titer	36.0%	36.0%	27.6%
					(29.5%, 42.4%)	(29.5%, 42.4%)	(20.7%, 34.5%)
				PsV Neutralization 80% Titer	42.1%	42.1%	36.8%
					(37.9%, 46.4%)	(37.9%, 46.4%)	(31.6%, 41.9%)
				WT LV Neutralization 50% Titer	37.9%	37.9%	30.5%
					(33.4%, 42.4%)	(33.4%, 42.4%)	(25.7%, 35.4%)
		Day 57	456	Binding Antibody to RBD	52.3%	52.3%	52.3%
					(49.0%, 55.6%)	(49.0%, 55.6%)	(49.0%, 55.6%)
				Binding Antibody to Spike	52.3%	52.3%	52.3%
					(49.0%, 55.6%)	(49.0%, 55.6%)	(49.0%, 55.6%)
				PsV Neutralization 50% Titer	50.4%	50.4%	48.3%
					(45.6%, 55.2%)	(45.6%, 55.2%)	(43.8%, 52.8%)
				PsV Neutralization 80% Titer	51.3%	51.3%	49.8%
					(47.9%, 54.7%)	(47.9%, 54.7%)	(46.8%, 52.7%)
				WT LV Neutralization 50% Titer	49.5%	49.5%	47.0%
					(45.9%, 53.2%)	(45.9%, 53.2%)	(43.4%, 50.5%)
	Positive	Day 29	224	Binding Antibody to RBD	100.0%	100.0%	99.7%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(99.1%, 100.4%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	65.2%	65.2%	48.9%
					(54.5%, 75.9%)	(54.5%, 75.9%)	(38.1%, 59.6%)

Table 2h. Responder rates by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
				PsV Neutralization 80% Titer	79.8% (76.2%, 83.4%)	79.8% (76.2%, 83.4%)	69.7% (63.4%, 76.0%)
				WT LV Neutralization 50% Titer	66.4% (58.7%, 74.1%)	66.4% (58.7%, 74.1%)	49.9% (40.1%, 59.6%)
		Day 57	224	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	91.8% (87.1%, 96.4%)	91.8% (87.1%, 96.4%)	86.8% (81.2%, 92.4%)
				PsV Neutralization 80% Titer	98.2% (97.4%, 98.9%)	98.2% (97.4%, 98.9%)	96.4% (95.7%, 97.0%)
				WT LV Neutralization 50% Titer	94.3% (91.7%, 96.9%)	94.3% (91.7%, 96.9%)	89.1% (85.5%, 92.7%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of quantification (LLOQ) with detectable ID50 neutralization titer above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in ID50.

Binding Antibody Responders are defined as participants who had baseline values below the LLOQ with detectable antibody concentration above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in antibody concentration.

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 2i. Responder rates by Race and ethnic group

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Race and ethnic group							
White Non-Hispanic	Negative	Day 29	456	Binding Antibody to RBD	52.3%	52.3%	52.3%
					(49.0%, 55.6%)	(49.0%, 55.6%)	(49.0%, 55.6%)
				Binding Antibody to Spike	52.3%	52.3%	52.3%
					(49.0%, 55.6%)	(49.0%, 55.6%)	(49.0%, 55.6%)
				PsV Neutralization 50% Titer	36.0%	36.0%	27.6%
					(29.5%, 42.4%)	(29.5%, 42.4%)	(20.7%, 34.5%)
				PsV Neutralization 80% Titer	42.1%	42.1%	36.8%
					(37.9%, 46.4%)	(37.9%, 46.4%)	(31.6%, 41.9%)
				WT LV Neutralization 50% Titer	37.9%	37.9%	30.5%
					(33.4%, 42.4%)	(33.4%, 42.4%)	(25.7%, 35.4%)
	Positive	Day 29	224	Binding Antibody to RBD	100.0%	100.0%	99.7%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(99.1%, 100.4%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	65.2%	65.2%	48.9%
					(54.5%, 75.9%)	(54.5%, 75.9%)	(38.1%, 59.6%)
				PsV Neutralization 80% Titer	79.8%	79.8%	69.7%
					(76.2%, 83.4%)	(76.2%, 83.4%)	(63.4%, 76.0%)
				WT LV Neutralization 50% Titer	66.4%	66.4%	49.9%
					(58.7%, 74.1%)	(58.7%, 74.1%)	(40.1%, 59.6%)
		Day 57	224	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%

Table 2i. Responder rates by Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Communities of Color	Negative	Day 29	535		(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	91.8%	91.8%	86.8%
					(87.1%, 96.4%)	(87.1%, 96.4%)	(81.2%, 92.4%)
				PsV Neutralization 80% Titer	98.2%	98.2%	96.4%
					(97.4%, 98.9%)	(97.4%, 98.9%)	(95.7%, 97.0%)
				WT LV Neutralization 50% Titer	94.3%	94.3%	89.1%
					(91.7%, 96.9%)	(91.7%, 96.9%)	(85.5%, 92.7%)
				Binding Antibody to RBD	51.0%	51.0%	51.0%
					(50.4%, 51.7%)	(50.4%, 51.7%)	(50.4%, 51.7%)
				Binding Antibody to Spike	51.0%	51.0%	51.0%
					(50.4%, 51.7%)	(50.4%, 51.7%)	(50.4%, 51.7%)
				PsV Neutralization 50% Titer	32.1%	32.1%	25.3%
					(26.0%, 38.2%)	(26.0%, 38.2%)	(18.3%, 32.2%)
				PsV Neutralization 80% Titer	40.4%	40.4%	34.1%
					(36.3%, 44.4%)	(36.3%, 44.4%)	(29.8%, 38.3%)
				WT LV Neutralization 50% Titer	34.6%	34.6%	25.6%
					(29.1%, 40.0%)	(29.1%, 40.0%)	(17.7%, 33.5%)
		Day 57	535	Binding Antibody to RBD	51.0%	51.0%	51.0%
					(50.4%, 51.7%)	(50.4%, 51.7%)	(50.4%, 51.7%)
				Binding Antibody to Spike	51.0%	51.0%	51.0%
					(50.4%, 51.7%)	(50.4%, 51.7%)	(50.4%, 51.7%)
				PsV Neutralization 50% Titer	48.4%	48.4%	45.3%
					(48.2%, 48.5%)	(48.2%, 48.5%)	(43.6%, 47.0%)
				PsV Neutralization 80% Titer	49.6%	49.6%	48.3%
					(49.1%, 50.0%)	(49.1%, 50.0%)	(47.3%, 49.3%)
				WT LV Neutralization 50% Titer	48.4%	48.4%	47.3%
					(47.5%, 49.3%)	(47.5%, 49.3%)	(46.7%, 47.8%)
	Positive	Day 29	261	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	61.8%	61.8%	41.6%
					(47.4%, 76.3%)	(47.4%, 76.3%)	(21.5%, 61.7%)
				PsV Neutralization 80% Titer	82.0%	82.0%	64.6%
					(74.7%, 89.3%)	(74.7%, 89.3%)	(50.2%, 79.0%)

Table 2i. Responder rates by Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
				WT LV Neutralization 50% Titer	64.9% (53.2%, 76.6%)	64.9% (53.2%, 76.6%)	51.0% (37.9%, 64.1%)
		Day 57	261	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	91.2% (86.8%, 95.7%)	91.2% (86.8%, 95.7%)	87.4% (82.1%, 92.8%)
				PsV Neutralization 80% Titer	98.7% (98.6%, 98.7%)	98.7% (98.6%, 98.7%)	95.2% (91.6%, 98.8%)
				WT LV Neutralization 50% Titer	93.6% (90.5%, 96.6%)	93.6% (90.5%, 96.6%)	85.5% (77.2%, 93.9%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of quantification (LLOQ) with detectable ID50 neutralization titer above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in ID50.

Binding Antibody Responders are defined as participants who had baseline values below the LLOQ with detectable antibody concentration above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in antibody concentration.

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 2j. Responder rates by Age, Race and ethnic group

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Age, Race and ethnic group Age < 65 Communities of Color	Negative	Day 29	253	Binding Antibody to RBD	51.3%	51.3%	51.3%
					(51.2%, 51.4%)	(51.2%, 51.4%)	(51.2%, 51.4%)
				Binding Antibody to Spike	51.3%	51.3%	51.3%
					(51.2%, 51.4%)	(51.2%, 51.4%)	(51.2%, 51.4%)
				PsV Neutralization 50% Titer	29.6%	29.6%	22.3%
					(29.4%, 29.7%)	(29.4%, 29.7%)	(21.1%, 23.5%)
				PsV Neutralization 80% Titer	38.6%	38.6%	32.3%
					(37.1%, 40.1%)	(37.1%, 40.1%)	(31.9%, 32.6%)
				WT LV Neutralization 50% Titer	32.3%	32.3%	22.7%
					(31.9%, 32.6%)	(31.9%, 32.6%)	(20.2%, 25.1%)
	Positive	Day 57	253	Binding Antibody to RBD	51.3%	51.3%	51.3%
					(51.2%, 51.4%)	(51.2%, 51.4%)	(51.2%, 51.4%)
				Binding Antibody to Spike	51.3%	51.3%	51.3%
					(51.2%, 51.4%)	(51.2%, 51.4%)	(51.2%, 51.4%)
				PsV Neutralization 50% Titer	48.3%	48.3%	44.6%
					(48.1%, 48.5%)	(48.1%, 48.5%)	(44.2%, 45.0%)
				PsV Neutralization 80% Titer	49.7%	49.7%	48.4%
					(49.6%, 49.9%)	(49.6%, 49.9%)	(47.1%, 49.6%)
				WT LV Neutralization 50% Titer	48.1%	48.1%	47.1%
					(47.4%, 48.8%)	(47.4%, 48.8%)	(46.4%, 47.8%)
	Positive	Day 29	148	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	56.4%	56.4%	34.2%
					(54.6%, 58.2%)	(54.6%, 58.2%)	(30.1%, 38.3%)
				PsV Neutralization 80% Titer	79.1%	79.1%	59.2%
					(73.5%, 84.7%)	(73.5%, 84.7%)	(56.7%, 61.8%)
				WT LV Neutralization 50% Titer	60.6%	60.6%	46.4%
					(58.3%, 62.9%)	(58.3%, 62.9%)	(42.4%, 50.4%)
	Positive	Day 57	148	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)

Table 2j. Responder rates by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Age < 65 White Non-Hispanic	Negative	Day 29	227	Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	89.6% (88.8%, 90.5%)	89.6% (88.8%, 90.5%)	85.4% (85.3%, 85.4%)
				PsV Neutralization 80% Titer	98.6% (98.6%, 98.7%)	98.6% (98.6%, 98.7%)	94.4% (91.5%, 97.4%)
				WT LV Neutralization 50% Titer	92.7% (91.0%, 94.3%)	92.7% (91.0%, 94.3%)	83.1% (78.5%, 87.7%)
				Binding Antibody to RBD	52.3% (48.1%, 56.4%)	52.3% (48.1%, 56.4%)	52.3% (48.1%, 56.4%)
				Binding Antibody to Spike	52.3% (48.1%, 56.4%)	52.3% (48.1%, 56.4%)	52.3% (48.1%, 56.4%)
				PsV Neutralization 50% Titer	33.8% (26.8%, 40.8%)	33.8% (26.8%, 40.8%)	24.8% (19.7%, 29.8%)
				PsV Neutralization 80% Titer	41.0% (35.7%, 46.2%)	41.0% (35.7%, 46.2%)	35.2% (29.2%, 41.3%)
				WT LV Neutralization 50% Titer	37.0% (31.2%, 42.8%)	37.0% (31.2%, 42.8%)	29.3% (23.3%, 35.3%)
		Day 57	227	Binding Antibody to RBD	52.3% (48.1%, 56.4%)	52.3% (48.1%, 56.4%)	52.3% (48.1%, 56.4%)
				Binding Antibody to Spike	52.3% (48.1%, 56.4%)	52.3% (48.1%, 56.4%)	52.3% (48.1%, 56.4%)
				PsV Neutralization 50% Titer	50.5% (44.5%, 56.5%)	50.5% (44.5%, 56.5%)	47.8% (41.9%, 53.7%)
				PsV Neutralization 80% Titer	51.1% (46.6%, 55.5%)	51.1% (46.6%, 55.5%)	49.1% (45.3%, 52.9%)
				WT LV Neutralization 50% Titer	49.3% (44.6%, 54.0%)	49.3% (44.6%, 54.0%)	46.6% (41.9%, 51.3%)
	Positive	Day 29	117	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	99.7% (98.8%, 100.5%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	61.0% (59.1%, 63.0%)	61.0% (59.1%, 63.0%)	44.8% (41.9%, 47.7%)

Table 2j. Responder rates by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Age >= 65 Communities of Color	Negative	Day 57	117	PsV Neutralization 80% Titer	78.4% (78.1%, 78.7%)	78.4% (78.1%, 78.7%)	67.1% (66.1%, 68.0%)
				WT LV Neutralization 50% Titer	63.1% (60.7%, 65.5%)	63.1% (60.7%, 65.5%)	45.8% (45.8%, 45.9%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	90.3% (87.7%, 92.9%)	90.3% (87.7%, 92.9%)	85.0% (82.0%, 88.0%)
				PsV Neutralization 80% Titer	97.9% (97.0%, 98.7%)	97.9% (97.0%, 98.7%)	96.1% (95.5%, 96.8%)
				WT LV Neutralization 50% Titer	93.5% (90.4%, 96.6%)	93.5% (90.4%, 96.6%)	87.6% (87.4%, 87.8%)
				Binding Antibody to RBD	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)
				Binding Antibody to Spike	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)
				PsV Neutralization 50% Titer	40.9% (40.9%, 40.9%)	40.9% (40.9%, 40.9%)	35.7% (35.7%, 35.7%)
	Day 57	282		PsV Neutralization 80% Titer	46.5% (46.5%, 46.5%)	46.5% (46.5%, 46.5%)	40.3% (40.3%, 40.3%)
				WT LV Neutralization 50% Titer	42.6% (42.6%, 42.6%)	42.6% (42.6%, 42.6%)	35.9% (35.9%, 35.9%)
				Binding Antibody to RBD	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)
				Binding Antibody to Spike	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)
				PsV Neutralization 50% Titer	48.6% (48.6%, 48.6%)	48.6% (48.6%, 48.6%)	47.6% (47.6%, 47.6%)
				PsV Neutralization 80% Titer	49.0% (49.0%, 49.0%)	49.0% (49.0%, 49.0%)	48.2% (48.2%, 48.2%)
				WT LV Neutralization 50% Titer	49.2% (49.2%, 49.2%)	49.2% (49.2%, 49.2%)	47.7% (47.7%, 47.7%)

Table 2j. Responder rates by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Age >= 65 White Non-Hispanic	Positive	Day 29	113	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	86.7% (86.7%, 86.7%)	86.7% (86.7%, 86.7%)	75.0% (75.0%, 75.0%)
				PsV Neutralization 80% Titer	95.1% (95.1%, 95.1%)	95.1% (95.1%, 95.1%)	88.9% (88.9%, 88.9%)
				WT LV Neutralization 50% Titer	84.4% (84.4%, 84.4%)	84.4% (84.4%, 84.4%)	71.9% (71.9%, 71.9%)
		Day 57	113	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	98.7% (98.7%, 98.7%)	98.7% (98.7%, 98.7%)	96.9% (96.9%, 96.9%)
				PsV Neutralization 80% Titer	98.7% (98.7%, 98.7%)	98.7% (98.7%, 98.7%)	98.7% (98.7%, 98.7%)
				WT LV Neutralization 50% Titer	97.8% (97.8%, 97.8%)	97.8% (97.8%, 97.8%)	96.9% (96.9%, 96.9%)
	Negative	Day 29	229	Binding Antibody to RBD	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)
				Binding Antibody to Spike	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)
				PsV Neutralization 50% Titer	44.6% (44.6%, 44.6%)	44.6% (44.6%, 44.6%)	38.7% (38.7%, 38.7%)
				PsV Neutralization 80% Titer	46.7% (46.7%, 46.7%)	46.7% (46.7%, 46.7%)	42.8% (42.8%, 42.8%)
				WT LV Neutralization 50% Titer	41.6% (41.6%, 41.6%)	41.6% (41.6%, 41.6%)	35.6% (35.6%, 35.6%)
		Day 57	229	Binding Antibody to RBD	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)
				Binding Antibody to Spike	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)

Table 2j. Responder rates by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	Responder	2-Fold Rise	4-Fold Rise
Positive	Day 29	107		PsV Neutralization 50% Titer	50.2% (50.2%, 50.2%)	50.2% (50.2%, 50.2%)	50.2% (50.2%, 50.2%)
				PsV Neutralization 80% Titer	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)
				WT LV Neutralization 50% Titer	50.2% (50.2%, 50.2%)	50.2% (50.2%, 50.2%)	48.3% (48.3%, 48.3%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	80.4% (80.4%, 80.4%)	80.4% (80.4%, 80.4%)	63.5% (63.5%, 63.5%)
				PsV Neutralization 80% Titer	85.0% (85.0%, 85.0%)	85.0% (85.0%, 85.0%)	79.4% (79.4%, 79.4%)
				WT LV Neutralization 50% Titer	78.5% (78.5%, 78.5%)	78.5% (78.5%, 78.5%)	64.5% (64.5%, 64.5%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
	Day 57	107		PsV Neutralization 50% Titer	97.2% (97.2%, 97.2%)	97.2% (97.2%, 97.2%)	93.5% (93.5%, 93.5%)
				PsV Neutralization 80% Titer	99.1% (99.1%, 99.1%)	99.1% (99.1%, 99.1%)	97.2% (97.2%, 97.2%)
				WT LV Neutralization 50% Titer	97.2% (97.2%, 97.2%)	97.2% (97.2%, 97.2%)	94.4% (94.4%, 94.4%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of quantification (LLOQ) with detectable ID50 neutralization titer above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in ID50.

Binding Antibody Responders are defined as participants who had baseline values below the LLOQ with detectable antibody concentration above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in antibody concentration.

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 3. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs)

Table 3a. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by All participants

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
All participants						
All participants	Negative	Day 1	1062	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	1062	Binding Antibody to RBD	710	(519, 972)
				Binding Antibody to Spike	980	(734, 1308)
				PsV Neutralization 50% Titer	56	(43, 73)
				PsV Neutralization 80% Titer	71	(57, 89)
				WT LV Neutralization 50% Titer	60	(50, 73)
		Day 57	1062	Binding Antibody to RBD	4920	(3704, 6536)
				Binding Antibody to Spike	7404	(5875, 9331)
				PsV Neutralization 50% Titer	225	(164, 309)
				PsV Neutralization 80% Titer	262	(208, 330)
				WT LV Neutralization 50% Titer	218	(167, 283)
	Positive	Day 1	543	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	543	Binding Antibody to RBD	22518	(11565, 43845)
				Binding Antibody to Spike	38849	(19937, 75698)
				PsV Neutralization 50% Titer	114	(65, 199)
				PsV Neutralization 80% Titer	229	(144, 364)
				WT LV Neutralization 50% Titer	130	(82, 204)
		Day 57	543	Binding Antibody to RBD	1121612	(554785, 2267569)
				Binding Antibody to Spike	2093735	(1075853, 4074650)
				PsV Neutralization 50% Titer	1667	(684, 4060)
				PsV Neutralization 80% Titer	3729	(2124, 6548)
				WT LV Neutralization 50% Titer	1860	(937, 3693)

Table 3a. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by All participants (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
-------	----------	-------	---	----------	---------	--------

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 3b. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Age

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Age						
Age < 65	Negative	Day 1	513	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	513	Binding Antibody to RBD	621	(583, 661)
				Binding Antibody to Spike	866	(807, 928)
				PsV Neutralization 50% Titer	50	(48, 53)
				PsV Neutralization 80% Titer	65	(60, 70)
				WT LV Neutralization 50% Titer	56	(53, 59)
		Day 57	513	Binding Antibody to RBD	4359	(4142, 4587)
				Binding Antibody to Spike	6698	(6169, 7271)
				PsV Neutralization 50% Titer	196	(183, 210)
				PsV Neutralization 80% Titer	237	(215, 261)
				WT LV Neutralization 50% Titer	195	(194, 197)
	Positive	Day 1	294	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	294	Binding Antibody to RBD	17204	(16849, 17567)
				Binding Antibody to Spike	29944	(28177, 31821)
				PsV Neutralization 50% Titer	92	(81, 105)
				PsV Neutralization 80% Titer	190	(188, 193)
				WT LV Neutralization 50% Titer	109	(103, 116)
		Day 57	294	Binding Antibody to RBD	849311	(818879, 880874)
				Binding Antibody to Spike	1610397	(1548171, 1675124)
				PsV Neutralization 50% Titer	1176	(1096, 1261)
				PsV Neutralization 80% Titer	2973	(2944, 3002)
				WT LV Neutralization 50% Titer	1419	(1364, 1478)
Age >= 65	Negative	Day 1	549	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)

Table 3b. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Age (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Positive		Day 29	549	PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	1154	(1154, 1154)
				Binding Antibody to Spike	1535	(1535, 1535)
				PsV Neutralization 50% Titer	85	(85, 85)
				PsV Neutralization 80% Titer	101	(101, 101)
		Day 57	549	WT LV Neutralization 50% Titer	81	(81, 81)
				Binding Antibody to RBD	7626	(7626, 7626)
				Binding Antibody to Spike	10643	(10643, 10643)
				PsV Neutralization 50% Titer	368	(368, 368)
				PsV Neutralization 80% Titer	377	(377, 377)
				WT LV Neutralization 50% Titer	322	(322, 322)
		Day 1	249	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	249	Binding Antibody to RBD	67301	(67301, 67301)
				Binding Antibody to Spike	112025	(112025, 112025)
				PsV Neutralization 50% Titer	265	(265, 265)
				PsV Neutralization 80% Titer	484	(484, 484)
				WT LV Neutralization 50% Titer	264	(264, 264)
		Day 57	249	Binding Antibody to RBD	3476290	(3476290, 3476290)
				Binding Antibody to Spike	6089580	(6089580, 6089580)
				PsV Neutralization 50% Titer	6890	(6890, 6890)
				PsV Neutralization 80% Titer	9374	(9374, 9374)
				WT LV Neutralization 50% Titer	5587	(5587, 5587)

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 3c. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Risk for Severe Covid-19

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Risk for Severe Covid-19						
At-risk	Negative	Day 1	541	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	21	(21, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	541	Binding Antibody to RBD	772	(409, 1457)
				Binding Antibody to Spike	1064	(567, 1997)
				PsV Neutralization 50% Titer	58	(38, 90)
				PsV Neutralization 80% Titer	71	(46, 111)
				WT LV Neutralization 50% Titer	61	(43, 87)
		Day 57	541	Binding Antibody to RBD	5511	(2925, 10383)
				Binding Antibody to Spike	7952	(4396, 14382)
				PsV Neutralization 50% Titer	233	(134, 404)
				PsV Neutralization 80% Titer	273	(154, 483)
				WT LV Neutralization 50% Titer	240	(153, 376)
	Positive	Day 1	246	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	21	(21, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	246	Binding Antibody to RBD	25128	(9811, 64355)
				Binding Antibody to Spike	46636	(20642, 105365)
				PsV Neutralization 50% Titer	139	(83, 234)
				PsV Neutralization 80% Titer	252	(138, 461)
				WT LV Neutralization 50% Titer	149	(89, 249)
		Day 57	246	Binding Antibody to RBD	1379449	(511168, 3722607)
				Binding Antibody to Spike	2471668	(1053363, 5799654)
				PsV Neutralization 50% Titer	2118	(693, 6480)
				PsV Neutralization 80% Titer	4084	(1906, 8751)
				WT LV Neutralization 50% Titer	2207	(915, 5322)
Not at-risk	Negative	Day 1	521	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	25	(24, 25)

Table 3c. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Positive		Day 29	521	PsV Neutralization 80% Titer	22	(21, 22)
				WT LV Neutralization 50% Titer	25	(24, 25)
				Binding Antibody to RBD	688	(548, 864)
				Binding Antibody to Spike	950	(783, 1152)
				PsV Neutralization 50% Titer	56	(44, 71)
				PsV Neutralization 80% Titer	71	(59, 86)
		Day 57	521	WT LV Neutralization 50% Titer	60	(51, 70)
				Binding Antibody to RBD	4716	(3972, 5600)
				Binding Antibody to Spike	7209	(6371, 8157)
				PsV Neutralization 50% Titer	222	(168, 293)
				PsV Neutralization 80% Titer	258	(224, 298)
				WT LV Neutralization 50% Titer	210	(172, 256)
	Positive	Day 1	297	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	297	Binding Antibody to RBD	21751	(11371, 41604)
				Binding Antibody to Spike	36669	(19265, 69796)
				PsV Neutralization 50% Titer	106	(62, 184)
				PsV Neutralization 80% Titer	222	(141, 349)
				WT LV Neutralization 50% Titer	124	(80, 193)
		Day 57	297	Binding Antibody to RBD	1050607	(550223, 2006049)
				Binding Antibody to Spike	1986752	(1045274, 3776220)
				PsV Neutralization 50% Titer	1545	(657, 3634)
				PsV Neutralization 80% Titer	3624	(2079, 6316)
				WT LV Neutralization 50% Titer	1762	(910, 3413)

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 3d. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Age, Risk for Severe Covid-19

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Age, Risk for Severe Covid-19						
Age < 65 At-risk	Negative	Day 1	257	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 25)
				PsV Neutralization 80% Titer	21	(21, 22)
				WT LV Neutralization 50% Titer	24	(24, 25)
		Day 29	257	Binding Antibody to RBD	568	(568, 568)
				Binding Antibody to Spike	786	(786, 786)
				PsV Neutralization 50% Titer	47	(47, 47)
				PsV Neutralization 80% Titer	58	(58, 58)
				WT LV Neutralization 50% Titer	52	(52, 52)
		Day 57	257	Binding Antibody to RBD	4061	(4061, 4061)
				Binding Antibody to Spike	5975	(5975, 5975)
				PsV Neutralization 50% Titer	179	(179, 179)
				PsV Neutralization 80% Titer	207	(207, 207)
				WT LV Neutralization 50% Titer	193	(193, 193)
	Positive	Day 1	148	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	21	(21, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	148	Binding Antibody to RBD	16690	(16690, 16690)
				Binding Antibody to Spike	32712	(32712, 32712)
				PsV Neutralization 50% Titer	111	(111, 111)
				PsV Neutralization 80% Titer	194	(194, 194)
				WT LV Neutralization 50% Titer	119	(119, 119)
		Day 57	148	Binding Antibody to RBD	895596	(895596, 895596)
				Binding Antibody to Spike	1705379	(1705379, 1705379)
				PsV Neutralization 50% Titer	1302	(1302, 1302)
				PsV Neutralization 80% Titer	2931	(2931, 2931)
				WT LV Neutralization 50% Titer	1505	(1505, 1505)
Age < 65 Not at-risk	Negative	Day 1	256	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)

Table 3d. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Age, Risk for Severe Covid-19 *(continued)*

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Age >= 65 At-risk	Positive	Day 29	256	PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	636	(636, 636)
				Binding Antibody to Spike	888	(888, 888)
				PsV Neutralization 50% Titer	51	(51, 51)
				PsV Neutralization 80% Titer	67	(67, 67)
		Day 57	256	WT LV Neutralization 50% Titer	57	(57, 57)
				Binding Antibody to RBD	4443	(4443, 4443)
				Binding Antibody to Spike	6906	(6906, 6906)
				PsV Neutralization 50% Titer	201	(201, 201)
				PsV Neutralization 80% Titer	246	(246, 246)
				WT LV Neutralization 50% Titer	196	(196, 196)
		Day 1	146	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	146	Binding Antibody to RBD	17337	(17337, 17337)
				Binding Antibody to Spike	29279	(29279, 29279)
				PsV Neutralization 50% Titer	88	(88, 88)
				PsV Neutralization 80% Titer	190	(190, 190)
				WT LV Neutralization 50% Titer	107	(107, 107)
		Day 57	146	Binding Antibody to RBD	837940	(837940, 837940)
				Binding Antibody to Spike	1587125	(1587125, 1587125)
				PsV Neutralization 50% Titer	1145	(1145, 1145)
				PsV Neutralization 80% Titer	2984	(2984, 2984)
				WT LV Neutralization 50% Titer	1399	(1399, 1399)
	Negative	Day 1	284	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 25)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 25)
		Day 29	284	Binding Antibody to RBD	1248	(1248, 1248)
				Binding Antibody to Spike	1714	(1714, 1714)
				PsV Neutralization 50% Titer	81	(81, 81)

Table 3d. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Age, Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Age >= 65 Not at-risk	Positive	Day 57	284	PsV Neutralization 80% Titer	99	(99, 99)
				WT LV Neutralization 50% Titer	80	(80, 80)
				Binding Antibody to RBD	8902	(8902, 8902)
				Binding Antibody to Spike	12453	(12453, 12453)
				PsV Neutralization 50% Titer	354	(354, 354)
				PsV Neutralization 80% Titer	421	(421, 421)
		Day 1	98	WT LV Neutralization 50% Titer	337	(337, 337)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	98	Binding Antibody to RBD	59244	(59244, 59244)
				Binding Antibody to Spike	98073	(98073, 98073)
				PsV Neutralization 50% Titer	223	(223, 223)
				PsV Neutralization 80% Titer	437	(437, 437)
				WT LV Neutralization 50% Titer	238	(238, 238)
		Day 57	98	Binding Antibody to RBD	3411234	(3411234, 3411234)
				Binding Antibody to Spike	5380342	(5380342, 5380342)
				PsV Neutralization 50% Titer	5873	(5873, 5873)
				PsV Neutralization 80% Titer	8184	(8184, 8184)
				WT LV Neutralization 50% Titer	4925	(4925, 4925)
	Negative	Day 1	265	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	265	Binding Antibody to RBD	1071	(1071, 1071)
				Binding Antibody to Spike	1381	(1381, 1381)
				PsV Neutralization 50% Titer	88	(88, 88)
				PsV Neutralization 80% Titer	102	(102, 102)
				WT LV Neutralization 50% Titer	82	(82, 82)
		Day 57	265	Binding Antibody to RBD	6578	(6578, 6578)
				Binding Antibody to Spike	9159	(9159, 9159)
				PsV Neutralization 50% Titer	381	(381, 381)

Table 3d. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Age, Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
	Positive	Day 1	151	PsV Neutralization 80% Titer	340	(340, 340)
				WT LV Neutralization 50% Titer	309	(309, 309)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
		Day 29	151	WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	73095	(73095, 73095)
				Binding Antibody to Spike	122104	(122104, 122104)
				PsV Neutralization 50% Titer	296	(296, 296)
				PsV Neutralization 80% Titer	518	(518, 518)
				WT LV Neutralization 50% Titer	282	(282, 282)
		Day 57	151	Binding Antibody to RBD	3519087	(3519087, 3519087)
				Binding Antibody to Spike	6598095	(6598095, 6598095)
				PsV Neutralization 50% Titer	7640	(7640, 7640)
				PsV Neutralization 80% Titer	10236	(10236, 10236)
				WT LV Neutralization 50% Titer	6063	(6063, 6063)

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 3e. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Sex

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Sex						
Female	Negative	Day 1	597	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	597	Binding Antibody to RBD	709	(444, 1130)
				Binding Antibody to Spike	1035	(669, 1600)
				PsV Neutralization 50% Titer	56	(42, 75)
				PsV Neutralization 80% Titer	71	(55, 92)
				WT LV Neutralization 50% Titer	59	(46, 75)
		Day 57	597	Binding Antibody to RBD	5318	(3348, 8447)
				Binding Antibody to Spike	7885	(5029, 12364)
				PsV Neutralization 50% Titer	218	(141, 336)
				PsV Neutralization 80% Titer	270	(197, 370)
				WT LV Neutralization 50% Titer	216	(154, 303)
	Positive	Day 1	298	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	298	Binding Antibody to RBD	21344	(11314, 40266)
				Binding Antibody to Spike	35351	(18851, 66296)
				PsV Neutralization 50% Titer	114	(76, 173)
				PsV Neutralization 80% Titer	232	(174, 308)
				WT LV Neutralization 50% Titer	130	(91, 184)
		Day 57	298	Binding Antibody to RBD	1088093	(563091, 2102585)
				Binding Antibody to Spike	2055696	(1108039, 3813843)
				PsV Neutralization 50% Titer	1625	(707, 3737)
				PsV Neutralization 80% Titer	3633	(2141, 6166)
				WT LV Neutralization 50% Titer	1686	(836, 3400)
Male	Negative	Day 1	465	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)

Table 3e. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Sex (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Positive		Day 29	465	PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	712	(608, 833)
				Binding Antibody to Spike	915	(776, 1079)
				PsV Neutralization 50% Titer	57	(45, 73)
				PsV Neutralization 80% Titer	72	(61, 86)
		Day 57	465	WT LV Neutralization 50% Titer	62	(55, 70)
				Binding Antibody to RBD	4462	(3734, 5331)
				Binding Antibody to Spike	6840	(6131, 7630)
				PsV Neutralization 50% Titer	234	(197, 278)
				PsV Neutralization 80% Titer	253	(222, 288)
				WT LV Neutralization 50% Titer	220	(186, 259)
		Day 1	245	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	21	(21, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	245	Binding Antibody to RBD	24168	(11963, 48828)
				Binding Antibody to Spike	44003	(21757, 88994)
				PsV Neutralization 50% Titer	112	(52, 245)
				PsV Neutralization 80% Titer	225	(110, 463)
				WT LV Neutralization 50% Titer	130	(71, 236)
		Day 57	245	Binding Antibody to RBD	1167467	(529122, 2575928)
				Binding Antibody to Spike	2145054	(1017360, 4522739)
				PsV Neutralization 50% Titer	1723	(622, 4773)
				PsV Neutralization 80% Titer	3860	(1840, 8097)
				WT LV Neutralization 50% Titer	2118	(1045, 4296)

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 3f. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Age, sex

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Age, sex						
Age < 65 Female	Negative	Day 1	291	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	291	Binding Antibody to RBD	580	(486, 693)
				Binding Antibody to Spike	859	(693, 1065)
				PsV Neutralization 50% Titer	49	(45, 54)
				PsV Neutralization 80% Titer	63	(57, 71)
				WT LV Neutralization 50% Titer	53	(51, 55)
		Day 57	291	Binding Antibody to RBD	4367	(3439, 5544)
				Binding Antibody to Spike	6517	(5033, 8440)
				PsV Neutralization 50% Titer	181	(161, 203)
				PsV Neutralization 80% Titer	236	(206, 271)
				WT LV Neutralization 50% Titer	188	(187, 189)
	Positive	Day 1	166	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	166	Binding Antibody to RBD	16504	(15130, 18001)
				Binding Antibody to Spike	27611	(27530, 27692)
				PsV Neutralization 50% Titer	97	(95, 99)
				PsV Neutralization 80% Titer	206	(187, 226)
				WT LV Neutralization 50% Titer	113	(108, 117)
		Day 57	166	Binding Antibody to RBD	830284	(720090, 957340)
				Binding Antibody to Spike	1598560	(1447108, 1765863)
				PsV Neutralization 50% Titer	1154	(952, 1398)
				PsV Neutralization 80% Titer	2920	(2118, 4025)
				WT LV Neutralization 50% Titer	1261	(1042, 1527)
Age < 65 Male	Negative	Day 1	222	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)

Table 3f. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Age >= 65 Female	Positive	Day 29	222	PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	677	(617, 744)
				Binding Antibody to Spike	874	(775, 985)
				PsV Neutralization 50% Titer	52	(50, 53)
				PsV Neutralization 80% Titer	67	(64, 70)
				WT LV Neutralization 50% Titer	59	(56, 63)
				Binding Antibody to RBD	4349	(3586, 5275)
				Binding Antibody to Spike	6940	(5969, 8067)
				PsV Neutralization 50% Titer	218	(216, 219)
		Day 57	222	PsV Neutralization 80% Titer	238	(228, 249)
				WT LV Neutralization 50% Titer	205	(204, 206)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	21	(21, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	18213	(17099, 19399)
				Binding Antibody to Spike	33464	(29222, 38320)
				PsV Neutralization 50% Titer	86	(61, 122)
		Day 29	128	PsV Neutralization 80% Titer	171	(144, 204)
				WT LV Neutralization 50% Titer	104	(85, 127)
				Binding Antibody to RBD	876095	(663403, 1156978)
				Binding Antibody to Spike	1626759	(1294251, 2044693)
				PsV Neutralization 50% Titer	1206	(787, 1850)
				PsV Neutralization 80% Titer	3047	(2015, 4609)
				WT LV Neutralization 50% Titer	1669	(1190, 2340)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
		Day 1	306	PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	1535	(1535, 1535)
				Binding Antibody to Spike	2126	(2126, 2126)
				PsV Neutralization 50% Titer	90	(90, 90)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	1535	(1535, 1535)
				Binding Antibody to Spike	2126	(2126, 2126)
				PsV Neutralization 50% Titer	90	(90, 90)
	Negative	Day 1	306	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	1535	(1535, 1535)
				Binding Antibody to Spike	2126	(2126, 2126)
				PsV Neutralization 50% Titer	90	(90, 90)
				Binding Antibody to RBD	1535	(1535, 1535)
				Binding Antibody to Spike	2126	(2126, 2126)
				PsV Neutralization 50% Titer	90	(90, 90)

Table 3f. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Age >= 65 Male	Positive	Day 57	306	PsV Neutralization 80% Titer	109	(109, 109)
				WT LV Neutralization 50% Titer	87	(87, 87)
				Binding Antibody to RBD	11412	(11412, 11412)
				Binding Antibody to Spike	16492	(16492, 16492)
				PsV Neutralization 50% Titer	445	(445, 445)
				PsV Neutralization 80% Titer	455	(455, 455)
		Day 1	132	WT LV Neutralization 50% Titer	369	(369, 369)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	25	(24, 25)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	25	(24, 25)
		Day 29	132	Binding Antibody to RBD	66473	(66473, 66473)
				Binding Antibody to Spike	105315	(105315, 105315)
				PsV Neutralization 50% Titer	238	(238, 238)
				PsV Neutralization 80% Titer	391	(391, 391)
				WT LV Neutralization 50% Titer	242	(242, 242)
				Binding Antibody to RBD	3592671	(3592671, 3592671)
		Day 57	132	Binding Antibody to Spike	6243753	(6243753, 6243753)
				PsV Neutralization 50% Titer	7379	(7379, 7379)
				PsV Neutralization 80% Titer	9539	(9539, 9539)
				WT LV Neutralization 50% Titer	6070	(6070, 6070)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
	Negative	Day 1	243	PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(21, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	839	(839, 839)
				Binding Antibody to Spike	1065	(1065, 1065)
				PsV Neutralization 50% Titer	79	(79, 79)
		Day 29	243	PsV Neutralization 80% Titer	93	(93, 93)
				WT LV Neutralization 50% Titer	75	(75, 75)
				Binding Antibody to RBD	4856	(4856, 4856)
				Binding Antibody to Spike	6517	(6517, 6517)
				PsV Neutralization 50% Titer	297	(297, 297)

Table 3f. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
	Positive	Day 1	117	PsV Neutralization 80% Titer	306	(306, 306)
				WT LV Neutralization 50% Titer	277	(277, 277)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
		Day 29	117	WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	68256	(68256, 68256)
				Binding Antibody to Spike	120187	(120187, 120187)
				PsV Neutralization 50% Titer	300	(300, 300)
				PsV Neutralization 80% Titer	618	(618, 618)
				WT LV Neutralization 50% Titer	291	(291, 291)
		Day 57	117	Binding Antibody to RBD	3348376	(3348376, 3348376)
				Binding Antibody to Spike	5918688	(5918688, 5918688)
				PsV Neutralization 50% Titer	6372	(6372, 6372)
				PsV Neutralization 80% Titer	9190	(9190, 9190)
				WT LV Neutralization 50% Titer	5084	(5084, 5084)

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 3g. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Hispanic or Latino ethnicity

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Hispanic or Latino ethnicity						
Hispanic or Latino	Negative	Day 1	125	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	125	Binding Antibody to RBD	473	(143, 1562)
				Binding Antibody to Spike	649	(201, 2095)
				PsV Neutralization 50% Titer	49	(29, 82)
				PsV Neutralization 80% Titer	60	(39, 94)
				WT LV Neutralization 50% Titer	49	(32, 76)
		Day 57	125	Binding Antibody to RBD	2692	(606, 11960)
				Binding Antibody to Spike	3953	(877, 17830)
				PsV Neutralization 50% Titer	182	(81, 412)
				PsV Neutralization 80% Titer	163	(60, 442)
				WT LV Neutralization 50% Titer	166	(79, 349)
	Positive	Day 1	77	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	77	Binding Antibody to RBD	25228	(15622, 40742)
				Binding Antibody to Spike	40480	(26316, 62267)
				PsV Neutralization 50% Titer	116	(74, 180)
				PsV Neutralization 80% Titer	195	(127, 299)
				WT LV Neutralization 50% Titer	122	(90, 165)
		Day 57	77	Binding Antibody to RBD	1406789	(887933, 2228833)
				Binding Antibody to Spike	2253681	(1635109, 3106262)
				PsV Neutralization 50% Titer	1804	(823, 3952)
				PsV Neutralization 80% Titer	3291	(2053, 5274)
				WT LV Neutralization 50% Titer	1401	(839, 2338)
Not Hispanic or Latino	Negative	Day 1	844	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)

Table 3g. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Hispanic or Latino ethnicity (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Not reported and unknown	Positive	Day 29	844	PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	829	(558, 1232)
				Binding Antibody to Spike	1151	(766, 1729)
				PsV Neutralization 50% Titer	59	(45, 76)
				PsV Neutralization 80% Titer	75	(59, 94)
		Day 57	844	WT LV Neutralization 50% Titer	64	(53, 76)
				Binding Antibody to RBD	6176	(3811, 10006)
				Binding Antibody to Spike	9216	(5525, 15375)
				PsV Neutralization 50% Titer	246	(178, 339)
				PsV Neutralization 80% Titer	302	(221, 412)
				WT LV Neutralization 50% Titer	242	(183, 320)
		Day 1	406	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	406	Binding Antibody to RBD	22511	(11096, 45669)
				Binding Antibody to Spike	40073	(19985, 80351)
				PsV Neutralization 50% Titer	117	(66, 209)
				PsV Neutralization 80% Titer	234	(147, 372)
				WT LV Neutralization 50% Titer	130	(82, 207)
		Day 57	406	Binding Antibody to RBD	1126522	(534243, 2375422)
				Binding Antibody to Spike	2008825	(947771, 4257755)
				PsV Neutralization 50% Titer	1737	(716, 4210)
				PsV Neutralization 80% Titer	4086	(2441, 6842)
				WT LV Neutralization 50% Titer	2088	(1100, 3963)
		Day 1	93	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	21	(21, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	93	Binding Antibody to RBD	344	(121, 973)
				Binding Antibody to Spike	458	(154, 1365)
				PsV Neutralization 50% Titer	50	(39, 64)

Table 3g. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Hispanic or Latino ethnicity (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
		Day 57	93	PsV Neutralization 80% Titer	62	(44, 88)
				WT LV Neutralization 50% Titer	52	(39, 69)
				Binding Antibody to RBD	1718	(343, 8612)
				Binding Antibody to Spike	2820	(563, 14126)
				PsV Neutralization 50% Titer	144	(74, 278)
				PsV Neutralization 80% Titer	152	(75, 309)
	Positive	Day 1	60	WT LV Neutralization 50% Titer	131	(60, 284)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	60	Binding Antibody to RBD	18889	(7792, 45786)
				Binding Antibody to Spike	29395	(10756, 80338)
				PsV Neutralization 50% Titer	89	(43, 182)
				PsV Neutralization 80% Titer	252	(159, 401)
				WT LV Neutralization 50% Titer	138	(76, 254)
		Day 57	60	Binding Antibody to RBD	763217	(198080, 2940730)
				Binding Antibody to Spike	2483841	(1136604, 5427981)
				PsV Neutralization 50% Titer	1107	(324, 3779)
				PsV Neutralization 80% Titer	2411	(749, 7761)
				WT LV Neutralization 50% Titer	1304	(400, 4257)

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 3h. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Race

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Race						
Not reported and unknown	Negative	Day 1	98	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	98	Binding Antibody to RBD	581	(363, 930)
				Binding Antibody to Spike	872	(489, 1554)
				PsV Neutralization 50% Titer	53	(41, 69)
				PsV Neutralization 80% Titer	73	(57, 93)
				WT LV Neutralization 50% Titer	60	(50, 71)
		Day 57	98	Binding Antibody to RBD	4022	(1969, 8216)
				Binding Antibody to Spike	5174	(2471, 10833)
				PsV Neutralization 50% Titer	229	(148, 353)
				PsV Neutralization 80% Titer	282	(160, 496)
				WT LV Neutralization 50% Titer	217	(146, 322)
	Positive	Day 1	48	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	48	Binding Antibody to RBD	24917	(11427, 54333)
				Binding Antibody to Spike	48777	(19856, 119822)
				PsV Neutralization 50% Titer	133	(55, 325)
				PsV Neutralization 80% Titer	286	(138, 592)
				WT LV Neutralization 50% Titer	151	(70, 324)
		Day 57	48	Binding Antibody to RBD	1324463	(507048, 3459634)
				Binding Antibody to Spike	2026513	(766324, 5359030)
				PsV Neutralization 50% Titer	2993	(993, 9019)
				PsV Neutralization 80% Titer	3099	(980, 9798)
				WT LV Neutralization 50% Titer	1877	(366, 9636)
American Indian or Alaska Native	Negative	Day 1	27	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)

Table 3h. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Asian	Positive	Day 29	27	PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	489	(281, 853)
				Binding Antibody to Spike	837	(492, 1425)
				PsV Neutralization 50% Titer	55	(37, 83)
				PsV Neutralization 80% Titer	58	(35, 98)
				WT LV Neutralization 50% Titer	45	(27, 73)
				Binding Antibody to RBD	3672	(2068, 6521)
				Binding Antibody to Spike	5261	(2606, 10621)
				PsV Neutralization 50% Titer	272	(207, 358)
				PsV Neutralization 80% Titer	247	(218, 279)
		Day 57	27	WT LV Neutralization 50% Titer	245	(149, 402)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	53675	(28935, 99568)
				Binding Antibody to Spike	70892	(39368, 127660)
				PsV Neutralization 50% Titer	115	(83, 160)
				PsV Neutralization 80% Titer	213	(104, 438)
				WT LV Neutralization 50% Titer	163	(97, 274)
				Binding Antibody to RBD	1414836	(664878, 3010719)
				Binding Antibody to Spike	5729584	(3126394, 10500318)
		Day 29	17	PsV Neutralization 50% Titer	2916	(1092, 7787)
				PsV Neutralization 80% Titer	5446	(2440, 12157)
				WT LV Neutralization 50% Titer	2680	(1773, 4053)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	1127	(734, 1730)
				Binding Antibody to Spike	1586	(1012, 2483)
		Day 57	17	PsV Neutralization 50% Titer	2916	(1092, 7787)
				PsV Neutralization 80% Titer	5446	(2440, 12157)
				WT LV Neutralization 50% Titer	2680	(1773, 4053)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	1127	(734, 1730)
				Binding Antibody to Spike	1586	(1012, 2483)
		Day 1	84	PsV Neutralization 50% Titer	2916	(1092, 7787)
				PsV Neutralization 80% Titer	5446	(2440, 12157)
				WT LV Neutralization 50% Titer	2680	(1773, 4053)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	1127	(734, 1730)
				Binding Antibody to Spike	1586	(1012, 2483)
		Day 29	84	PsV Neutralization 50% Titer	2916	(1092, 7787)
				PsV Neutralization 80% Titer	5446	(2440, 12157)
				WT LV Neutralization 50% Titer	2680	(1773, 4053)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	1127	(734, 1730)
				Binding Antibody to Spike	1586	(1012, 2483)
		Day 57	84	PsV Neutralization 50% Titer	2916	(1092, 7787)
				PsV Neutralization 80% Titer	5446	(2440, 12157)
				WT LV Neutralization 50% Titer	2680	(1773, 4053)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	1127	(734, 1730)
				Binding Antibody to Spike	1586	(1012, 2483)
		Day 1	84	PsV Neutralization 50% Titer	2916	(1092, 7787)
				PsV Neutralization 80% Titer	5446	(2440, 12157)
				WT LV Neutralization 50% Titer	2680	(1773, 4053)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	1127	(734, 1730)
				Binding Antibody to Spike	1586	(1012, 2483)

Table 3h. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Black or African American	Positive	Day 57	84	PsV Neutralization 50% Titer	63	(57, 69)
				PsV Neutralization 80% Titer	92	(85, 99)
				WT LV Neutralization 50% Titer	69	(57, 85)
				Binding Antibody to RBD	7935	(4075, 15451)
				Binding Antibody to Spike	16151	(6122, 42606)
				PsV Neutralization 50% Titer	403	(271, 601)
		Day 1	46	PsV Neutralization 80% Titer	374	(271, 515)
				WT LV Neutralization 50% Titer	246	(206, 293)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
		Day 29	46	WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	11604	(1986, 67801)
				Binding Antibody to Spike	36553	(11539, 115790)
				PsV Neutralization 50% Titer	87	(23, 332)
				PsV Neutralization 80% Titer	149	(50, 443)
				WT LV Neutralization 50% Titer	105	(43, 256)
		Day 57	46	Binding Antibody to RBD	521177	(99485, 2730321)
				Binding Antibody to Spike	1751796	(658687, 4658952)
				PsV Neutralization 50% Titer	1290	(245, 6803)
				PsV Neutralization 80% Titer	2186	(440, 10849)
				WT LV Neutralization 50% Titer	1051	(196, 5650)
	Negative	Day 1	216	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	216	Binding Antibody to RBD	675	(424, 1075)
				Binding Antibody to Spike	902	(560, 1452)
				PsV Neutralization 50% Titer	56	(44, 72)
				PsV Neutralization 80% Titer	66	(50, 87)
				WT LV Neutralization 50% Titer	57	(42, 76)
		Day 57	216	Binding Antibody to RBD	4862	(3135, 7541)
				Binding Antibody to Spike	7068	(4604, 10852)

Table 3h. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Multiracial	Positive	Day 1	91	PsV Neutralization 50% Titer	208	(121, 358)
				PsV Neutralization 80% Titer	241	(172, 339)
				WT LV Neutralization 50% Titer	201	(131, 307)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
		Day 29	91	PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	22144	(12777, 38378)
				Binding Antibody to Spike	27285	(15963, 46636)
				PsV Neutralization 50% Titer	107	(71, 162)
				PsV Neutralization 80% Titer	229	(147, 355)
		Day 57	91	WT LV Neutralization 50% Titer	132	(99, 176)
				Binding Antibody to RBD	947243	(484619, 1851494)
				Binding Antibody to Spike	1416171	(718842, 2789959)
				PsV Neutralization 50% Titer	1610	(914, 2835)
				PsV Neutralization 80% Titer	3220	(2243, 4623)
				WT LV Neutralization 50% Titer	2268	(1309, 3928)
	Negative	Day 1	62	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	62	Binding Antibody to RBD	219	(55, 880)
				Binding Antibody to Spike	292	(70, 1215)
				PsV Neutralization 50% Titer	39	(21, 70)
				PsV Neutralization 80% Titer	53	(33, 84)
				WT LV Neutralization 50% Titer	48	(34, 66)
		Day 57	62	Binding Antibody to RBD	935	(161, 5430)
				Binding Antibody to Spike	1322	(220, 7934)
				PsV Neutralization 50% Titer	113	(47, 271)
				PsV Neutralization 80% Titer	100	(34, 290)
				WT LV Neutralization 50% Titer	98	(43, 224)
	Positive	Day 1	28	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)

Table 3h. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Native Hawaiian or Other Pacific Islander	Negative	Day 29	28	PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	37228	(22768, 60869)
				Binding Antibody to Spike	47446	(33239, 67725)
				PsV Neutralization 50% Titer	150	(122, 184)
		Day 57	28	PsV Neutralization 80% Titer	327	(220, 486)
				WT LV Neutralization 50% Titer	189	(138, 261)
				Binding Antibody to RBD	2288360	(1624482, 3223544)
				Binding Antibody to Spike	2986566	(2024450, 4405926)
				PsV Neutralization 50% Titer	1831	(716, 4679)
				PsV Neutralization 80% Titer	8243	(5678, 11967)
		Day 1	20	WT LV Neutralization 50% Titer	2578	(1664, 3996)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	20	Binding Antibody to RBD	2765	(126, 60560)
				Binding Antibody to Spike	3844	(109, 136137)
				PsV Neutralization 50% Titer	79	(48, 131)
				PsV Neutralization 80% Titer	179	(28, 1143)
				WT LV Neutralization 50% Titer	126	(36, 438)
		Day 57	20	Binding Antibody to RBD	26198	(243, 2820301)
				Binding Antibody to Spike	51105	(184, 14167891)
				PsV Neutralization 50% Titer	501	(55, 4556)
				PsV Neutralization 80% Titer	936	(81, 10851)
				WT LV Neutralization 50% Titer	1027	(50, 21122)
	Positive	Day 1	7	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	33785	(16618, 68685)

Table 3h. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Other	Negative	Day 57	7	Binding Antibody to Spike	67752	(19638, 233748)
				PsV Neutralization 50% Titer	99	(46, 215)
				PsV Neutralization 80% Titer	391	(214, 717)
				WT LV Neutralization 50% Titer	188	(98, 361)
				Binding Antibody to RBD	1775012	(399615, 7884248)
				Binding Antibody to Spike	2028355	(382922, 10744284)
				PsV Neutralization 50% Titer	798	(36, 17442)
				PsV Neutralization 80% Titer	24331	(8035, 73681)
		Day 1	28	WT LV Neutralization 50% Titer	4580	(669, 31353)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	28	Binding Antibody to RBD	6240	(1066, 36536)
				Binding Antibody to Spike	8282	(1239, 55366)
				PsV Neutralization 50% Titer	103	(89, 120)
				PsV Neutralization 80% Titer	102	(50, 208)
				WT LV Neutralization 50% Titer	78	(46, 131)
		Day 57	28	Binding Antibody to RBD	104179	(8316, 1305121)
				Binding Antibody to Spike	218582	(8040, 5942461)
				PsV Neutralization 50% Titer	855	(480, 1523)
				PsV Neutralization 80% Titer	620	(438, 878)
				WT LV Neutralization 50% Titer	559	(285, 1097)
	Positive	Day 1	24	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	24	Binding Antibody to RBD	17239	(10830, 27441)
				Binding Antibody to Spike	43958	(38445, 50261)
				PsV Neutralization 50% Titer	101	(51, 201)
				PsV Neutralization 80% Titer	142	(80, 252)
				WT LV Neutralization 50% Titer	87	(52, 147)
		Day 57	24	Binding Antibody to RBD	796059	(550867, 1150386)

Table 3h. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
White	Negative	Day 1	43	Binding Antibody to Spike	2208253	(1837646, 2653603)
				PsV Neutralization 50% Titer	1882	(885, 4003)
				PsV Neutralization 80% Titer	2714	(1112, 6624)
				WT LV Neutralization 50% Titer	579	(206, 1623)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
		Day 29	43	WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	462	(166, 1288)
				Binding Antibody to Spike	680	(225, 2052)
				PsV Neutralization 50% Titer	62	(55, 71)
				PsV Neutralization 80% Titer	77	(56, 106)
				WT LV Neutralization 50% Titer	57	(46, 70)
		Day 57	43	Binding Antibody to RBD	3224	(573, 18135)
				Binding Antibody to Spike	5545	(975, 31541)
				PsV Neutralization 50% Titer	153	(69, 339)
				PsV Neutralization 80% Titer	174	(68, 444)
				WT LV Neutralization 50% Titer	176	(79, 392)
	Positive	Day 1	38	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	38	Binding Antibody to RBD	21524	(7871, 58859)
				Binding Antibody to Spike	32737	(11009, 97346)
				PsV Neutralization 50% Titer	113	(62, 205)
				PsV Neutralization 80% Titer	280	(168, 464)
				WT LV Neutralization 50% Titer	154	(80, 298)
		Day 57	38	Binding Antibody to RBD	900133	(270431, 2996097)
				Binding Antibody to Spike	2852744	(1216749, 6688435)
				PsV Neutralization 50% Titer	1186	(284, 4949)
				PsV Neutralization 80% Titer	2820	(744, 10683)
				WT LV Neutralization 50% Titer	1924	(667, 5545)
White Non-Hispanic	Negative	Day 1	456	Binding Antibody to RBD	17	(17, 17)

Table 3h. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	817	(550, 1214)
				Binding Antibody to Spike	1098	(736, 1636)
				PsV Neutralization 50% Titer	58	(43, 77)
				PsV Neutralization 80% Titer	72	(57, 91)
				WT LV Neutralization 50% Titer	64	(54, 75)
				Binding Antibody to RBD	5747	(3647, 9056)
				Binding Antibody to Spike	8494	(5281, 13661)
				PsV Neutralization 50% Titer	229	(164, 319)
				PsV Neutralization 80% Titer	296	(219, 401)
				WT LV Neutralization 50% Titer	233	(186, 293)
	Positive	Day 1	224	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	21386	(10646, 42962)
		Day 29	224	Binding Antibody to Spike	39715	(19715, 80003)
				PsV Neutralization 50% Titer	114	(66, 196)
				PsV Neutralization 80% Titer	237	(172, 328)
				WT LV Neutralization 50% Titer	123	(81, 186)
				Binding Antibody to RBD	1197056	(640933, 2235715)
				Binding Antibody to Spike	2009948	(958809, 4213447)
		Day 57	224	PsV Neutralization 50% Titer	1606	(724, 3560)
				PsV Neutralization 80% Titer	4350	(3352, 5646)
				WT LV Neutralization 50% Titer	2097	(1305, 3369)

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 3i. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Race and ethnic group

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Race and ethnic group						
White Non-Hispanic	Negative	Day 1	456	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	456	Binding Antibody to RBD	817	(550, 1214)
				Binding Antibody to Spike	1098	(736, 1636)
				PsV Neutralization 50% Titer	58	(43, 77)
				PsV Neutralization 80% Titer	72	(57, 91)
				WT LV Neutralization 50% Titer	64	(54, 75)
		Day 57	456	Binding Antibody to RBD	5747	(3647, 9056)
				Binding Antibody to Spike	8494	(5281, 13661)
				PsV Neutralization 50% Titer	229	(164, 319)
				PsV Neutralization 80% Titer	296	(219, 401)
				WT LV Neutralization 50% Titer	233	(186, 293)
	Positive	Day 1	224	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	224	Binding Antibody to RBD	21386	(10646, 42962)
				Binding Antibody to Spike	39715	(19715, 80003)
				PsV Neutralization 50% Titer	114	(66, 196)
				PsV Neutralization 80% Titer	237	(172, 328)
				WT LV Neutralization 50% Titer	123	(81, 186)
		Day 57	224	Binding Antibody to RBD	1197056	(640933, 2235715)
				Binding Antibody to Spike	2009948	(958809, 4213447)
				PsV Neutralization 50% Titer	1606	(724, 3560)
				PsV Neutralization 80% Titer	4350	(3352, 5646)
				WT LV Neutralization 50% Titer	2097	(1305, 3369)
Communities of Color	Negative	Day 1	535	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)

Table 3i. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	655	(447, 961)
				Binding Antibody to Spike	913	(653, 1278)
				PsV Neutralization 50% Titer	55	(42, 72)
				PsV Neutralization 80% Titer	71	(56, 90)
				WT LV Neutralization 50% Titer	59	(46, 75)
				Binding Antibody to RBD	4478	(3173, 6320)
				Binding Antibody to Spike	6782	(5239, 8780)
				PsV Neutralization 50% Titer	231	(166, 320)
				PsV Neutralization 80% Titer	248	(194, 318)
				WT LV Neutralization 50% Titer	206	(149, 287)
	Positive	Day 1	261	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	261	Binding Antibody to RBD	22240	(11403, 43376)
				Binding Antibody to Spike	38754	(21040, 71380)
				PsV Neutralization 50% Titer	111	(61, 202)
				PsV Neutralization 80% Titer	218	(124, 386)
				WT LV Neutralization 50% Titer	132	(82, 212)
		Day 57	261	Binding Antibody to RBD	1019309	(478807, 2169956)
				Binding Antibody to Spike	1988667	(1044881, 3784928)
				PsV Neutralization 50% Titer	1817	(722, 4574)
				PsV Neutralization 80% Titer	3532	(1766, 7066)
				WT LV Neutralization 50% Titer	1702	(754, 3842)

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 3j. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Age, Race and ethnic group

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Age, Race and ethnic group						
Age < 65 Communities of Color	Negative	Day 1	253	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	253	Binding Antibody to RBD	562	(539, 585)
				Binding Antibody to Spike	794	(792, 796)
				PsV Neutralization 50% Titer	49	(49, 49)
				PsV Neutralization 80% Titer	64	(60, 68)
				WT LV Neutralization 50% Titer	53	(53, 53)
		Day 57	253	Binding Antibody to RBD	3881	(3870, 3891)
				Binding Antibody to Spike	6082	(5980, 6185)
				PsV Neutralization 50% Titer	201	(192, 210)
				PsV Neutralization 80% Titer	223	(208, 239)
				WT LV Neutralization 50% Titer	180	(178, 182)
	Positive	Day 1	148	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	148	Binding Antibody to RBD	16914	(14519, 19704)
				Binding Antibody to Spike	30339	(28661, 32115)
				PsV Neutralization 50% Titer	88	(85, 91)
				PsV Neutralization 80% Titer	174	(172, 177)
				WT LV Neutralization 50% Titer	109	(107, 112)
		Day 57	148	Binding Antibody to RBD	760367	(739099, 782247)
				Binding Antibody to Spike	1539271	(1479466, 1601494)
				PsV Neutralization 50% Titer	1264	(1257, 1272)
				PsV Neutralization 80% Titer	2677	(2533, 2830)
				WT LV Neutralization 50% Titer	1247	(1161, 1338)
Age < 65 White Non-Hispanic	Negative	Day 1	227	Binding Antibody to RBD	17	(17, 17)

Table 3j. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Age >= 65 Communities of Color	Positive	Day 29	227	Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	718	(461, 1118)
				Binding Antibody to Spike	958	(623, 1474)
				PsV Neutralization 50% Titer	51	(45, 58)
				PsV Neutralization 80% Titer	66	(55, 78)
		Day 57	227	WT LV Neutralization 50% Titer	60	(51, 70)
				Binding Antibody to RBD	5003	(2940, 8515)
				Binding Antibody to Spike	7478	(4165, 13426)
				PsV Neutralization 50% Titer	200	(156, 257)
				PsV Neutralization 80% Titer	268	(191, 376)
				WT LV Neutralization 50% Titer	213	(178, 254)
		Day 1	117	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	117	Binding Antibody to RBD	16433	(13625, 19819)
				Binding Antibody to Spike	30314	(26034, 35298)
				PsV Neutralization 50% Titer	94	(73, 123)
				PsV Neutralization 80% Titer	209	(200, 218)
				WT LV Neutralization 50% Titer	105	(96, 114)
		Day 57	117	Binding Antibody to RBD	930380	(881989, 981427)
				Binding Antibody to Spike	1512757	(1277034, 1791991)
				PsV Neutralization 50% Titer	1167	(1076, 1265)
				PsV Neutralization 80% Titer	3885	(3534, 4271)
				WT LV Neutralization 50% Titer	1722	(1702, 1743)
	Negative	Day 1	282	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 25)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 25)

Table 3j. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Age >= 65 White Non-Hispanic	Positive	Day 29	282	Binding Antibody to RBD	1120	(1120, 1120)
				Binding Antibody to Spike	1484	(1484, 1484)
				PsV Neutralization 50% Titer	81	(81, 81)
				PsV Neutralization 80% Titer	101	(101, 101)
				WT LV Neutralization 50% Titer	83	(83, 83)
		Day 57	282	Binding Antibody to RBD	7354	(7354, 7354)
				Binding Antibody to Spike	9897	(9897, 9897)
				PsV Neutralization 50% Titer	374	(374, 374)
				PsV Neutralization 80% Titer	360	(360, 360)
				WT LV Neutralization 50% Titer	333	(333, 333)
		Day 1	113	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	113	Binding Antibody to RBD	77378	(77378, 77378)
				Binding Antibody to Spike	118160	(118160, 118160)
				PsV Neutralization 50% Titer	318	(318, 318)
				PsV Neutralization 80% Titer	607	(607, 607)
				WT LV Neutralization 50% Titer	306	(306, 306)
		Day 57	113	Binding Antibody to RBD	3872288	(3872288, 3872288)
				Binding Antibody to Spike	6385528	(6385528, 6385528)
				PsV Neutralization 50% Titer	9473	(9473, 9473)
				PsV Neutralization 80% Titer	12476	(12476, 12476)
				WT LV Neutralization 50% Titer	7017	(7017, 7017)
	Negative	Day 1	229	Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(22, 22)
				WT LV Neutralization 50% Titer	24	(24, 24)
		Day 29	229	Binding Antibody to RBD	1360	(1360, 1360)
				Binding Antibody to Spike	1878	(1878, 1878)
				PsV Neutralization 50% Titer	94	(94, 94)
				PsV Neutralization 80% Titer	105	(105, 105)

Table 3j. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	GMT/GMC	95% CI
Positive		Day 57	229	WT LV Neutralization 50% Titer	82	(82, 82)
				Binding Antibody to RBD	9923	(9923, 9923)
				Binding Antibody to Spike	14038	(14038, 14038)
				PsV Neutralization 50% Titer	391	(391, 391)
				PsV Neutralization 80% Titer	438	(438, 438)
		Day 1	107	WT LV Neutralization 50% Titer	335	(335, 335)
				Binding Antibody to RBD	17	(17, 17)
				Binding Antibody to Spike	17	(17, 17)
				PsV Neutralization 50% Titer	24	(24, 24)
				PsV Neutralization 80% Titer	22	(21, 22)
		Day 29	107	WT LV Neutralization 50% Titer	24	(24, 24)
				Binding Antibody to RBD	55615	(55615, 55615)
				Binding Antibody to Spike	105802	(105802, 105802)
				PsV Neutralization 50% Titer	221	(221, 221)
				PsV Neutralization 80% Titer	379	(379, 379)
		Day 57	107	WT LV Neutralization 50% Titer	219	(219, 219)
				Binding Antibody to RBD	2986544	(2986544, 2986544)
				Binding Antibody to Spike	5634914	(5634914, 5634914)
				PsV Neutralization 50% Titer	5121	(5121, 5121)
				PsV Neutralization 80% Titer	6556	(6556, 6556)
				WT LV Neutralization 50% Titer	4283	(4283, 4283)

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 4. GMTRs or GMCRs between post-vaccinations vs. pre-vaccination

Table 4a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
All participants						
All participants	Negative	D29 fold-rise over D1	1062	Binding Antibody to RBD	188.97	(126.89, 281.44)
				Binding Antibody to Spike	243.77	(157.85, 376.45)
				PsV Neutralization 50% Titer	10.55	(7.20, 15.45)
				PsV Neutralization 80% Titer	15.65	(12.14, 20.18)
				WT LV Neutralization 50% Titer	11.17	(8.49, 14.68)
		D57 fold-rise over D1	1062	Binding Antibody to RBD	1415.04	(934.45, 2142.81)
				Binding Antibody to Spike	1887.26	(1206.78, 2951.45)
				PsV Neutralization 50% Titer	43.34	(28.71, 65.41)
				PsV Neutralization 80% Titer	56.58	(41.80, 76.58)
				WT LV Neutralization 50% Titer	42.31	(30.66, 58.39)
		D57 fold-rise over D29	1062	Binding Antibody to RBD	7.49	(7.26, 7.72)
				Binding Antibody to Spike	7.74	(7.53, 7.96)
				PsV Neutralization 50% Titer	4.11	(3.86, 4.38)
				PsV Neutralization 80% Titer	3.61	(3.32, 3.93)
				WT LV Neutralization 50% Titer	3.79	(3.49, 4.12)
	Positive	D29 fold-rise over D1	543	Binding Antibody to RBD	22101.84	(11239.54, 43461.89)
				Binding Antibody to Spike	36334.71	(17969.72, 73468.66)
				PsV Neutralization 50% Titer	94.09	(47.53, 186.29)
				PsV Neutralization 80% Titer	217.47	(132.69, 356.41)
				WT LV Neutralization 50% Titer	110.82	(68.41, 179.51)
		D57 fold-rise over D1	543	Binding Antibody to RBD	1228614.89	(548890.54, 2750082.98)
				Binding Antibody to Spike	2265407.86	(984346.68, 5213684.22)
				PsV Neutralization 50% Titer	1632.03	(633.30, 4205.78)
				PsV Neutralization 80% Titer	3639.39	(2029.71, 6525.63)
				WT LV Neutralization 50% Titer	1782.49	(880.13, 3609.99)
		D57 fold-rise over D29	543	Binding Antibody to RBD	55.59	(48.68, 63.48)
				Binding Antibody to Spike	62.35	(54.73, 71.02)
				PsV Neutralization 50% Titer	17.34	(13.29, 22.64)
				PsV Neutralization 80% Titer	16.74	(15.29, 18.32)
				WT LV Neutralization 50% Titer	16.08	(12.86, 20.13)

Table 4a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
-------	----------	-------	---	----------	-----------	--------

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 4b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Age						
Age < 65	Negative	D29 fold-rise over D1	513	Binding Antibody to RBD	159.40	(147.62, 172.11)
				Binding Antibody to Spike	202.87	(192.42, 213.88)
				PsV Neutralization 50% Titer	8.97	(8.43, 9.54)
				PsV Neutralization 80% Titer	14.13	(11.33, 17.63)
				WT LV Neutralization 50% Titer	9.92	(8.51, 11.57)
		D57 fold-rise over D1	513	Binding Antibody to RBD	1183.16	(1055.27, 1326.56)
				Binding Antibody to Spike	1566.56	(1533.98, 1599.83)
				PsV Neutralization 50% Titer	36.26	(31.44, 41.81)
				PsV Neutralization 80% Titer	49.66	(41.56, 59.35)
				WT LV Neutralization 50% Titer	36.83	(33.76, 40.17)
		D57 fold-rise over D29	513	Binding Antibody to RBD	7.42	(7.15, 7.71)
				Binding Antibody to Spike	7.72	(7.48, 7.97)
				PsV Neutralization 50% Titer	4.04	(3.73, 4.38)
				PsV Neutralization 80% Titer	3.51	(3.37, 3.67)
				WT LV Neutralization 50% Titer	3.71	(3.47, 3.97)
	Positive	D29 fold-rise over D1	294	Binding Antibody to RBD	16830.81	(16596.74, 17068.20)
				Binding Antibody to Spike	27379.88	(27174.13, 27587.18)
				PsV Neutralization 50% Titer	71.77	(69.86, 73.74)
				PsV Neutralization 80% Titer	178.29	(177.13, 179.45)
				WT LV Neutralization 50% Titer	91.18	(89.66, 92.73)
		D57 fold-rise over D1	294	Binding Antibody to RBD	891936.05	(870077.76, 914343.46)
				Binding Antibody to Spike	1617243.10	(1570174.97, 1665722.17)
				PsV Neutralization 50% Titer	1114.13	(1088.59, 1140.27)
				PsV Neutralization 80% Titer	2881.62	(2866.31, 2897.00)
				WT LV Neutralization 50% Titer	1344.13	(1336.96, 1351.33)
		D57 fold-rise over D29	294	Binding Antibody to RBD	52.99	(50.98, 55.09)
				Binding Antibody to Spike	59.07	(57.78, 60.38)
				PsV Neutralization 50% Titer	15.52	(14.76, 16.32)
				PsV Neutralization 80% Titer	16.16	(15.97, 16.36)
				WT LV Neutralization 50% Titer	14.74	(14.42, 15.07)
Age >= 65	Negative	D29 fold-rise over D1	549	Binding Antibody to RBD	349.85	(349.85, 349.85)
				Binding Antibody to Spike	473.82	(473.82, 473.82)
				PsV Neutralization 50% Titer	18.99	(18.99, 18.99)

Table 4b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age
(continued)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
		D57 fold-rise over D1	549	PsV Neutralization 80% Titer	22.66	(22.66, 22.66)
				WT LV Neutralization 50% Titer	17.12	(17.12, 17.12)
				Binding Antibody to RBD	2704.06	(2704.06, 2704.06)
				Binding Antibody to Spike	3702.67	(3702.67, 3702.67)
				PsV Neutralization 50% Titer	82.65	(82.65, 82.65)
				PsV Neutralization 80% Titer	90.66	(90.66, 90.66)
				WT LV Neutralization 50% Titer	69.92	(69.92, 69.92)
		D57 fold-rise over D29	549	Binding Antibody to RBD	7.73	(7.73, 7.73)
				Binding Antibody to Spike	7.81	(7.81, 7.81)
				PsV Neutralization 50% Titer	4.35	(4.35, 4.35)
				PsV Neutralization 80% Titer	4.00	(4.00, 4.00)
				WT LV Neutralization 50% Titer	4.08	(4.08, 4.08)
	Positive	D29 fold-rise over D1	249	Binding Antibody to RBD	66946.13	(66946.13, 66946.13)
				Binding Antibody to Spike	114866.92	(114866.92, 114866.92)
				PsV Neutralization 50% Titer	283.08	(283.08, 283.08)
				PsV Neutralization 80% Titer	487.92	(487.92, 487.92)
				WT LV Neutralization 50% Titer	244.97	(244.97, 244.97)
		D57 fold-rise over D1	249	Binding Antibody to RBD	4520137.68	(4520137.68, 4520137.68)
				Binding Antibody to Spike	8923422.97	(8923422.97, 8923422.97)
				PsV Neutralization 50% Titer	7711.12	(7711.12, 7711.12)
				PsV Neutralization 80% Titer	9407.11	(9407.11, 9407.11)
				WT LV Neutralization 50% Titer	5619.11	(5619.11, 5619.11)
		D57 fold-rise over D29	249	Binding Antibody to RBD	67.52	(67.52, 67.52)
				Binding Antibody to Spike	77.68	(77.68, 77.68)
				PsV Neutralization 50% Titer	27.24	(27.24, 27.24)
				PsV Neutralization 80% Titer	19.28	(19.28, 19.28)
				WT LV Neutralization 50% Titer	22.94	(22.94, 22.94)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 4c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Risk for Severe Covid-19						
At-risk	Negative	D29 fold-rise over D1	541	Binding Antibody to RBD	220.58	(90.16, 539.69)
				Binding Antibody to Spike	282.41	(122.12, 653.09)
				PsV Neutralization 50% Titer	11.51	(5.75, 23.08)
				PsV Neutralization 80% Titer	14.05	(7.52, 26.23)
				WT LV Neutralization 50% Titer	10.99	(5.71, 21.14)
		D57 fold-rise over D1	541	Binding Antibody to RBD	1662.77	(590.52, 4681.99)
				Binding Antibody to Spike	2201.77	(1023.14, 4738.15)
				PsV Neutralization 50% Titer	45.95	(18.65, 113.18)
				PsV Neutralization 80% Titer	56.59	(25.84, 123.97)
				WT LV Neutralization 50% Titer	45.08	(23.07, 88.10)
		D57 fold-rise over D29	541	Binding Antibody to RBD	7.54	(6.55, 8.68)
				Binding Antibody to Spike	7.80	(7.26, 8.38)
				PsV Neutralization 50% Titer	3.99	(3.25, 4.90)
				PsV Neutralization 80% Titer	4.03	(3.43, 4.73)
				WT LV Neutralization 50% Titer	4.10	(4.04, 4.17)
	Positive	D29 fold-rise over D1	246	Binding Antibody to RBD	26205.91	(9039.09, 75975.54)
				Binding Antibody to Spike	42092.31	(15275.71, 115985.62)
				PsV Neutralization 50% Titer	109.50	(45.41, 264.09)
				PsV Neutralization 80% Titer	242.37	(117.09, 501.69)
				WT LV Neutralization 50% Titer	121.43	(59.42, 248.13)
		D57 fold-rise over D1	246	Binding Antibody to RBD	1650844.79	(435737.21, 6254431.49)
				Binding Antibody to Spike	2628330.98	(779991.63, 8856663.88)
				PsV Neutralization 50% Titer	1989.46	(485.70, 8148.99)
				PsV Neutralization 80% Titer	4134.61	(1835.69, 9312.59)
				WT LV Neutralization 50% Titer	2124.15	(755.40, 5973.00)
		D57 fold-rise over D29	246	Binding Antibody to RBD	63.00	(48.21, 82.32)
				Binding Antibody to Spike	62.44	(51.06, 76.36)
				PsV Neutralization 50% Titer	18.17	(10.70, 30.86)
				PsV Neutralization 80% Titer	17.06	(15.68, 18.56)
				WT LV Neutralization 50% Titer	17.49	(12.71, 24.07)
Not at-risk	Negative	D29 fold-rise over D1	521	Binding Antibody to RBD	178.37	(140.15, 227.00)
				Binding Antibody to Spike	230.73	(168.62, 315.72)

Table 4c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
		D57 fold-rise over D1	521	PsV Neutralization 50% Titer	10.21	(7.51, 13.88)
				PsV Neutralization 80% Titer	16.30	(13.71, 19.37)
				WT LV Neutralization 50% Titer	11.23	(9.27, 13.61)
				Binding Antibody to RBD	1332.29	(1070.67, 1657.83)
				Binding Antibody to Spike	1781.67	(1258.31, 2522.71)
				PsV Neutralization 50% Titer	42.40	(31.49, 57.09)
		D57 fold-rise over D29	521	PsV Neutralization 80% Titer	56.57	(47.11, 67.93)
				WT LV Neutralization 50% Titer	41.32	(32.58, 52.41)
				Binding Antibody to RBD	7.47	(7.30, 7.64)
				Binding Antibody to Spike	7.72	(7.46, 7.99)
				PsV Neutralization 50% Titer	4.15	(4.11, 4.19)
				PsV Neutralization 80% Titer	3.47	(3.44, 3.51)
	Positive	D29 fold-rise over D1	297	WT LV Neutralization 50% Titer	3.68	(3.51, 3.85)
				Binding Antibody to RBD	20943.50	(11375.31, 38559.84)
				Binding Antibody to Spike	34684.17	(17778.76, 67664.56)
				PsV Neutralization 50% Titer	89.69	(46.08, 174.55)
				PsV Neutralization 80% Titer	210.14	(132.23, 333.97)
				WT LV Neutralization 50% Titer	107.66	(68.15, 170.07)
		D57 fold-rise over D1	297	Binding Antibody to RBD	1119097.91	(569779.34, 2198009.02)
				Binding Antibody to Spike	2161472.90	(972861.96, 4802289.84)
				PsV Neutralization 50% Titer	1533.01	(630.67, 3726.40)
				PsV Neutralization 80% Titer	3495.56	(2000.78, 6107.07)
				WT LV Neutralization 50% Titer	1686.39	(876.55, 3244.42)
		D57 fold-rise over D29	297	Binding Antibody to RBD	53.43	(50.09, 57.00)
				Binding Antibody to Spike	62.32	(54.72, 70.97)
				PsV Neutralization 50% Titer	17.09	(13.69, 21.35)
				PsV Neutralization 80% Titer	16.63	(15.13, 18.29)
				WT LV Neutralization 50% Titer	15.66	(12.86, 19.08)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 4d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Age, Risk for Severe Covid-19						
Age < 65 At-risk	Negative	D29 fold-rise over D1	257	Binding Antibody to RBD	143.28	(143.28, 143.28)
				Binding Antibody to Spike	188.50	(188.50, 188.50)
				PsV Neutralization 50% Titer	8.23	(8.23, 8.23)
				PsV Neutralization 80% Titer	10.40	(10.40, 10.40)
				WT LV Neutralization 50% Titer	8.02	(8.02, 8.02)
		D57 fold-rise over D1	257	Binding Antibody to RBD	1009.30	(1009.30, 1009.30)
				Binding Antibody to Spike	1521.48	(1521.48, 1521.48)
				PsV Neutralization 50% Titer	29.75	(29.75, 29.75)
				PsV Neutralization 80% Titer	38.77	(38.77, 38.77)
				WT LV Neutralization 50% Titer	32.64	(32.64, 32.64)
		D57 fold-rise over D29	257	Binding Antibody to RBD	7.04	(7.04, 7.04)
				Binding Antibody to Spike	8.07	(8.07, 8.07)
				PsV Neutralization 50% Titer	3.61	(3.61, 3.61)
				PsV Neutralization 80% Titer	3.73	(3.73, 3.73)
				WT LV Neutralization 50% Titer	4.07	(4.07, 4.07)
	Positive	D29 fold-rise over D1	148	Binding Antibody to RBD	16491.48	(16491.48, 16491.48)
				Binding Antibody to Spike	27081.18	(27081.18, 27081.18)
				PsV Neutralization 50% Titer	74.66	(74.66, 74.66)
				PsV Neutralization 80% Titer	176.60	(176.60, 176.60)
				WT LV Neutralization 50% Titer	88.97	(88.97, 88.97)
		D57 fold-rise over D1	148	Binding Antibody to RBD	924707.07	(924707.07, 924707.07)
				Binding Antibody to Spike	1549249.24	(1549249.24, 1549249.24)
				PsV Neutralization 50% Titer	1077.18	(1077.18, 1077.18)
				PsV Neutralization 80% Titer	2904.02	(2904.02, 2904.02)
				WT LV Neutralization 50% Titer	1354.62	(1354.62, 1354.62)
		D57 fold-rise over D29	148	Binding Antibody to RBD	56.07	(56.07, 56.07)
				Binding Antibody to Spike	57.21	(57.21, 57.21)
				PsV Neutralization 50% Titer	14.43	(14.43, 14.43)
				PsV Neutralization 80% Titer	16.44	(16.44, 16.44)
				WT LV Neutralization 50% Titer	15.22	(15.22, 15.22)
Age < 65 Not at-risk	Negative	D29 fold-rise over D1	256	Binding Antibody to RBD	164.04	(164.04, 164.04)
				Binding Antibody to Spike	206.92	(206.92, 206.92)

Table 4d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19 *(continued)*

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
		D57 fold-rise over D1	256	PsV Neutralization 50% Titer	9.18	(9.18, 9.18)
				PsV Neutralization 80% Titer	15.35	(15.35, 15.35)
				WT LV Neutralization 50% Titer	10.51	(10.51, 10.51)
				Binding Antibody to RBD	1234.86	(1234.86, 1234.86)
				Binding Antibody to Spike	1578.91	(1578.91, 1578.91)
				PsV Neutralization 50% Titer	38.24	(38.24, 38.24)
		D57 fold-rise over D29	256	PsV Neutralization 80% Titer	53.08	(53.08, 53.08)
				WT LV Neutralization 50% Titer	38.04	(38.04, 38.04)
				Binding Antibody to RBD	7.53	(7.53, 7.53)
				Binding Antibody to Spike	7.63	(7.63, 7.63)
				PsV Neutralization 50% Titer	4.17	(4.17, 4.17)
				PsV Neutralization 80% Titer	3.46	(3.46, 3.46)
	Positive	D29 fold-rise over D1	146	WT LV Neutralization 50% Titer	3.62	(3.62, 3.62)
				Binding Antibody to RBD	16918.12	(16918.12, 16918.12)
				Binding Antibody to Spike	27456.27	(27456.27, 27456.27)
				PsV Neutralization 50% Titer	71.06	(71.06, 71.06)
				PsV Neutralization 80% Titer	178.72	(178.72, 178.72)
				WT LV Neutralization 50% Titer	91.75	(91.75, 91.75)
		D57 fold-rise over D1	146	Binding Antibody to RBD	883798.43	(883798.43, 883798.43)
				Binding Antibody to Spike	1634984.56	(1634984.56, 1634984.56)
				PsV Neutralization 50% Titer	1123.71	(1123.71, 1123.71)
				PsV Neutralization 80% Titer	2875.95	(2875.95, 2875.95)
				WT LV Neutralization 50% Titer	1341.47	(1341.47, 1341.47)
		D57 fold-rise over D29	146	Binding Antibody to RBD	52.24	(52.24, 52.24)
				Binding Antibody to Spike	59.55	(59.55, 59.55)
				PsV Neutralization 50% Titer	15.81	(15.81, 15.81)
				PsV Neutralization 80% Titer	16.09	(16.09, 16.09)
				WT LV Neutralization 50% Titer	14.62	(14.62, 14.62)
	Age >= 65 At-risk	D29 fold-rise over D1	284	Binding Antibody to RBD	434.22	(434.22, 434.22)
				Binding Antibody to Spike	532.70	(532.70, 532.70)
				PsV Neutralization 50% Titer	19.49	(19.49, 19.49)
				PsV Neutralization 80% Titer	22.53	(22.53, 22.53)
				WT LV Neutralization 50% Titer	18.03	(18.03, 18.03)
		D57 fold-rise over D1	284	Binding Antibody to RBD	3640.49	(3640.49, 3640.49)

Table 4d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Age >= 65 Not at-risk	Positive	D57 fold-rise over D29	284	Binding Antibody to Spike	3932.93	(3932.93, 3932.93)
				PsV Neutralization 50% Titer	90.91	(90.91, 90.91)
				PsV Neutralization 80% Titer	102.46	(102.46, 102.46)
				WT LV Neutralization 50% Titer	74.86	(74.86, 74.86)
				Binding Antibody to RBD	8.38	(8.38, 8.38)
				Binding Antibody to Spike	7.38	(7.38, 7.38)
		D29 fold-rise over D1	98	PsV Neutralization 50% Titer	4.66	(4.66, 4.66)
				PsV Neutralization 80% Titer	4.55	(4.55, 4.55)
				WT LV Neutralization 50% Titer	4.15	(4.15, 4.15)
				Binding Antibody to RBD	69182.89	(69182.89, 69182.89)
				Binding Antibody to Spike	106089.22	(106089.22, 106089.22)
				PsV Neutralization 50% Titer	244.40	(244.40, 244.40)
	Negative	D57 fold-rise over D1	98	PsV Neutralization 80% Titer	470.58	(470.58, 470.58)
				WT LV Neutralization 50% Titer	233.01	(233.01, 233.01)
				Binding Antibody to RBD	5562727.49	(5562727.49, 5562727.49)
				Binding Antibody to Spike	7958807.54	(7958807.54, 7958807.54)
				PsV Neutralization 50% Titer	7198.17	(7198.17, 7198.17)
				PsV Neutralization 80% Titer	8670.46	(8670.46, 8670.46)
		D57 fold-rise over D29	98	WT LV Neutralization 50% Titer	5453.62	(5453.62, 5453.62)
				Binding Antibody to RBD	80.41	(80.41, 80.41)
				Binding Antibody to Spike	75.02	(75.02, 75.02)
				PsV Neutralization 50% Titer	29.45	(29.45, 29.45)
				PsV Neutralization 80% Titer	18.43	(18.43, 18.43)
				WT LV Neutralization 50% Titer	23.41	(23.41, 23.41)
		D29 fold-rise over D1	265	Binding Antibody to RBD	284.56	(284.56, 284.56)
				Binding Antibody to Spike	423.63	(423.63, 423.63)
				PsV Neutralization 50% Titer	18.52	(18.52, 18.52)
				PsV Neutralization 80% Titer	22.78	(22.78, 22.78)
		D57 fold-rise over D1	265	WT LV Neutralization 50% Titer	16.29	(16.29, 16.29)
				Binding Antibody to RBD	2034.91	(2034.91, 2034.91)
				Binding Antibody to Spike	3495.13	(3495.13, 3495.13)
				PsV Neutralization 50% Titer	75.45	(75.45, 75.45)
				PsV Neutralization 80% Titer	80.65	(80.65, 80.65)
				WT LV Neutralization 50% Titer	65.50	(65.50, 65.50)

Table 4d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
	Positive	D57 fold-rise over D29	265	Binding Antibody to RBD	7.15	(7.15, 7.15)
				Binding Antibody to Spike	8.25	(8.25, 8.25)
				PsV Neutralization 50% Titer	4.07	(4.07, 4.07)
				PsV Neutralization 80% Titer	3.54	(3.54, 3.54)
				WT LV Neutralization 50% Titer	4.02	(4.02, 4.02)
		D29 fold-rise over D1	151	Binding Antibody to RBD	65536.14	(65536.14, 65536.14)
				Binding Antibody to Spike	120936.03	(120936.03, 120936.03)
				PsV Neutralization 50% Titer	311.33	(311.33, 311.33)
				PsV Neutralization 80% Titer	499.49	(499.49, 499.49)
				WT LV Neutralization 50% Titer	253.04	(253.04, 253.04)
		D57 fold-rise over D1	151	Binding Antibody to RBD	3951583.83	(3951583.83, 3951583.83)
				Binding Antibody to Spike	9609727.65	(9609727.65, 9609727.65)
				PsV Neutralization 50% Titer	8062.70	(8062.70, 8062.70)
				PsV Neutralization 80% Titer	9917.30	(9917.30, 9917.30)
				WT LV Neutralization 50% Titer	5728.96	(5728.96, 5728.96)
		D57 fold-rise over D29	151	Binding Antibody to RBD	60.30	(60.30, 60.30)
				Binding Antibody to Spike	79.46	(79.46, 79.46)
				PsV Neutralization 50% Titer	25.90	(25.90, 25.90)
				PsV Neutralization 80% Titer	19.85	(19.85, 19.85)
				WT LV Neutralization 50% Titer	22.64	(22.64, 22.64)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 4e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Sex						
Female	Negative	D29 fold-rise over D1	597	Binding Antibody to RBD	185.18	(101.95, 336.37)
				Binding Antibody to Spike	279.65	(164.69, 474.85)
				PsV Neutralization 50% Titer	11.52	(7.28, 18.23)
				PsV Neutralization 80% Titer	16.82	(11.97, 23.62)
				WT LV Neutralization 50% Titer	11.85	(8.23, 17.05)
		D57 fold-rise over D1	597	Binding Antibody to RBD	1526.42	(857.41, 2717.41)
				Binding Antibody to Spike	2183.15	(1166.43, 4086.07)
				PsV Neutralization 50% Titer	43.63	(23.91, 79.61)
				PsV Neutralization 80% Titer	64.13	(43.07, 95.48)
				WT LV Neutralization 50% Titer	44.39	(29.90, 65.89)
		D57 fold-rise over D29	597	Binding Antibody to RBD	8.24	(7.28, 9.33)
				Binding Antibody to Spike	7.81	(6.89, 8.85)
				PsV Neutralization 50% Titer	3.79	(3.28, 4.37)
				PsV Neutralization 80% Titer	3.81	(3.38, 4.30)
				WT LV Neutralization 50% Titer	3.75	(3.27, 4.29)
	Positive	D29 fold-rise over D1	298	Binding Antibody to RBD	22034.03	(11963.80, 40580.64)
				Binding Antibody to Spike	32082.60	(16209.53, 63499.27)
				PsV Neutralization 50% Titer	90.72	(50.27, 163.73)
				PsV Neutralization 80% Titer	211.77	(143.86, 311.72)
				WT LV Neutralization 50% Titer	109.04	(74.64, 159.30)
		D57 fold-rise over D1	298	Binding Antibody to RBD	1257373.59	(629478.45, 2511584.54)
				Binding Antibody to Spike	2172016.12	(997732.41, 4728376.02)
				PsV Neutralization 50% Titer	1561.36	(605.37, 4027.05)
				PsV Neutralization 80% Titer	3419.04	(1900.32, 6151.52)
				WT LV Neutralization 50% Titer	1531.94	(733.46, 3199.70)
		D57 fold-rise over D29	298	Binding Antibody to RBD	57.07	(51.39, 63.37)
				Binding Antibody to Spike	67.70	(58.88, 77.85)
				PsV Neutralization 50% Titer	17.21	(11.94, 24.81)
				PsV Neutralization 80% Titer	16.15	(12.80, 20.36)
				WT LV Neutralization 50% Titer	14.05	(9.82, 20.09)
Male	Negative	D29 fold-rise over D1	465	Binding Antibody to RBD	193.86	(155.70, 241.36)
				Binding Antibody to Spike	205.07	(128.56, 327.12)
				PsV Neutralization 50% Titer	9.44	(6.75, 13.21)

Table 4e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex
(*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
		D57 fold-rise over D1	465	PsV Neutralization 80% Titer	14.30	(11.52, 17.75)
				WT LV Neutralization 50% Titer	10.37	(8.48, 12.67)
				Binding Antibody to RBD	1286.33	(904.11, 1830.14)
				Binding Antibody to Spike	1571.14	(1078.22, 2289.41)
				PsV Neutralization 50% Titer	42.98	(35.69, 51.74)
			465	PsV Neutralization 80% Titer	48.32	(37.62, 62.06)
				WT LV Neutralization 50% Titer	39.84	(31.32, 50.66)
				Binding Antibody to RBD	6.64	(5.80, 7.59)
				Binding Antibody to Spike	7.66	(6.78, 8.65)
				PsV Neutralization 50% Titer	4.55	(3.88, 5.34)
	Positive	D29 fold-rise over D1	245	PsV Neutralization 80% Titer	3.38	(3.21, 3.55)
				WT LV Neutralization 50% Titer	3.84	(3.68, 4.02)
				Binding Antibody to RBD	22191.72	(10314.87, 47743.93)
				Binding Antibody to Spike	42826.03	(20844.62, 87987.64)
				PsV Neutralization 50% Titer	98.74	(44.18, 220.64)
			245	PsV Neutralization 80% Titer	225.24	(119.77, 423.60)
				WT LV Neutralization 50% Titer	113.21	(60.60, 211.48)
				Binding Antibody to RBD	1191639.11	(438991.99, 3234691.75)
				Binding Antibody to Spike	2394931.18	(971477.39, 5904095.60)
				PsV Neutralization 50% Titer	1730.29	(659.27, 4541.24)
	D57 fold-rise over D1			PsV Neutralization 80% Titer	3952.31	(2103.66, 7425.50)
				WT LV Neutralization 50% Titer	2177.25	(1103.91, 4294.22)
				Binding Antibody to RBD	53.70	(40.91, 70.48)
				Binding Antibody to Spike	55.92	(45.08, 69.37)
				PsV Neutralization 50% Titer	17.52	(14.83, 20.71)
		D57 fold-rise over D29	245	PsV Neutralization 80% Titer	17.55	(14.19, 21.70)
				WT LV Neutralization 50% Titer	19.23	(16.98, 21.78)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 4f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Age, sex						
Age < 65 Female	Negative	D29 fold-rise over D1	291	Binding Antibody to RBD	143.44	(111.30, 184.87)
				Binding Antibody to Spike	223.91	(159.80, 313.75)
				PsV Neutralization 50% Titer	9.47	(7.68, 11.67)
				PsV Neutralization 80% Titer	15.03	(10.31, 21.92)
				WT LV Neutralization 50% Titer	10.22	(7.68, 13.59)
		D57 fold-rise over D1	291	Binding Antibody to RBD	1200.16	(813.42, 1770.76)
				Binding Antibody to Spike	1670.22	(1241.34, 2247.28)
				PsV Neutralization 50% Titer	33.73	(26.14, 43.53)
				PsV Neutralization 80% Titer	54.83	(38.87, 77.35)
				WT LV Neutralization 50% Titer	37.48	(32.40, 43.37)
		D57 fold-rise over D29	291	Binding Antibody to RBD	8.37	(7.31, 9.58)
				Binding Antibody to Spike	7.46	(7.16, 7.77)
				PsV Neutralization 50% Titer	3.56	(3.40, 3.73)
				PsV Neutralization 80% Titer	3.65	(3.53, 3.77)
				WT LV Neutralization 50% Titer	3.67	(3.19, 4.22)
	Positive	D29 fold-rise over D1	166	Binding Antibody to RBD	17210.84	(15911.51, 18616.27)
				Binding Antibody to Spike	24679.73	(23512.40, 25905.01)
				PsV Neutralization 50% Titer	71.60	(68.08, 75.31)
				PsV Neutralization 80% Titer	181.62	(178.51, 184.79)
				WT LV Neutralization 50% Titer	93.29	(85.34, 101.99)
		D57 fold-rise over D1	166	Binding Antibody to RBD	944992.97	(789552.46, 1131035.32)
				Binding Antibody to Spike	1587258.72	(1455066.75, 1731460.25)
				PsV Neutralization 50% Titer	1057.94	(857.52, 1305.20)
				PsV Neutralization 80% Titer	2677.52	(2168.63, 3305.84)
				WT LV Neutralization 50% Titer	1130.39	(934.58, 1367.23)
		D57 fold-rise over D29	166	Binding Antibody to RBD	54.91	(49.62, 60.76)
				Binding Antibody to Spike	64.31	(56.17, 73.64)
				PsV Neutralization 50% Titer	14.78	(12.60, 17.33)
				PsV Neutralization 80% Titer	14.74	(12.15, 17.89)
				WT LV Neutralization 50% Titer	12.12	(10.95, 13.41)
Age < 65 Male	Negative	D29 fold-rise over D1	222	Binding Antibody to RBD	182.83	(154.78, 215.96)
				Binding Antibody to Spike	178.43	(131.55, 242.02)

Table 4f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Age >= 65 Female	Positive	D57 fold-rise over D1	222	PsV Neutralization 50% Titer	8.36	(7.38, 9.45)
				PsV Neutralization 80% Titer	13.04	(12.70, 13.37)
				WT LV Neutralization 50% Titer	9.55	(9.42, 9.68)
				Binding Antibody to RBD	1161.42	(912.81, 1477.74)
				Binding Antibody to Spike	1441.31	(1036.58, 2004.06)
				PsV Neutralization 50% Titer	39.83	(39.32, 40.35)
		D57 fold-rise over D29	222	PsV Neutralization 80% Titer	43.66	(42.57, 44.78)
				WT LV Neutralization 50% Titer	35.99	(35.54, 36.45)
				Binding Antibody to RBD	6.35	(5.90, 6.84)
				Binding Antibody to Spike	8.08	(7.88, 8.28)
				PsV Neutralization 50% Titer	4.77	(4.27, 5.32)
				PsV Neutralization 80% Titer	3.35	(3.18, 3.52)
	Negative	D29 fold-rise over D1	128	WT LV Neutralization 50% Titer	3.77	(3.67, 3.87)
				Binding Antibody to RBD	16323.64	(15101.14, 17645.11)
				Binding Antibody to Spike	31566.18	(28549.87, 34901.16)
				PsV Neutralization 50% Titer	72.01	(63.04, 82.25)
				PsV Neutralization 80% Titer	173.81	(171.90, 175.75)
				WT LV Neutralization 50% Titer	88.37	(81.11, 96.28)
		D57 fold-rise over D1	128	Binding Antibody to RBD	824033.86	(601930.02, 1128090.95)
				Binding Antibody to Spike	1659254.17	(1584279.38, 1737777.08)
				PsV Neutralization 50% Titer	1196.01	(955.23, 1497.47)
				PsV Neutralization 80% Titer	3186.79	(2384.41, 4259.17)
				WT LV Neutralization 50% Titer	1704.15	(1331.98, 2180.31)
		D57 fold-rise over D29	128	Binding Antibody to RBD	50.48	(39.86, 63.93)
				Binding Antibody to Spike	52.56	(45.39, 60.87)
				PsV Neutralization 50% Titer	16.61	(15.15, 18.21)
				PsV Neutralization 80% Titer	18.33	(13.87, 24.23)
				WT LV Neutralization 50% Titer	19.28	(16.42, 22.65)
		D29 fold-rise over D1	306	Binding Antibody to RBD	497.86	(497.86, 497.86)
				Binding Antibody to Spike	661.38	(661.38, 661.38)
				PsV Neutralization 50% Titer	24.63	(24.63, 24.63)
				PsV Neutralization 80% Titer	25.95	(25.95, 25.95)
				WT LV Neutralization 50% Titer	20.99	(20.99, 20.99)
		D57 fold-rise over D1	306	Binding Antibody to RBD	3873.17	(3873.17, 3873.17)

Table 4f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCs) between post-vaccinations/pre-vaccination by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Age >= 65 Male	Positive	D57 fold-rise over D29	306	Binding Antibody to Spike	6158.20	(6158.20, 6158.20)
				PsV Neutralization 50% Titer	118.19	(118.19, 118.19)
				PsV Neutralization 80% Titer	117.57	(117.57, 117.57)
				WT LV Neutralization 50% Titer	85.40	(85.40, 85.40)
				Binding Antibody to RBD	7.78	(7.78, 7.78)
				Binding Antibody to Spike	9.31	(9.31, 9.31)
		D29 fold-rise over D1	132	PsV Neutralization 50% Titer	4.80	(4.80, 4.80)
				PsV Neutralization 80% Titer	4.53	(4.53, 4.53)
				WT LV Neutralization 50% Titer	4.07	(4.07, 4.07)
				Binding Antibody to RBD	65617.70	(65617.70, 65617.70)
				Binding Antibody to Spike	102214.88	(102214.88, 102214.88)
				PsV Neutralization 50% Titer	258.12	(258.12, 258.12)
	Negative	D57 fold-rise over D1	132	PsV Neutralization 80% Titer	417.26	(417.26, 417.26)
				WT LV Neutralization 50% Titer	217.19	(217.19, 217.19)
				Binding Antibody to RBD	4439677.78	(4439677.78, 4439677.78)
				Binding Antibody to Spike	8680593.01	(8680593.01, 8680593.01)
				PsV Neutralization 50% Titer	8713.68	(8713.68, 8713.68)
				PsV Neutralization 80% Titer	10066.53	(10066.53, 10066.53)
		D57 fold-rise over D29	132	WT LV Neutralization 50% Titer	5866.43	(5866.43, 5866.43)
				Binding Antibody to RBD	67.66	(67.66, 67.66)
				Binding Antibody to Spike	84.92	(84.92, 84.92)
				PsV Neutralization 50% Titer	33.76	(33.76, 33.76)
				PsV Neutralization 80% Titer	24.13	(24.13, 24.13)
				WT LV Neutralization 50% Titer	27.01	(27.01, 27.01)
		D29 fold-rise over D1	243	Binding Antibody to RBD	235.67	(235.67, 235.67)
				Binding Antibody to Spike	326.17	(326.17, 326.17)
				PsV Neutralization 50% Titer	14.18	(14.18, 14.18)
				PsV Neutralization 80% Titer	19.46	(19.46, 19.46)
				WT LV Neutralization 50% Titer	13.63	(13.63, 13.63)
		D57 fold-rise over D1	243	Binding Antibody to RBD	1808.33	(1808.33, 1808.33)
				Binding Antibody to Spike	2094.66	(2094.66, 2094.66)
				PsV Neutralization 50% Titer	55.37	(55.37, 55.37)
				PsV Neutralization 80% Titer	67.76	(67.76, 67.76)
				WT LV Neutralization 50% Titer	55.89	(55.89, 55.89)

Table 4f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCs) between post-vaccinations/pre-vaccination by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
	Positive	D57 fold-rise over D29	243	Binding Antibody to RBD	7.67	(7.67, 7.67)
				Binding Antibody to Spike	6.42	(6.42, 6.42)
				PsV Neutralization 50% Titer	3.90	(3.90, 3.90)
				PsV Neutralization 80% Titer	3.48	(3.48, 3.48)
				WT LV Neutralization 50% Titer	4.10	(4.10, 4.10)
		D29 fold-rise over D1	117	Binding Antibody to RBD	68491.27	(68491.27, 68491.27)
				Binding Antibody to Spike	131187.72	(131187.72, 131187.72)
				PsV Neutralization 50% Titer	314.43	(314.43, 314.43)
				PsV Neutralization 80% Titer	583.03	(583.03, 583.03)
				WT LV Neutralization 50% Titer	280.94	(280.94, 280.94)
		D57 fold-rise over D1	117	Binding Antibody to RBD	4613514.68	(4613514.68, 4613514.68)
				Binding Antibody to Spike	9208155.07	(9208155.07, 9208155.07)
				PsV Neutralization 50% Titer	6709.40	(6709.40, 6709.40)
				PsV Neutralization 80% Titer	8708.81	(8708.81, 8708.81)
				WT LV Neutralization 50% Titer	5350.20	(5350.20, 5350.20)
		D57 fold-rise over D29	117	Binding Antibody to RBD	67.36	(67.36, 67.36)
				Binding Antibody to Spike	70.19	(70.19, 70.19)
				PsV Neutralization 50% Titer	21.34	(21.34, 21.34)
				PsV Neutralization 80% Titer	14.94	(14.94, 14.94)
				WT LV Neutralization 50% Titer	19.04	(19.04, 19.04)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 4g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Hispanic or Latino ethnicity						
Hispanic or Latino	Negative	D29 fold-rise over D1	125	Binding Antibody to RBD	138.68	(44.05, 436.56)
				Binding Antibody to Spike	132.83	(27.73, 636.36)
				PsV Neutralization 50% Titer	6.90	(2.18, 21.81)
				PsV Neutralization 80% Titer	6.77	(2.53, 18.10)
				WT LV Neutralization 50% Titer	5.33	(2.25, 12.59)
		D57 fold-rise over D1	125	Binding Antibody to RBD	765.94	(171.00, 3430.90)
				Binding Antibody to Spike	893.01	(132.13, 6035.57)
				PsV Neutralization 50% Titer	39.21	(17.96, 85.60)
				PsV Neutralization 80% Titer	20.14	(4.12, 98.48)
				WT LV Neutralization 50% Titer	18.23	(4.12, 80.67)
		D57 fold-rise over D29	125	Binding Antibody to RBD	5.52	(3.87, 7.88)
				Binding Antibody to Spike	6.72	(4.76, 9.50)
				PsV Neutralization 50% Titer	5.69	(3.82, 8.46)
				PsV Neutralization 80% Titer	2.97	(1.61, 5.48)
				WT LV Neutralization 50% Titer	3.42	(1.78, 6.60)
	Positive	D29 fold-rise over D1	77	Binding Antibody to RBD	29196.69	(16627.73, 51266.58)
				Binding Antibody to Spike	31013.68	(19781.22, 48624.31)
				PsV Neutralization 50% Titer	102.88	(55.79, 189.74)
				PsV Neutralization 80% Titer	188.87	(119.85, 297.66)
				WT LV Neutralization 50% Titer	100.67	(67.80, 149.47)
		D57 fold-rise over D1	77	Binding Antibody to RBD	1883876.11	(954159.22, 3719493.69)
				Binding Antibody to Spike	2088292.76	(1376225.20, 3168788.54)
				PsV Neutralization 50% Titer	1965.72	(941.02, 4106.25)
				PsV Neutralization 80% Titer	3052.53	(1794.80, 5191.63)
				WT LV Neutralization 50% Titer	1299.28	(750.90, 2248.15)
		D57 fold-rise over D29	77	Binding Antibody to RBD	64.52	(56.74, 73.37)
				Binding Antibody to Spike	67.33	(59.62, 76.05)
				PsV Neutralization 50% Titer	19.11	(13.58, 26.88)
				PsV Neutralization 80% Titer	16.16	(14.06, 18.58)
				WT LV Neutralization 50% Titer	12.91	(9.77, 17.05)
Not Hispanic or Latino	Negative	D29 fold-rise over D1	844	Binding Antibody to RBD	234.47	(139.56, 393.95)
				Binding Antibody to Spike	312.54	(181.73, 537.50)

Table 4g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
		D57 fold-rise over D1	844	PsV Neutralization 50% Titer	12.01	(8.51, 16.95)
				PsV Neutralization 80% Titer	19.23	(12.43, 29.75)
				WT LV Neutralization 50% Titer	13.24	(9.21, 19.05)
				Binding Antibody to RBD	1980.53	(1028.61, 3813.41)
				Binding Antibody to Spike	2550.76	(1384.71, 4698.73)
				PsV Neutralization 50% Titer	51.92	(32.11, 83.95)
		D57 fold-rise over D29	844	PsV Neutralization 80% Titer	75.08	(44.35, 127.11)
				WT LV Neutralization 50% Titer	52.62	(33.31, 83.15)
				Binding Antibody to RBD	8.45	(6.84, 10.43)
				Binding Antibody to Spike	8.16	(7.46, 8.93)
				PsV Neutralization 50% Titer	4.32	(3.66, 5.10)
				PsV Neutralization 80% Titer	3.90	(3.57, 4.27)
	Positive	D29 fold-rise over D1	406	WT LV Neutralization 50% Titer	3.97	(3.62, 4.37)
				Binding Antibody to RBD	21028.70	(9431.35, 46886.84)
				Binding Antibody to Spike	37733.85	(18349.48, 77595.85)
				PsV Neutralization 50% Titer	93.06	(44.56, 194.36)
				PsV Neutralization 80% Titer	220.00	(132.79, 364.49)
				WT LV Neutralization 50% Titer	110.84	(66.72, 184.14)
		D57 fold-rise over D1	406	Binding Antibody to RBD	1173935.27	(464817.83, 2964869.09)
				Binding Antibody to Spike	2172162.60	(871740.03, 5412497.08)
				PsV Neutralization 50% Titer	1623.83	(611.61, 4311.24)
				PsV Neutralization 80% Titer	4043.95	(2379.55, 6872.55)
				WT LV Neutralization 50% Titer	2005.67	(1033.66, 3891.73)
		D57 fold-rise over D29	406	Binding Antibody to RBD	55.83	(49.05, 63.53)
				Binding Antibody to Spike	57.57	(47.40, 69.91)
				PsV Neutralization 50% Titer	17.45	(13.35, 22.81)
				PsV Neutralization 80% Titer	18.38	(17.91, 18.86)
				WT LV Neutralization 50% Titer	18.10	(15.46, 21.18)
	Not reported and unknown	D29 fold-rise over D1	93	Binding Antibody to RBD	52.72	(13.76, 202.04)
				Binding Antibody to Spike	72.97	(12.66, 420.60)
				PsV Neutralization 50% Titer	6.30	(2.67, 14.86)
				PsV Neutralization 80% Titer	8.21	(3.03, 22.23)
		D57 fold-rise over D1	93	WT LV Neutralization 50% Titer	6.86	(3.10, 15.16)
				Binding Antibody to RBD	222.32	(26.38, 1873.43)

Table 4g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
		D57 fold-rise over D29	93	Binding Antibody to Spike	442.94	(46.47, 4221.73)
				PsV Neutralization 50% Titer	12.58	(3.07, 51.63)
				PsV Neutralization 80% Titer	20.53	(5.17, 81.51)
				WT LV Neutralization 50% Titer	20.33	(6.77, 61.08)
				Binding Antibody to RBD	4.22	(1.89, 9.42)
				Binding Antibody to Spike	6.07	(3.48, 10.59)
			60	PsV Neutralization 50% Titer	2.00	(1.15, 3.48)
				PsV Neutralization 80% Titer	2.50	(1.69, 3.70)
				WT LV Neutralization 50% Titer	2.96	(1.88, 4.67)
				Binding Antibody to RBD	20159.83	(8988.89, 45213.42)
				Binding Antibody to Spike	35859.21	(13163.23, 97687.51)
				PsV Neutralization 50% Titer	88.29	(29.01, 268.70)
				PsV Neutralization 80% Titer	250.32	(149.18, 420.03)
		D57 fold-rise over D1	60	WT LV Neutralization 50% Titer	128.64	(71.35, 231.92)
				Binding Antibody to RBD	861687.64	(229982.48, 3228531.13)
				Binding Antibody to Spike	3440993.12	(1247294.72, 9492891.63)
				PsV Neutralization 50% Titer	1262.78	(284.60, 5603.02)
				PsV Neutralization 80% Titer	2313.24	(665.08, 8045.78)
				WT LV Neutralization 50% Titer	1294.14	(393.19, 4259.51)
		D57 fold-rise over D29	60	Binding Antibody to RBD	42.74	(20.26, 90.18)
				Binding Antibody to Spike	95.96	(77.69, 118.53)
				PsV Neutralization 50% Titer	14.30	(9.77, 20.94)
				PsV Neutralization 80% Titer	9.24	(4.45, 19.18)
				WT LV Neutralization 50% Titer	10.06	(5.41, 18.71)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 4h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Race						
Not reported and unknown	Negative	D29 fold-rise over D1	98	Binding Antibody to RBD	135.57	(77.50, 237.18)
				Binding Antibody to Spike	220.09	(88.79, 545.51)
				PsV Neutralization 50% Titer	9.93	(5.74, 17.18)
				PsV Neutralization 80% Titer	16.40	(6.27, 42.88)
				WT LV Neutralization 50% Titer	12.01	(6.11, 23.62)
		D57 fold-rise over D1	98	Binding Antibody to RBD	962.33	(466.45, 1985.39)
				Binding Antibody to Spike	1239.51	(415.69, 3696.00)
				PsV Neutralization 50% Titer	24.23	(9.54, 61.56)
				PsV Neutralization 80% Titer	52.27	(16.50, 165.65)
				WT LV Neutralization 50% Titer	48.10	(22.04, 104.97)
		D57 fold-rise over D29	98	Binding Antibody to RBD	7.10	(5.17, 9.75)
				Binding Antibody to Spike	5.63	(4.39, 7.22)
				PsV Neutralization 50% Titer	2.44	(1.59, 3.75)
				PsV Neutralization 80% Titer	3.19	(2.59, 3.92)
				WT LV Neutralization 50% Titer	4.00	(3.43, 4.67)
	Positive	D29 fold-rise over D1	48	Binding Antibody to RBD	27518.83	(10841.47, 69850.84)
				Binding Antibody to Spike	42021.74	(17621.93, 100206.18)
				PsV Neutralization 50% Titer	123.13	(47.21, 321.13)
				PsV Neutralization 80% Titer	267.52	(123.52, 579.39)
				WT LV Neutralization 50% Titer	112.32	(50.72, 248.71)
		D57 fold-rise over D1	48	Binding Antibody to RBD	1646097.60	(483211.36, 5607561.28)
				Binding Antibody to Spike	2151655.42	(701963.24, 6595247.20)
				PsV Neutralization 50% Titer	3186.34	(1018.93, 9964.16)
				PsV Neutralization 80% Titer	2980.98	(1100.82, 8072.37)
				WT LV Neutralization 50% Titer	1682.77	(429.49, 6593.17)
		D57 fold-rise over D29	48	Binding Antibody to RBD	59.82	(41.50, 86.21)
				Binding Antibody to Spike	51.20	(39.71, 66.03)
				PsV Neutralization 50% Titer	25.88	(18.87, 35.49)
				PsV Neutralization 80% Titer	11.14	(6.69, 18.56)
				WT LV Neutralization 50% Titer	14.98	(6.38, 35.20)
American Indian or Alaska Native	Negative	D29 fold-rise over D1	27	Binding Antibody to RBD	107.79	(37.55, 309.42)

Table 4h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Asian	Positive	D57 fold-rise over D1	27	Binding Antibody to Spike	189.00	(69.75, 512.15)
				PsV Neutralization 50% Titer	11.15	(8.72, 14.25)
				PsV Neutralization 80% Titer	7.65	(3.75, 15.58)
				WT LV Neutralization 50% Titer	8.19	(6.68, 10.03)
				Binding Antibody to RBD	513.71	(185.91, 1419.50)
				Binding Antibody to Spike	2329.49	(523.03, 10375.11)
				PsV Neutralization 50% Titer	71.35	(41.48, 122.74)
				PsV Neutralization 80% Titer	54.53	(37.52, 79.24)
		D57 fold-rise over D29	27	WT LV Neutralization 50% Titer	68.71	(40.94, 115.33)
				Binding Antibody to RBD	4.77	(2.22, 10.22)
				Binding Antibody to Spike	12.33	(7.02, 21.65)
				PsV Neutralization 50% Titer	6.40	(3.99, 10.27)
				PsV Neutralization 80% Titer	7.13	(4.74, 10.72)
				WT LV Neutralization 50% Titer	8.39	(5.87, 12.01)
		D29 fold-rise over D1	17	Binding Antibody to RBD	21903.33	(12664.91, 37880.72)
				Binding Antibody to Spike	41449.50	(25323.53, 67844.46)
				PsV Neutralization 50% Titer	90.89	(54.93, 150.40)
				PsV Neutralization 80% Titer	182.58	(100.65, 331.21)
				WT LV Neutralization 50% Titer	116.18	(72.38, 186.50)
		D57 fold-rise over D1	17	Binding Antibody to RBD	589745.40	(257049.16, 1353047.17)
				Binding Antibody to Spike	3602256.01	(1815017.46, 7149379.38)
				PsV Neutralization 50% Titer	2243.44	(754.57, 6670.06)
				PsV Neutralization 80% Titer	4473.11	(2170.47, 9218.63)
				WT LV Neutralization 50% Titer	2000.92	(1529.11, 2618.31)
		D57 fold-rise over D29	17	Binding Antibody to RBD	26.92	(13.95, 51.97)
				Binding Antibody to Spike	86.91	(59.42, 127.12)
				PsV Neutralization 50% Titer	24.68	(13.05, 46.69)
				PsV Neutralization 80% Titer	24.50	(21.00, 28.58)
				WT LV Neutralization 50% Titer	17.22	(13.15, 22.55)
	Negative	D29 fold-rise over D1	84	Binding Antibody to RBD	328.62	(237.86, 454.00)
				Binding Antibody to Spike	481.66	(248.19, 934.76)
				PsV Neutralization 50% Titer	12.58	(8.45, 18.72)
				PsV Neutralization 80% Titer	20.92	(12.96, 33.77)
				WT LV Neutralization 50% Titer	17.70	(12.85, 24.36)

Table 4h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Black or African American	Positive	D57 fold-rise over D1	84	Binding Antibody to RBD	2598.72	(1467.72, 4601.27)
				Binding Antibody to Spike	6096.36	(1773.56, 20955.39)
				PsV Neutralization 50% Titer	106.91	(39.11, 292.21)
				PsV Neutralization 80% Titer	84.73	(43.33, 165.67)
				WT LV Neutralization 50% Titer	59.40	(36.62, 96.38)
		D57 fold-rise over D29	84	Binding Antibody to RBD	7.91	(5.27, 11.87)
				Binding Antibody to Spike	12.66	(7.14, 22.44)
				PsV Neutralization 50% Titer	8.50	(4.62, 15.64)
				PsV Neutralization 80% Titer	4.05	(3.24, 5.07)
				WT LV Neutralization 50% Titer	3.36	(2.30, 4.89)
		D29 fold-rise over D1	46	Binding Antibody to RBD	14022.07	(3107.65, 63269.26)
				Binding Antibody to Spike	35816.07	(13803.10, 92934.97)
				PsV Neutralization 50% Titer	55.28	(9.61, 317.84)
				PsV Neutralization 80% Titer	158.68	(43.89, 573.61)
				WT LV Neutralization 50% Titer	80.57	(25.36, 255.95)
		D57 fold-rise over D1	46	Binding Antibody to RBD	684991.54	(138490.97, 3388043.27)
				Binding Antibody to Spike	1949384.44	(687286.61, 5529133.89)
				PsV Neutralization 50% Titer	1142.21	(191.37, 6817.28)
				PsV Neutralization 80% Titer	2651.56	(467.06, 15053.22)
				WT LV Neutralization 50% Titer	1034.62	(172.35, 6210.98)
		D57 fold-rise over D29	46	Binding Antibody to RBD	48.85	(44.42, 53.72)
				Binding Antibody to Spike	54.43	(49.45, 59.91)
				PsV Neutralization 50% Titer	20.66	(18.92, 22.57)
				PsV Neutralization 80% Titer	16.71	(10.33, 27.03)
				WT LV Neutralization 50% Titer	12.84	(6.79, 24.29)
	Negative	D29 fold-rise over D1	216	Binding Antibody to RBD	150.89	(78.01, 291.89)
				Binding Antibody to Spike	211.74	(109.54, 409.30)
				PsV Neutralization 50% Titer	11.56	(6.87, 19.43)
				PsV Neutralization 80% Titer	14.26	(9.21, 22.09)
				WT LV Neutralization 50% Titer	10.64	(6.89, 16.44)
		D57 fold-rise over D1	216	Binding Antibody to RBD	1034.07	(545.79, 1959.16)
				Binding Antibody to Spike	1559.75	(779.61, 3120.58)
				PsV Neutralization 50% Titer	48.29	(25.10, 92.91)
				PsV Neutralization 80% Titer	55.61	(35.16, 87.96)

Table 4h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Multiracial	Positive	D57 fold-rise over D29	216	WT LV Neutralization 50% Titer	40.19	(23.56, 68.55)
				Binding Antibody to RBD	6.85	(6.56, 7.16)
				Binding Antibody to Spike	7.37	(7.12, 7.63)
				PsV Neutralization 50% Titer	4.18	(3.63, 4.80)
				PsV Neutralization 80% Titer	3.90	(3.82, 3.98)
		D29 fold-rise over D1	91	WT LV Neutralization 50% Titer	3.78	(3.21, 4.44)
				Binding Antibody to RBD	22515.60	(12241.11, 41413.90)
				Binding Antibody to Spike	29552.83	(16116.21, 54192.01)
				PsV Neutralization 50% Titer	77.57	(38.74, 155.33)
				PsV Neutralization 80% Titer	281.40	(181.60, 436.05)
		D57 fold-rise over D1	91	WT LV Neutralization 50% Titer	144.91	(96.78, 216.98)
				Binding Antibody to RBD	1132866.64	(501266.26, 2560289.69)
				Binding Antibody to Spike	1685134.60	(773504.99, 3671183.32)
				PsV Neutralization 50% Titer	1373.61	(655.24, 2879.54)
				PsV Neutralization 80% Titer	4099.32	(2797.66, 6006.60)
	Negative	D57 fold-rise over D29	91	WT LV Neutralization 50% Titer	2913.93	(1526.01, 5564.20)
				Binding Antibody to RBD	50.31	(39.75, 63.69)
				Binding Antibody to Spike	57.02	(44.86, 72.47)
				PsV Neutralization 50% Titer	17.71	(16.38, 19.14)
				PsV Neutralization 80% Titer	14.57	(12.66, 16.77)
		D29 fold-rise over D1	62	WT LV Neutralization 50% Titer	20.11	(15.22, 26.57)
				Binding Antibody to RBD	61.21	(17.36, 215.89)
				Binding Antibody to Spike	46.19	(7.63, 279.54)
				PsV Neutralization 50% Titer	5.26	(1.82, 15.25)
				PsV Neutralization 80% Titer	6.28	(2.59, 15.21)
		D57 fold-rise over D1	62	WT LV Neutralization 50% Titer	4.71	(2.38, 9.32)
				Binding Antibody to RBD	252.38	(44.39, 1434.90)
				Binding Antibody to Spike	181.77	(15.92, 2074.99)
				PsV Neutralization 50% Titer	21.68	(7.10, 66.16)
				PsV Neutralization 80% Titer	12.83	(2.93, 56.20)
		D57 fold-rise over D29	62	WT LV Neutralization 50% Titer	9.89	(2.76, 35.41)
				Binding Antibody to RBD	4.12	(2.56, 6.65)
				Binding Antibody to Spike	3.94	(2.08, 7.45)
				PsV Neutralization 50% Titer	4.12	(3.82, 4.44)

Table 4h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Native Hawaiian or Other Pacific Islander	Positive	D29 fold-rise over D1	28	PsV Neutralization 80% Titer	2.04	(1.12, 3.71)
				WT LV Neutralization 50% Titer	2.10	(1.14, 3.88)
				Binding Antibody to RBD	43727.17	(19737.59, 96874.32)
				Binding Antibody to Spike	34708.44	(22182.83, 54306.70)
				PsV Neutralization 50% Titer	141.70	(77.17, 260.18)
		D57 fold-rise over D1	28	PsV Neutralization 80% Titer	294.89	(179.02, 485.78)
				WT LV Neutralization 50% Titer	178.49	(126.90, 251.05)
				Binding Antibody to RBD	3327303.96	(1773885.08, 6241076.04)
				Binding Antibody to Spike	3030232.23	(1919262.96, 4784288.33)
				PsV Neutralization 50% Titer	1747.47	(712.65, 4284.91)
		D57 fold-rise over D29	28	PsV Neutralization 80% Titer	6976.89	(4493.12, 10833.69)
				WT LV Neutralization 50% Titer	2308.64	(1321.92, 4031.87)
				Binding Antibody to RBD	76.09	(63.81, 90.74)
				Binding Antibody to Spike	87.31	(85.03, 89.65)
				PsV Neutralization 50% Titer	12.33	(4.63, 32.82)
	Negative	D29 fold-rise over D1	20	PsV Neutralization 80% Titer	23.66	(15.57, 35.94)
				WT LV Neutralization 50% Titer	12.93	(10.37, 16.14)
				Binding Antibody to RBD	917.84	(14.11, 59713.58)
		D57 fold-rise over D1	20	Binding Antibody to Spike	1408.63	(24.45, 81159.24)
				PsV Neutralization 50% Titer	26.41	(3.06, 227.73)
				PsV Neutralization 80% Titer	55.35	(3.28, 935.26)
				WT LV Neutralization 50% Titer	33.20	(3.00, 367.04)
		D57 fold-rise over D29	20	Binding Antibody to RBD	8441.73	(23.19, 3072989.63)
				Binding Antibody to Spike	23844.34	(49.11, 11576345.27)
				PsV Neutralization 50% Titer	192.12	(3.11, 11887.50)
				PsV Neutralization 80% Titer	229.49	(5.76, 9143.90)
				WT LV Neutralization 50% Titer	245.70	(3.34, 18092.14)
	Positive	D29 fold-rise over D1	7	Binding Antibody to RBD	9.20	(1.57, 53.81)
				Binding Antibody to Spike	16.93	(1.97, 145.11)
				PsV Neutralization 50% Titer	7.28	(0.98, 54.22)
				PsV Neutralization 80% Titer	4.15	(1.75, 9.81)
				WT LV Neutralization 50% Titer	7.40	(1.11, 49.34)
				Binding Antibody to RBD	47892.17	(22133.56, 103628.18)

Table 4h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Other	Negative	D57 fold-rise over D1	7	Binding Antibody to Spike	53258.50	(19918.26, 142405.40)
				PsV Neutralization 50% Titer	95.71	(38.14, 240.19)
				PsV Neutralization 80% Titer	249.46	(175.98, 353.63)
				WT LV Neutralization 50% Titer	225.90	(133.27, 382.91)
				Binding Antibody to RBD	2537359.33	(1032901.40, 6233114.21)
				Binding Antibody to Spike	1904559.80	(282644.72, 12833595.51)
				PsV Neutralization 50% Titer	775.54	(36.75, 16366.58)
				PsV Neutralization 80% Titer	15504.60	(6666.14, 36061.76)
		D57 fold-rise over D29	7	WT LV Neutralization 50% Titer	5316.87	(1073.81, 26326.07)
				Binding Antibody to RBD	52.98	(22.03, 127.42)
				Binding Antibody to Spike	35.76	(11.23, 113.91)
				PsV Neutralization 50% Titer	8.10	(0.92, 71.44)
				PsV Neutralization 80% Titer	62.15	(37.46, 103.11)
				WT LV Neutralization 50% Titer	23.54	(5.20, 106.47)
		D29 fold-rise over D1	28	Binding Antibody to RBD	3890.92	(196.66, 76980.49)
				Binding Antibody to Spike	4272.26	(228.29, 79951.26)
				PsV Neutralization 50% Titer	49.88	(26.07, 95.43)
				PsV Neutralization 80% Titer	29.98	(14.52, 61.88)
				WT LV Neutralization 50% Titer	18.63	(10.20, 34.00)
		D57 fold-rise over D1	28	Binding Antibody to RBD	75843.10	(2175.81, 2643691.89)
				Binding Antibody to Spike	147618.48	(3028.50, 7195391.03)
				PsV Neutralization 50% Titer	427.24	(99.90, 1827.15)
				PsV Neutralization 80% Titer	218.32	(73.06, 652.44)
				WT LV Neutralization 50% Titer	204.38	(68.06, 613.76)
		D57 fold-rise over D29	28	Binding Antibody to RBD	19.49	(8.65, 43.95)
				Binding Antibody to Spike	34.55	(13.23, 90.25)
				PsV Neutralization 50% Titer	8.56	(3.80, 19.30)
				PsV Neutralization 80% Titer	7.28	(4.18, 12.69)
				WT LV Neutralization 50% Titer	10.97	(5.28, 22.82)
	Positive	D29 fold-rise over D1	24	Binding Antibody to RBD	28832.89	(18113.98, 45894.70)
				Binding Antibody to Spike	31586.81	(27722.21, 35990.17)
				PsV Neutralization 50% Titer	107.03	(70.77, 161.87)
				PsV Neutralization 80% Titer	98.79	(53.04, 184.00)
				WT LV Neutralization 50% Titer	67.37	(40.95, 110.84)

Table 4h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
White		D57 fold-rise over D1	24	Binding Antibody to RBD	1375380.28	(857949.22, 2204875.15)
				Binding Antibody to Spike	2031337.81	(1590162.37, 2594913.17)
				PsV Neutralization 50% Titer	2273.47	(1050.41, 4920.61)
				PsV Neutralization 80% Titer	1790.88	(704.95, 4549.65)
				WT LV Neutralization 50% Titer	451.37	(152.21, 1338.56)
		D57 fold-rise over D29	24	Binding Antibody to RBD	47.70	(41.90, 54.31)
				Binding Antibody to Spike	64.31	(50.65, 81.65)
				PsV Neutralization 50% Titer	21.24	(11.91, 37.89)
				PsV Neutralization 80% Titer	18.13	(12.80, 25.68)
				WT LV Neutralization 50% Titer	6.70	(3.70, 12.14)
	Negative	D29 fold-rise over D1	43	Binding Antibody to RBD	91.46	(23.71, 352.77)
				Binding Antibody to Spike	124.35	(21.81, 708.82)
				PsV Neutralization 50% Titer	6.02	(2.48, 14.57)
				PsV Neutralization 80% Titer	15.36	(7.23, 32.63)
				WT LV Neutralization 50% Titer	9.92	(5.25, 18.72)
		D57 fold-rise over D1	43	Binding Antibody to RBD	609.00	(65.66, 5648.95)
				Binding Antibody to Spike	910.44	(86.84, 9545.63)
				PsV Neutralization 50% Titer	11.90	(2.08, 68.20)
				PsV Neutralization 80% Titer	30.93	(7.55, 126.65)
				WT LV Neutralization 50% Titer	30.12	(8.42, 107.79)
		D57 fold-rise over D29	43	Binding Antibody to RBD	6.66	(2.74, 16.16)
				Binding Antibody to Spike	7.32	(3.73, 14.37)
				PsV Neutralization 50% Titer	1.98	(0.82, 4.76)
				PsV Neutralization 80% Titer	2.01	(1.01, 4.01)
				WT LV Neutralization 50% Titer	3.04	(1.60, 5.78)
	Positive	D29 fold-rise over D1	38	Binding Antibody to RBD	22753.82	(10060.38, 51462.90)
				Binding Antibody to Spike	41658.15	(16823.90, 103150.98)
				PsV Neutralization 50% Titer	123.59	(57.11, 267.48)
				PsV Neutralization 80% Titer	270.09	(139.75, 521.98)
				WT LV Neutralization 50% Titer	137.07	(60.23, 311.93)
		D57 fold-rise over D1	38	Binding Antibody to RBD	1032490.09	(327056.53, 3259484.84)
				Binding Antibody to Spike	4235831.99	(1681716.37, 10669024.19)
				PsV Neutralization 50% Titer	1404.47	(301.65, 6539.16)
				PsV Neutralization 80% Titer	2615.33	(576.50, 11864.57)

Table 4h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
White Non-Hispanic	Negative	D57 fold-rise over D29	38	WT LV Neutralization 50% Titer	1809.13	(534.53, 6123.10)
				Binding Antibody to RBD	45.38	(29.10, 70.77)
				Binding Antibody to Spike	101.68	(89.88, 115.03)
				PsV Neutralization 50% Titer	11.36	(5.27, 24.50)
				PsV Neutralization 80% Titer	9.68	(4.09, 22.92)
		D29 fold-rise over D1	456	WT LV Neutralization 50% Titer	13.20	(8.11, 21.48)
				Binding Antibody to RBD	229.57	(138.40, 380.80)
				Binding Antibody to Spike	294.61	(178.08, 487.40)
				PsV Neutralization 50% Titer	10.95	(7.40, 16.22)
				PsV Neutralization 80% Titer	18.83	(12.76, 27.78)
		D57 fold-rise over D1	456	WT LV Neutralization 50% Titer	12.43	(8.72, 17.73)
				Binding Antibody to RBD	1991.26	(1000.15, 3964.53)
				Binding Antibody to Spike	2332.43	(1345.03, 4044.69)
				PsV Neutralization 50% Titer	43.88	(28.30, 68.02)
				PsV Neutralization 80% Titer	71.97	(44.73, 115.79)
	Positive	D57 fold-rise over D29	456	WT LV Neutralization 50% Titer	46.72	(31.50, 69.30)
				Binding Antibody to RBD	8.67	(6.50, 11.58)
				Binding Antibody to Spike	7.92	(7.54, 8.31)
				PsV Neutralization 50% Titer	4.01	(3.82, 4.21)
				PsV Neutralization 80% Titer	3.82	(3.43, 4.25)
		D29 fold-rise over D1	224	WT LV Neutralization 50% Titer	3.76	(3.59, 3.93)
				Binding Antibody to RBD	18250.07	(7723.00, 43126.39)
				Binding Antibody to Spike	36818.71	(15951.67, 84982.81)
				PsV Neutralization 50% Titer	92.48	(45.87, 186.44)
				PsV Neutralization 80% Titer	200.22	(123.33, 325.04)
		D57 fold-rise over D1	224	WT LV Neutralization 50% Titer	97.19	(59.93, 157.62)
				Binding Antibody to RBD	1120622.52	(466700.44, 2690794.19)
				Binding Antibody to Spike	2118413.45	(779294.01, 5758642.39)
				PsV Neutralization 50% Titer	1585.66	(652.08, 3855.84)
				PsV Neutralization 80% Titer	3850.35	(2633.53, 5629.39)
	D57 fold-rise over D29	224	224	WT LV Neutralization 50% Titer	1850.54	(1063.59, 3219.76)
				Binding Antibody to RBD	61.40	(56.26, 67.02)
				Binding Antibody to Spike	57.54	(48.71, 67.96)
				PsV Neutralization 50% Titer	17.15	(13.18, 22.30)

Table 4h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
				PsV Neutralization 80% Titer	19.23	(17.12, 21.60)
				WT LV Neutralization 50% Titer	19.04	(17.05, 21.26)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 4i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race and ethnic group

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Race and ethnic group						
White Non-Hispanic	Negative	D29 fold-rise over D1	456	Binding Antibody to RBD	229.57	(138.40, 380.80)
				Binding Antibody to Spike	294.61	(178.08, 487.40)
				PsV Neutralization 50% Titer	10.95	(7.40, 16.22)
				PsV Neutralization 80% Titer	18.83	(12.76, 27.78)
				WT LV Neutralization 50% Titer	12.43	(8.72, 17.73)
		D57 fold-rise over D1	456	Binding Antibody to RBD	1991.26	(1000.15, 3964.53)
				Binding Antibody to Spike	2332.43	(1345.03, 4044.69)
				PsV Neutralization 50% Titer	43.88	(28.30, 68.02)
				PsV Neutralization 80% Titer	71.97	(44.73, 115.79)
				WT LV Neutralization 50% Titer	46.72	(31.50, 69.30)
		D57 fold-rise over D29	456	Binding Antibody to RBD	8.67	(6.50, 11.58)
				Binding Antibody to Spike	7.92	(7.54, 8.31)
				PsV Neutralization 50% Titer	4.01	(3.82, 4.21)
				PsV Neutralization 80% Titer	3.82	(3.43, 4.25)
				WT LV Neutralization 50% Titer	3.76	(3.59, 3.93)
	Positive	D29 fold-rise over D1	224	Binding Antibody to RBD	18250.07	(7723.00, 43126.39)
				Binding Antibody to Spike	36818.71	(15951.67, 84982.81)
				PsV Neutralization 50% Titer	92.48	(45.87, 186.44)
				PsV Neutralization 80% Titer	200.22	(123.33, 325.04)
				WT LV Neutralization 50% Titer	97.19	(59.93, 157.62)
		D57 fold-rise over D1	224	Binding Antibody to RBD	1120622.52	(466700.44, 2690794.19)
				Binding Antibody to Spike	2118413.45	(779294.01, 5758642.39)
				PsV Neutralization 50% Titer	1585.66	(652.08, 3855.84)
				PsV Neutralization 80% Titer	3850.35	(2633.53, 5629.39)
				WT LV Neutralization 50% Titer	1850.54	(1063.59, 3219.76)
		D57 fold-rise over D29	224	Binding Antibody to RBD	61.40	(56.26, 67.02)
				Binding Antibody to Spike	57.54	(48.71, 67.96)
				PsV Neutralization 50% Titer	17.15	(13.18, 22.30)
				PsV Neutralization 80% Titer	19.23	(17.12, 21.60)
				WT LV Neutralization 50% Titer	19.04	(17.05, 21.26)
Communities of Color	Negative	D29 fold-rise over D1	535	Binding Antibody to RBD	165.60	(106.12, 258.40)
				Binding Antibody to Spike	219.91	(138.29, 349.69)

Table 4i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
		D57 fold-rise over D1	535	PsV Neutralization 50% Titer	10.83	(7.29, 16.09)
				PsV Neutralization 80% Titer	14.09	(10.93, 18.15)
				WT LV Neutralization 50% Titer	10.74	(8.20, 14.07)
				Binding Antibody to RBD	1102.64	(645.81, 1882.62)
				Binding Antibody to Spike	1676.22	(1058.60, 2654.20)
				PsV Neutralization 50% Titer	48.24	(31.47, 73.92)
		D57 fold-rise over D29	535	PsV Neutralization 80% Titer	50.91	(38.13, 67.99)
				WT LV Neutralization 50% Titer	40.62	(28.27, 58.38)
				Binding Antibody to RBD	6.66	(6.00, 7.39)
				Binding Antibody to Spike	7.62	(7.54, 7.71)
				PsV Neutralization 50% Titer	4.45	(3.75, 5.29)
				PsV Neutralization 80% Titer	3.61	(3.41, 3.83)
	Positive	D29 fold-rise over D1	261	WT LV Neutralization 50% Titer	3.78	(3.39, 4.22)
				Binding Antibody to RBD	24136.62	(12802.21, 45505.93)
				Binding Antibody to Spike	34434.44	(19206.44, 61736.10)
				PsV Neutralization 50% Titer	89.19	(42.31, 188.02)
				PsV Neutralization 80% Titer	217.41	(124.37, 380.06)
				WT LV Neutralization 50% Titer	116.68	(69.31, 196.42)
		D57 fold-rise over D1	261	Binding Antibody to RBD	1247211.35	(572310.18, 2717994.89)
				Binding Antibody to Spike	2084294.98	(996451.98, 4359754.04)
				PsV Neutralization 50% Titer	1699.83	(637.99, 4528.97)
				PsV Neutralization 80% Titer	3599.58	(1835.24, 7060.07)
				WT LV Neutralization 50% Titer	1708.29	(767.40, 3802.81)
		D57 fold-rise over D29	261	Binding Antibody to RBD	51.67	(42.64, 62.61)
				Binding Antibody to Spike	60.53	(51.88, 70.62)
				PsV Neutralization 50% Titer	19.06	(15.06, 24.11)
				PsV Neutralization 80% Titer	16.56	(14.75, 18.58)
				WT LV Neutralization 50% Titer	14.64	(10.77, 19.91)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 4j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Race and ethnic group

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Age, Race and ethnic group						
Age < 65 Communities of Color	Negative	D29 fold-rise over D1	253	Binding Antibody to RBD	137.52	(136.67, 138.38)
				Binding Antibody to Spike	180.66	(173.81, 187.78)
				PsV Neutralization 50% Titer	9.15	(8.76, 9.55)
				PsV Neutralization 80% Titer	12.68	(10.30, 15.62)
				WT LV Neutralization 50% Titer	9.54	(8.35, 10.91)
		D57 fold-rise over D1	253	Binding Antibody to RBD	889.89	(828.97, 955.28)
				Binding Antibody to Spike	1378.06	(1308.08, 1451.78)
				PsV Neutralization 50% Titer	40.12	(30.47, 52.82)
				PsV Neutralization 80% Titer	44.92	(37.52, 53.78)
				WT LV Neutralization 50% Titer	34.70	(31.68, 38.01)
		D57 fold-rise over D29	253	Binding Antibody to RBD	6.47	(5.99, 6.99)
				Binding Antibody to Spike	7.63	(7.53, 7.73)
				PsV Neutralization 50% Titer	4.39	(3.48, 5.53)
				PsV Neutralization 80% Titer	3.54	(3.44, 3.64)
				WT LV Neutralization 50% Titer	3.64	(3.48, 3.80)
	Positive	D29 fold-rise over D1	148	Binding Antibody to RBD	18564.47	(14952.91, 23048.33)
				Binding Antibody to Spike	27155.23	(24516.56, 30077.89)
				PsV Neutralization 50% Titer	65.69	(55.18, 78.20)
				PsV Neutralization 80% Titer	173.00	(153.45, 195.04)
				WT LV Neutralization 50% Titer	94.07	(79.16, 111.77)
		D57 fold-rise over D1	148	Binding Antibody to RBD	911596.64	(834547.28, 995759.55)
				Binding Antibody to Spike	1543560.34	(1353557.49, 1760234.46)
				PsV Neutralization 50% Titer	1139.26	(935.97, 1386.71)
				PsV Neutralization 80% Titer	2733.76	(2385.24, 3133.20)
				WT LV Neutralization 50% Titer	1240.86	(1165.71, 1320.85)
		D57 fold-rise over D29	148	Binding Antibody to RBD	49.10	(43.20, 55.81)
				Binding Antibody to Spike	56.84	(55.21, 58.52)
				PsV Neutralization 50% Titer	17.34	(16.96, 17.73)
				PsV Neutralization 80% Titer	15.80	(15.54, 16.06)
				WT LV Neutralization 50% Titer	13.19	(11.82, 14.73)

Table 4j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCs) between post-vaccinations/pre-vaccination by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Age < 65 White Non-Hispanic	Negative	D29 fold-rise over D1	227	Binding Antibody to RBD	189.81	(117.23, 307.32)
				Binding Antibody to Spike	243.28	(152.23, 388.78)
				PsV Neutralization 50% Titer	9.30	(7.12, 12.15)
				PsV Neutralization 80% Titer	16.98	(10.51, 27.45)
				WT LV Neutralization 50% Titer	11.03	(7.49, 16.24)
		D57 fold-rise over D1	227	Binding Antibody to RBD	1649.30	(710.21, 3830.11)
				Binding Antibody to Spike	1895.75	(1124.49, 3195.97)
				PsV Neutralization 50% Titer	36.63	(26.69, 50.27)
				PsV Neutralization 80% Titer	62.07	(35.83, 107.53)
				WT LV Neutralization 50% Titer	40.68	(26.92, 61.45)
		D57 fold-rise over D29	227	Binding Antibody to RBD	8.69	(6.06, 12.46)
				Binding Antibody to Spike	7.79	(7.39, 8.22)
				PsV Neutralization 50% Titer	3.94	(3.75, 4.14)
				PsV Neutralization 80% Titer	3.65	(3.41, 3.92)
				WT LV Neutralization 50% Titer	3.69	(3.59, 3.78)
	Positive	D29 fold-rise over D1	117	Binding Antibody to RBD	13516.69	(9378.06, 19481.74)
				Binding Antibody to Spike	26392.79	(23690.95, 29402.75)
				PsV Neutralization 50% Titer	72.49	(53.46, 98.31)
				PsV Neutralization 80% Titer	167.20	(144.36, 193.66)
				WT LV Neutralization 50% Titer	81.26	(69.85, 94.53)
		D57 fold-rise over D1	117	Binding Antibody to RBD	808321.77	(623162.08, 1048497.82)
				Binding Antibody to Spike	1431583.70	(1202141.74, 1704817.18)
				PsV Neutralization 50% Titer	1113.25	(992.90, 1248.19)
				PsV Neutralization 80% Titer	3313.13	(3132.85, 3503.78)
				WT LV Neutralization 50% Titer	1480.93	(1405.07, 1560.89)
		D57 fold-rise over D29	117	Binding Antibody to RBD	59.80	(53.82, 66.45)
				Binding Antibody to Spike	54.24	(50.74, 57.98)
				PsV Neutralization 50% Titer	15.36	(12.70, 18.57)
				PsV Neutralization 80% Titer	19.81	(18.09, 21.70)
				WT LV Neutralization 50% Titer	18.22	(16.51, 20.11)
Age >= 65 Communities of Color	Negative	D29 fold-rise over D1	282	Binding Antibody to RBD	315.32	(315.32, 315.32)
				Binding Antibody to Spike	434.69	(434.69, 434.69)

Table 4j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCs) between post-vaccinations/pre-vaccination by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
Age >= 65 White Non-Hispanic	Positive	D57 fold-rise over D1	282	PsV Neutralization 50% Titer	19.43	(19.43, 19.43)
				PsV Neutralization 80% Titer	20.27	(20.27, 20.27)
				WT LV Neutralization 50% Titer	16.17	(16.17, 16.17)
				Binding Antibody to RBD	2318.31	(2318.31, 2318.31)
				Binding Antibody to Spike	3305.36	(3305.36, 3305.36)
		D57 fold-rise over D29	282	PsV Neutralization 50% Titer	91.36	(91.36, 91.36)
				PsV Neutralization 80% Titer	78.58	(78.58, 78.58)
				WT LV Neutralization 50% Titer	70.13	(70.13, 70.13)
				Binding Antibody to RBD	7.35	(7.35, 7.35)
				Binding Antibody to Spike	7.60	(7.60, 7.60)
		D29 fold-rise over D1	113	PsV Neutralization 50% Titer	4.70	(4.70, 4.70)
				PsV Neutralization 80% Titer	3.88	(3.88, 3.88)
				WT LV Neutralization 50% Titer	4.34	(4.34, 4.34)
				Binding Antibody to RBD	79766.39	(79766.39, 79766.39)
				Binding Antibody to Spike	101555.87	(101555.87, 101555.87)
	Negative	D57 fold-rise over D1	113	PsV Neutralization 50% Titer	359.12	(359.12, 359.12)
				PsV Neutralization 80% Titer	615.51	(615.51, 615.51)
				WT LV Neutralization 50% Titer	311.26	(311.26, 311.26)
				Binding Antibody to RBD	5199099.85	(5199099.85, 5199099.85)
				Binding Antibody to Spike	8184283.15	(8184283.15, 8184283.15)
		D57 fold-rise over D29	113	PsV Neutralization 50% Titer	10515.60	(10515.60, 10515.60)
				PsV Neutralization 80% Titer	12601.76	(12601.76, 12601.76)
				WT LV Neutralization 50% Titer	7325.87	(7325.87, 7325.87)
				Binding Antibody to RBD	65.18	(65.18, 65.18)
				Binding Antibody to Spike	80.59	(80.59, 80.59)
		D29 fold-rise over D1	229	PsV Neutralization 50% Titer	29.28	(29.28, 29.28)
				PsV Neutralization 80% Titer	20.47	(20.47, 20.47)
				WT LV Neutralization 50% Titer	23.54	(23.54, 23.54)
				Binding Antibody to RBD	486.03	(486.03, 486.03)
				Binding Antibody to Spike	626.84	(626.84, 626.84)
				PsV Neutralization 50% Titer	20.84	(20.84, 20.84)
				PsV Neutralization 80% Titer	28.30	(28.30, 28.30)
				WT LV Neutralization 50% Titer	19.95	(19.95, 19.95)

Table 4j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCs) between post-vaccinations/pre-vaccination by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	GMTR/GMCR	95% CI
		D57 fold-rise over D1	229	Binding Antibody to RBD	4186.41	(4186.41, 4186.41)
				Binding Antibody to Spike	5282.74	(5282.74, 5282.74)
				PsV Neutralization 50% Titer	89.39	(89.39, 89.39)
				PsV Neutralization 80% Titer	128.97	(128.97, 128.97)
				WT LV Neutralization 50% Titer	80.68	(80.68, 80.68)
		D57 fold-rise over D29	229	Binding Antibody to RBD	8.61	(8.61, 8.61)
				Binding Antibody to Spike	8.43	(8.43, 8.43)
				PsV Neutralization 50% Titer	4.29	(4.29, 4.29)
				PsV Neutralization 80% Titer	4.56	(4.56, 4.56)
				WT LV Neutralization 50% Titer	4.04	(4.04, 4.04)
	Positive	D29 fold-rise over D1	107	Binding Antibody to RBD	54235.32	(54235.32, 54235.32)
				Binding Antibody to Spike	123185.22	(123185.22, 123185.22)
				PsV Neutralization 50% Titer	223.65	(223.65, 223.65)
				PsV Neutralization 80% Titer	384.93	(384.93, 384.93)
				WT LV Neutralization 50% Titer	186.05	(186.05, 186.05)
		D57 fold-rise over D1	107	Binding Antibody to RBD	3665429.27	(3665429.27, 3665429.27)
				Binding Antibody to Spike	8778206.78	(8778206.78, 8778206.78)
				PsV Neutralization 50% Titer	5720.88	(5720.88, 5720.88)
				PsV Neutralization 80% Titer	6641.17	(6641.17, 6641.17)
				WT LV Neutralization 50% Titer	4152.59	(4152.59, 4152.59)
		D57 fold-rise over D29	107	Binding Antibody to RBD	67.58	(67.58, 67.58)
				Binding Antibody to Spike	71.26	(71.26, 71.26)
				PsV Neutralization 50% Titer	25.58	(25.58, 25.58)
				PsV Neutralization 80% Titer	17.25	(17.25, 17.25)
				WT LV Neutralization 50% Titer	22.32	(22.32, 22.32)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 5. Ratios of GMTs/GMCs between the vaccine arm vs. placebo arm, by baseline status

Table 5. Ratios of GMTs/GMCs between the vaccine arm vs. placebo arm, by baseline status

Baseline	Visit	N	Endpoint	Ratios of GMT/GMC	95% CI
All participants					
Negative	Day 29	1062	Binding Antibody to RBD	0.00	(0.00, 0.00)
			Binding Antibody to Spike	0.00	(0.00, 0.00)
			PsV Neutralization 50% Titer	0.20	(0.17, 0.23)
			PsV Neutralization 80% Titer	0.10	(0.08, 0.11)
			WT LV Neutralization 50% Titer	0.17	(0.15, 0.20)
	Day 57	1062	Binding Antibody to RBD	0.00	(0.00, 0.00)
			Binding Antibody to Spike	0.00	(0.00, 0.00)
			PsV Neutralization 50% Titer	0.01	(0.01, 0.02)
			PsV Neutralization 80% Titer	0.01	(0.01, 0.01)
			WT LV Neutralization 50% Titer	0.01	(0.01, 0.02)
	Day 29	543	Binding Antibody to RBD	0.30	(0.23, 0.40)
			Binding Antibody to Spike	0.23	(0.18, 0.28)
			PsV Neutralization 50% Titer	0.38	(0.29, 0.49)
			PsV Neutralization 80% Titer	0.46	(0.35, 0.61)
			WT LV Neutralization 50% Titer	0.38	(0.29, 0.49)
	Day 57	543	Binding Antibody to RBD	0.17	(0.13, 0.22)
			Binding Antibody to Spike	0.12	(0.10, 0.15)
			PsV Neutralization 50% Titer	0.12	(0.08, 0.17)
			PsV Neutralization 80% Titer	0.24	(0.17, 0.35)
			WT LV Neutralization 50% Titer	0.12	(0.09, 0.17)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 6. Ratios of GMTs/GMCs between baseline positive participants vs. negative participants, among the vaccinees

Table 6. Ratios of GMTs/GMCs between baseline positive participants vs. negative participants, among the vaccine recipients

Visit	N	Endpoint	Ratios of GMT/GMC	95% CI
All participants				
Day 29	1180	Binding Antibody to RBD	1.66	(1.21, 2.28)
		Binding Antibody to Spike	1.76	(1.35, 2.30)
		PsV Neutralization 50% Titer	1.47	(1.09, 1.98)
		PsV Neutralization 80% Titer	1.50	(1.08, 2.09)
		WT LV Neutralization 50% Titer	1.47	(1.09, 1.98)
Day 57	1180	Binding Antibody to RBD	2.54	(1.83, 3.53)
		Binding Antibody to Spike	2.51	(1.91, 3.30)
		PsV Neutralization 50% Titer	2.62	(1.71, 4.01)
		PsV Neutralization 80% Titer	2.67	(1.78, 4.00)
		WT LV Neutralization 50% Titer	3.03	(1.99, 4.63)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 7. Ratios of GMTs/GMCs between demographic subgroups among the vaccine recipients

Table 7. Ratios of GMTs/GMCs between demographic subgroups among the vaccine recipients

Baseline	Visit	Endpoint	N	Ratios of GMT/GMC	95% CI
Age					
Negative	Day 29	Binding Antibody to RBD	847	0.78	(0.63, 0.97)
		Binding Antibody to Spike		0.85	(0.70, 1.03)
		PsV Neutralization 50% Titer		0.94	(0.76, 1.16)
		PsV Neutralization 80% Titer		1.01	(0.80, 1.28)
		WT LV Neutralization 50% Titer		0.89	(0.72, 1.10)
		Binding Antibody to RBD	907	4.08	(3.19, 5.21)
				1.18	(0.96, 1.47)
				0.89	(0.70, 1.13)
				1.08	(0.76, 1.55)
		Binding Antibody to Spike		3.77	(3.07, 4.64)
				0.94	(0.78, 1.13)
				0.90	(0.73, 1.11)
				1.01	(0.74, 1.37)
		PsV Neutralization 50% Titer		2.90	(2.29, 3.67)
				1.08	(0.88, 1.32)
				0.93	(0.74, 1.17)
				1.16	(0.83, 1.62)
		PsV Neutralization 80% Titer		2.54	(1.94, 3.32)
				1.09	(0.87, 1.37)
				1.03	(0.80, 1.33)
Sex					
				1.11	(0.76, 1.62)
		WT LV Neutralization 50% Titer		2.18	(1.71, 2.78)
				1.16	(0.95, 1.43)
				0.98	(0.78, 1.23)
				1.33	(0.95, 1.87)
	Day 57	Binding Antibody to RBD	847	0.81	(0.64, 1.02)
		Binding Antibody to Spike		0.86	(0.71, 1.05)
		PsV Neutralization 50% Titer		1.13	(0.84, 1.52)
		PsV Neutralization 80% Titer		0.80	(0.61, 1.06)
		WT LV Neutralization 50% Titer		0.88	(0.65, 1.18)

Table 7. Ratios of GMTs/GMCs between demographic subgroups among the vaccine recipients (*continued*)

Baseline	Visit	Endpoint	N	Ratios of GMT/GMC	95% CI
		Binding Antibody to RBD	907	3.97	(3.07, 5.14)
				0.91	(0.72, 1.14)
				0.87	(0.68, 1.12)
				1.08	(0.74, 1.57)
		Binding Antibody to Spike		3.35	(2.69, 4.17)
				0.98	(0.81, 1.19)
				0.98	(0.80, 1.22)
				0.99	(0.72, 1.36)
		PsV Neutralization 50% Titer		3.85	(2.74, 5.41)
				1.26	(0.95, 1.69)
				0.97	(0.70, 1.33)
				0.97	(0.60, 1.58)
		PsV Neutralization 80% Titer		2.82	(2.04, 3.91)
				0.98	(0.74, 1.28)
				0.97	(0.71, 1.31)
				1.75	(1.11, 2.76)
		WT LV Neutralization 50% Titer		3.00	(2.12, 4.24)
				1.14	(0.85, 1.52)
				0.82	(0.59, 1.13)
				1.16	(0.71, 1.88)
Positive	Day 29	Binding Antibody to RBD	241	1.00	(0.65, 1.53)
				1.05	(0.75, 1.46)
		PsV Neutralization 50% Titer		1.10	(0.71, 1.71)
		PsV Neutralization 80% Titer		1.21	(0.76, 1.91)
		WT LV Neutralization 50% Titer		1.31	(0.86, 2.00)
		Binding Antibody to RBD	273	3.61	(2.25, 5.80)
				0.99	(0.66, 1.47)
				0.97	(0.61, 1.53)
				0.85	(0.49, 1.47)
		Binding Antibody to Spike		3.76	(2.62, 5.40)
				1.12	(0.82, 1.54)
				0.84	(0.58, 1.21)
				1.05	(0.68, 1.62)
		PsV Neutralization 50% Titer		3.15	(1.92, 5.15)
				0.94	(0.62, 1.41)

Table 7. Ratios of GMTs/GMCs between demographic subgroups among the vaccine recipients (*continued*)

Baseline	Visit	Endpoint	N	Ratios of GMT/GMC	95% CI
				0.78	(0.49, 1.25)
				0.96	(0.55, 1.68)
		PsV Neutralization 80% Titer		2.96	(1.77, 4.94)
				0.96	(0.63, 1.47)
				0.88	(0.54, 1.43)
				1.08	(0.61, 1.94)
		WT LV Neutralization 50% Titer		2.62	(1.62, 4.24)
				0.94	(0.64, 1.40)
				0.91	(0.58, 1.43)
				0.78	(0.45, 1.33)
	Day 57	Binding Antibody to RBD	241	0.97	(0.64, 1.48)
		Binding Antibody to Spike		1.14	(0.84, 1.56)
		PsV Neutralization 50% Titer		1.24	(0.71, 2.18)
		PsV Neutralization 80% Titer		0.67	(0.38, 1.20)
		WT LV Neutralization 50% Titer		0.69	(0.41, 1.16)
		Binding Antibody to RBD	273	3.31	(2.08, 5.26)
				0.95	(0.64, 1.40)
				0.88	(0.56, 1.37)
				0.55	(0.33, 0.94)
		Binding Antibody to Spike		2.82	(2.02, 3.93)
				1.05	(0.79, 1.40)
				1.03	(0.74, 1.42)
				0.80	(0.54, 1.17)
		PsV Neutralization 50% Titer		5.60	(2.91, 10.76)
				1.00	(0.58, 1.74)
				0.97	(0.52, 1.83)
				0.83	(0.39, 1.77)
		PsV Neutralization 80% Titer		4.09	(2.08, 8.04)
				0.89	(0.51, 1.56)
				0.80	(0.42, 1.51)
				1.12	(0.52, 2.41)
		WT LV Neutralization 50% Titer		3.74	(2.02, 6.92)
				1.11	(0.67, 1.84)
				0.98	(0.55, 1.75)
				1.71	(0.86, 3.42)

Table 7. Ratios of GMTs/GMCs between demographic subgroups among the vaccine recipients (*continued*)

Baseline	Visit	Endpoint	N	Ratios of GMT/GMC	95% CI
----------	-------	----------	---	-------------------	--------

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 8. Differences of responder rates between the vaccine arm and the placebo arm

Table 8a. Differences of responder rates between the vaccine arm and the placebo arm by All participants

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
All participants	Negative	Day 29	1062	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	65.8% (61.7%, 69.9%)	51.6% (47.3%, 56.0%)	65.8% (61.7%, 69.9%)
				PsV Neutralization 80% Titer	79.8% (76.4%, 83.3%)	68.7% (64.7%, 72.7%)	79.8% (76.4%, 83.3%)
				WT LV Neutralization 50% Titer	69.8% (65.9%, 73.8%)	53.9% (49.6%, 58.2%)	69.8% (65.9%, 73.8%)
		Day 57	1062	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	95.4% (93.6%, 97.2%)	89.9% (87.3%, 92.5%)	95.4% (93.6%, 97.2%)
				PsV Neutralization 80% Titer	97.3% (95.9%, 98.7%)	94.5% (92.6%, 96.5%)	97.3% (95.9%, 98.7%)
				WT LV Neutralization 50% Titer	94.6% (92.7%, 96.6%)	91.3% (88.9%, 93.8%)	94.6% (92.7%, 96.6%)
	Positive	Day 29	543	Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.2% (-0.3%, 0.7%)	0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	24.6% (16.8%, 32.4%)	21.1% (12.9%, 29.3%)	24.6% (16.8%, 32.4%)
				PsV Neutralization 80% Titer	7.7% (1.3%, 14.1%)	13.7% (6.0%, 21.5%)	7.7% (1.3%, 14.1%)
				WT LV Neutralization 50% Titer	23.9% (16.1%, 31.6%)	31.5% (23.6%, 39.5%)	23.9% (16.1%, 31.6%)

Table 8a. Differences of responder rates between the vaccine arm and the placebo arm by All participants (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
		Day 57	543	Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	12.5% (7.6%, 17.4%)	17.5% (11.8%, 23.2%)	12.5% (7.6%, 17.4%)
				PsV Neutralization 80% Titer	1.6% (-0.7%, 3.9%)	4.8% (1.4%, 8.2%)	1.6% (-0.7%, 3.9%)
				WT LV Neutralization 50% Titer	11.4% (7.5%, 15.3%)	19.6% (14.4%, 24.9%)	11.4% (7.5%, 15.3%)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 8b. Differences of responder rates between the vaccine arm and the placebo arm by Age

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Age < 65	Negative	Day 29	513	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	61.1% (55.0%, 67.2%)	46.0% (39.8%, 52.2%)	61.1% (55.0%, 67.2%)
				PsV Neutralization 80% Titer	76.7% (71.4%, 82.0%)	65.4% (59.4%, 71.3%)	76.7% (71.4%, 82.0%)
				WT LV Neutralization 50% Titer	66.5% (60.6%, 72.4%)	49.6% (43.4%, 55.9%)	66.5% (60.6%, 72.4%)
		Day 57	513	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	95.1% (92.4%, 97.8%)	88.4% (84.5%, 92.4%)	95.1% (92.4%, 97.8%)
				PsV Neutralization 80% Titer	96.9% (94.8%, 99.1%)	93.6% (90.5%, 96.6%)	96.9% (94.8%, 99.1%)
				WT LV Neutralization 50% Titer	94.0% (91.0%, 96.9%)	90.7% (87.1%, 94.3%)	94.0% (91.0%, 96.9%)
	Positive	Day 29	294	Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.3% (-0.6%, 1.1%)	0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	26.5% (15.7%, 37.4%)	20.0% (9.0%, 31.1%)	26.5% (15.7%, 37.4%)
				PsV Neutralization 80% Titer	7.0% (-2.1%, 16.1%)	13.0% (2.1%, 23.8%)	7.0% (-2.1%, 16.1%)
				WT LV Neutralization 50% Titer	24.9% (14.2%, 35.7%)	32.0% (21.1%, 42.8%)	24.9% (14.2%, 35.7%)
		Day 57	294	Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)

Table 8b. Differences of responder rates between the vaccine arm and the placebo arm by Age (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Age >= 65	Negative	Day 29	549	Binding Antibody to Spike	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	15.0%	20.6%	15.0%
					(7.9%, 22.2%)	(12.5%, 28.8%)	(7.9%, 22.2%)
				PsV Neutralization 80% Titer	1.3%	4.8%	1.3%
					(-1.9%, 4.5%)	(-0.1%, 9.7%)	(-1.9%, 4.5%)
				WT LV Neutralization 50% Titer	13.4%	22.9%	13.4%
					(7.8%, 19.0%)	(15.4%, 30.4%)	(7.8%, 19.0%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
	Positive	Day 29	249	Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	83.2%	72.5%	83.2%
					(78.8%, 87.7%)	(67.2%, 77.8%)	(78.8%, 87.7%)
				PsV Neutralization 80% Titer	91.4%	81.0%	91.4%
					(88.1%, 94.8%)	(76.3%, 85.6%)	(88.1%, 94.8%)
				WT LV Neutralization 50% Titer	82.2%	69.7%	82.2%
					(77.6%, 86.7%)	(64.3%, 75.2%)	(77.6%, 86.7%)
		Day 57	549	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	96.5%	95.5%	96.5%
					(94.4%, 98.7%)	(93.0%, 97.9%)	(94.4%, 98.7%)
				PsV Neutralization 80% Titer	98.9%	98.1%	98.9%
					(97.7%, 100.2%)	(96.4%, 99.7%)	(97.7%, 100.2%)
				WT LV Neutralization 50% Titer	97.0%	93.8%	97.0%
					(95.0%, 99.0%)	(90.9%, 96.6%)	(95.0%, 99.0%)
				Binding Antibody to RBD	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 8b. Differences of responder rates between the vaccine arm and the placebo arm by Age (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
				PsV Neutralization 50% Titer	16.3%	25.2%	16.3%
					(7.2%, 25.4%)	(14.0%, 36.5%)	(7.2%, 25.4%)
				PsV Neutralization 80% Titer	10.6%	16.6%	10.6%
					(3.3%, 17.9%)	(7.9%, 25.3%)	(3.3%, 17.9%)
				WT LV Neutralization 50% Titer	19.2%	29.6%	19.2%
					(9.8%, 28.6%)	(18.6%, 40.6%)	(9.8%, 28.6%)
		Day 57	249	Binding Antibody to RBD	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	2.1%	4.7%	2.1%
					(-1.8%, 6.1%)	(-0.9%, 10.3%)	(-1.8%, 6.1%)
				PsV Neutralization 80% Titer	2.9%	4.5%	2.9%
					(-0.0%, 5.8%)	(0.9%, 8.2%)	(-0.0%, 5.8%)
				WT LV Neutralization 50% Titer	2.9%	6.2%	2.9%
					(-0.7%, 6.6%)	(1.5%, 11.0%)	(-0.7%, 6.6%)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 8c. Differences of responder rates between the vaccine arm and the placebo arm by Risk for Severe Covid-19

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
At-risk	Negative	Day 29	541	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	65.1% (59.3%, 70.9%)	50.8% (44.7%, 56.9%)	65.1% (59.3%, 70.9%)
				PsV Neutralization 80% Titer	78.7% (73.7%, 83.7%)	67.2% (61.5%, 72.9%)	78.7% (73.7%, 83.7%)
				WT LV Neutralization 50% Titer	69.0% (63.3%, 74.6%)	55.2% (49.1%, 61.2%)	69.0% (63.3%, 74.6%)
		Day 57	541	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	93.6% (90.6%, 96.6%)	89.5% (85.8%, 93.2%)	93.6% (90.6%, 96.6%)
				PsV Neutralization 80% Titer	97.4% (95.5%, 99.4%)	94.5% (91.7%, 97.3%)	97.4% (95.5%, 99.4%)
				WT LV Neutralization 50% Titer	95.2% (92.5%, 97.8%)	90.5% (86.9%, 94.1%)	95.2% (92.5%, 97.8%)
	Positive	Day 29	246	Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	0.9% (-0.7%, 2.5%)	-0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	21.5% (10.2%, 32.8%)	21.6% (9.3%, 33.9%)	21.5% (10.2%, 32.8%)
				PsV Neutralization 80% Titer	14.3% (4.0%, 24.5%)	18.3% (7.1%, 29.5%)	14.3% (4.0%, 24.5%)
				WT LV Neutralization 50% Titer	17.3% (5.7%, 28.9%)	31.7% (19.8%, 43.5%)	17.3% (5.7%, 28.9%)
		Day 57	246	Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)

Table 8c. Differences of responder rates between the vaccine arm and the placebo arm by Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Not at-risk	Negative	Day 29	521	Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	8.1%	10.5%	8.1%
					(1.4%, 14.7%)	(2.3%, 18.6%)	(1.4%, 14.7%)
				PsV Neutralization 80% Titer	3.0%	4.6%	3.0%
					(-0.8%, 6.8%)	(0.3%, 9.0%)	(-0.8%, 6.8%)
				WT LV Neutralization 50% Titer	8.4%	13.2%	8.4%
					(2.8%, 14.0%)	(6.4%, 20.1%)	(2.8%, 14.0%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
	Positive	Day 29	297	Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	66.0%	52.0%	66.0%
					(60.2%, 71.9%)	(45.8%, 58.1%)	(60.2%, 71.9%)
				PsV Neutralization 80% Titer	80.3%	69.2%	80.3%
					(75.4%, 85.2%)	(63.6%, 74.9%)	(75.4%, 85.2%)
				WT LV Neutralization 50% Titer	70.2%	53.4%	70.2%
					(64.5%, 75.8%)	(47.3%, 59.6%)	(64.5%, 75.8%)
		Day 57	521	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	96.1%	90.1%	96.1%
					(93.7%, 98.5%)	(86.4%, 93.8%)	(93.7%, 98.5%)
				PsV Neutralization 80% Titer	97.3%	94.5%	97.3%
					(95.3%, 99.3%)	(91.7%, 97.3%)	(95.3%, 99.3%)
				WT LV Neutralization 50% Titer	94.4%	91.6%	94.4%
					(91.6%, 97.2%)	(88.2%, 95.1%)	(91.6%, 97.2%)
	Positive	Day 29	297	Binding Antibody to RBD	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 8c. Differences of responder rates between the vaccine arm and the placebo arm by Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
				PsV Neutralization 50% Titer	25.4%	20.8%	25.4%
					(14.7%, 36.0%)	(9.7%, 31.9%)	(14.7%, 36.0%)
				PsV Neutralization 80% Titer	5.8%	12.2%	5.8%
					(-2.7%, 14.3%)	(1.6%, 22.8%)	(-2.7%, 14.3%)
				WT LV Neutralization 50% Titer	25.9%	31.4%	25.9%
					(15.5%, 36.3%)	(20.5%, 42.2%)	(15.5%, 36.3%)
		Day 57	297	Binding Antibody to RBD	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	13.8%	19.7%	13.8%
					(7.1%, 20.6%)	(11.9%, 27.5%)	(7.1%, 20.6%)
				PsV Neutralization 80% Titer	1.2%	4.8%	1.2%
					(-1.8%, 4.2%)	(-0.0%, 9.6%)	(-1.8%, 4.2%)
				WT LV Neutralization 50% Titer	12.3%	21.5%	12.3%
					(7.0%, 17.6%)	(14.2%, 28.8%)	(7.0%, 17.6%)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 8d. Differences of responder rates between the vaccine arm and the placebo arm by Age, Risk for Severe Covid-19

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Age < 65 At-risk	Negative	Day 29	257	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	55.7%	39.8%	55.7%
					(47.0%, 64.5%)	(31.2%, 48.4%)	(47.0%, 64.5%)
				PsV Neutralization 80% Titer	72.7%	60.6%	72.7%
					(64.9%, 80.6%)	(52.0%, 69.2%)	(64.9%, 80.6%)
				WT LV Neutralization 50% Titer	62.4%	48.3%	62.4%
					(53.9%, 71.0%)	(39.5%, 57.1%)	(53.9%, 71.0%)
		Day 57	257	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	92.4%	86.8%	92.4%
					(87.7%, 97.1%)	(80.8%, 92.8%)	(87.7%, 97.1%)
				PsV Neutralization 80% Titer	95.7%	92.0%	95.7%
					(92.2%, 99.3%)	(87.2%, 96.8%)	(92.2%, 99.3%)
				WT LV Neutralization 50% Titer	93.9%	88.7%	93.9%
					(89.7%, 98.1%)	(83.1%, 94.3%)	(89.7%, 98.1%)
	Positive	Day 29	148	Binding Antibody to RBD	0.0%	1.3%	0.0%
					(-0.0%, 0.0%)	(-1.2%, 3.9%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	21.9%	18.8%	21.9%
					(6.6%, 37.3%)	(2.9%, 34.6%)	(6.6%, 37.3%)
				PsV Neutralization 80% Titer	10.1%	13.9%	10.1%
					(-3.9%, 24.2%)	(-1.5%, 29.3%)	(-3.9%, 24.2%)
				WT LV Neutralization 50% Titer	13.9%	28.4%	13.9%
					(-1.6%, 29.4%)	(12.8%, 44.0%)	(-1.6%, 29.4%)
		Day 57	148	Binding Antibody to RBD	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 8d. Differences of responder rates between the vaccine arm and the placebo arm by Age, Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Age < 65 Not at-risk	Negative	Day 29	256	Binding Antibody to Spike	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	10.6%	11.8%	10.6%
					(1.4%, 19.7%)	(0.8%, 22.8%)	(1.4%, 19.7%)
				PsV Neutralization 80% Titer	1.3%	2.6%	1.3%
					(-3.2%, 5.8%)	(-2.5%, 7.8%)	(-3.2%, 5.8%)
				WT LV Neutralization 50% Titer	13.3%	17.3%	13.3%
					(5.0%, 21.6%)	(7.6%, 27.0%)	(5.0%, 21.6%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
	Positive	Day 29	146	Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	62.5%	47.7%	62.5%
					(53.9%, 71.1%)	(38.8%, 56.5%)	(53.9%, 71.1%)
				PsV Neutralization 80% Titer	77.8%	66.7%	77.8%
					(70.4%, 85.1%)	(58.3%, 75.0%)	(70.4%, 85.1%)
				WT LV Neutralization 50% Titer	67.6%	50.0%	67.6%
					(59.3%, 75.9%)	(41.2%, 58.8%)	(59.3%, 75.9%)
		Day 57	256	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	95.8%	88.9%	95.8%
					(92.3%, 99.4%)	(83.3%, 94.5%)	(92.3%, 99.4%)
				PsV Neutralization 80% Titer	97.2%	94.0%	97.2%
					(94.3%, 100.1%)	(89.8%, 98.2%)	(94.3%, 100.1%)
				WT LV Neutralization 50% Titer	94.0%	91.2%	94.0%
					(89.8%, 98.2%)	(86.2%, 96.2%)	(89.8%, 98.2%)
				Binding Antibody to RBD	-0.0%	-0.0%	-0.0%
					(-0.0%, -0.0%)	(-0.0%, -0.0%)	(-0.0%, -0.0%)
				Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, -0.0%)	(-0.0%, -0.0%)	(-0.0%, -0.0%)

Table 8d. Differences of responder rates between the vaccine arm and the placebo arm by Age, Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Age >= 65 At-risk	Negative	Day 57	146	PsV Neutralization 50% Titer	27.6%	20.3%	27.6%
					(12.2%, 43.1%)	(4.6%, 35.9%)	(12.2%, 43.1%)
				PsV Neutralization 80% Titer	6.3%	12.7%	6.3%
					(-6.3%, 19.0%)	(-2.8%, 28.2%)	(-6.3%, 19.0%)
				WT LV Neutralization 50% Titer	27.7%	32.8%	27.7%
					(12.6%, 42.9%)	(17.4%, 48.2%)	(12.6%, 42.9%)
				Binding Antibody to RBD	-0.0%	-0.0%	-0.0%
					(-0.0%, -0.0%)	(-0.0%, -0.0%)	(-0.0%, -0.0%)
				Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, -0.0%)	(-0.0%, -0.0%)	(-0.0%, -0.0%)
				PsV Neutralization 50% Titer	16.1%	22.8%	16.1%
					(5.8%, 26.5%)	(11.2%, 34.5%)	(5.8%, 26.5%)
				PsV Neutralization 80% Titer	1.3%	5.3%	1.3%
					(-3.3%, 5.9%)	(-2.0%, 12.7%)	(-3.3%, 5.9%)
				WT LV Neutralization 50% Titer	13.5%	24.2%	13.5%
					(5.6%, 21.4%)	(13.3%, 35.2%)	(5.6%, 21.4%)
		Day 29	284	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	79.4%	67.6%	79.4%
					(72.5%, 86.2%)	(59.6%, 75.5%)	(72.5%, 86.2%)
				PsV Neutralization 80% Titer	87.9%	77.4%	87.9%
					(82.3%, 93.4%)	(70.3%, 84.5%)	(82.3%, 93.4%)
		Day 57	284	WT LV Neutralization 50% Titer	79.0%	65.6%	79.0%
					(72.0%, 85.9%)	(57.5%, 73.6%)	(72.0%, 85.9%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	95.3%	93.7%	95.3%
					(91.7%, 98.9%)	(89.5%, 97.8%)	(91.7%, 98.9%)

Table 8d. Differences of responder rates between the vaccine arm and the placebo arm by Age, Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Age < 65 At-risk	Positive	Day 29	98	PsV Neutralization 80% Titer	100.0% (100.0%, 100.0%)	98.3% (96.1%, 100.5%)	100.0% (100.0%, 100.0%)
				WT LV Neutralization 50% Titer	97.1% (94.2%, 99.9%)	93.2% (89.0%, 97.5%)	97.1% (94.2%, 99.9%)
				Binding Antibody to RBD	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
				PsV Neutralization 50% Titer	20.4% (5.5%, 35.2%)	27.4% (8.8%, 45.9%)	20.4% (5.5%, 35.2%)
				PsV Neutralization 80% Titer	22.9% (9.5%, 36.2%)	27.3% (13.5%, 41.1%)	22.9% (9.5%, 36.2%)
				WT LV Neutralization 50% Titer	24.4% (7.9%, 41.0%)	38.4% (20.9%, 55.9%)	24.4% (7.9%, 41.0%)
		Day 57	98	Binding Antibody to RBD	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
				PsV Neutralization 50% Titer	2.9% (-6.0%, 11.7%)	7.6% (-3.9%, 19.1%)	2.9% (-6.0%, 11.7%)
				PsV Neutralization 80% Titer	6.7% (-0.1%, 13.5%)	8.9% (1.1%, 16.7%)	6.7% (-0.1%, 13.5%)
				WT LV Neutralization 50% Titer	-1.9% (-5.9%, 2.1%)	4.8% (-3.1%, 12.7%)	-1.9% (-5.9%, 2.1%)
	Negative	Day 29	265	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	87.3% (81.7%, 92.9%)	77.6% (70.6%, 84.6%)	87.3% (81.7%, 92.9%)
				PsV Neutralization 80% Titer	95.2% (91.6%, 98.8%)	84.6% (78.6%, 90.7%)	95.2% (91.6%, 98.8%)

Table 8d. Differences of responder rates between the vaccine arm and the placebo arm by Age, Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Positive		Day 57	265	WT LV Neutralization 50% Titer	85.5% (79.6%, 91.4%)	74.1% (66.8%, 81.5%)	85.5% (79.6%, 91.4%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	97.8% (95.4%, 100.3%)	97.4% (94.7%, 100.1%)	97.8% (95.4%, 100.3%)
				PsV Neutralization 80% Titer	97.8% (95.4%, 100.3%)	97.8% (95.4%, 100.3%)	97.8% (95.4%, 100.3%)
				WT LV Neutralization 50% Titer	96.9% (94.0%, 99.8%)	94.3% (90.4%, 98.2%)	96.9% (94.0%, 99.8%)
		Day 29	151	Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	13.8% (2.2%, 25.4%)	24.4% (10.2%, 38.5%)	13.8% (2.2%, 25.4%)
				PsV Neutralization 80% Titer	3.2% (-4.9%, 11.4%)	9.8% (-1.3%, 21.0%)	3.2% (-4.9%, 11.4%)
				WT LV Neutralization 50% Titer	16.5% (5.3%, 27.6%)	24.4% (10.2%, 38.5%)	16.5% (5.3%, 27.6%)
				Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
		Day 57	151	Binding Antibody to Spike	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	1.9% (-1.2%, 5.1%)	3.3% (-2.2%, 8.7%)	1.9% (-1.2%, 5.1%)
				PsV Neutralization 80% Titer	0.6% (-1.2%, 2.4%)	1.9% (-1.2%, 5.1%)	0.6% (-1.2%, 2.4%)
				WT LV Neutralization 50% Titer	5.9% (0.5%, 11.3%)	7.2% (1.3%, 13.1%)	5.9% (0.5%, 11.3%)

Table 8d. Differences of responder rates between the vaccine arm and the placebo arm by Age, Risk for Severe Covid-19 (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
-------	----------	-------	---	----------	-------------	-------------	-----------

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 8e. Differences of responder rates between the vaccine arm and the placebo arm by Sex

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Female	Negative	Day 29	597	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	65.6% (60.1%, 71.1%)	51.9% (46.1%, 57.7%)	65.6% (60.1%, 71.1%)
				PsV Neutralization 80% Titer	78.9% (74.1%, 83.6%)	68.3% (63.0%, 73.7%)	78.9% (74.1%, 83.6%)
				WT LV Neutralization 50% Titer	68.9% (63.5%, 74.2%)	54.6% (48.8%, 60.4%)	68.9% (63.5%, 74.2%)
		Day 57	597	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	95.0% (92.5%, 97.5%)	91.1% (87.8%, 94.4%)	95.0% (92.5%, 97.5%)
				PsV Neutralization 80% Titer	98.4% (97.0%, 99.9%)	94.8% (92.2%, 97.3%)	98.4% (97.0%, 99.9%)
				WT LV Neutralization 50% Titer	94.0% (91.2%, 96.7%)	90.7% (87.3%, 94.0%)	94.0% (91.2%, 96.7%)
	Positive	Day 29	298	Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.3% (-0.6%, 1.3%)	0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	21.4% (10.5%, 32.2%)	21.3% (10.2%, 32.4%)	21.4% (10.5%, 32.2%)
				PsV Neutralization 80% Titer	1.9% (-6.7%, 10.6%)	13.4% (2.8%, 23.9%)	1.9% (-6.7%, 10.6%)
				WT LV Neutralization 50% Titer	22.7% (12.3%, 33.2%)	34.4% (23.7%, 45.1%)	22.7% (12.3%, 33.2%)
		Day 57	298	Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)

Table 8e. Differences of responder rates between the vaccine arm and the placebo arm by Sex (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Male	Negative	Day 29	465	Binding Antibody to Spike	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	15.0%	19.0%	15.0%
					(8.1%, 21.8%)	(11.1%, 26.9%)	(8.1%, 21.8%)
				PsV Neutralization 80% Titer	3.8%	6.7%	3.8%
					(0.4%, 7.2%)	(1.6%, 11.8%)	(0.4%, 7.2%)
				WT LV Neutralization 50% Titer	13.1%	23.0%	13.1%
					(7.4%, 18.7%)	(15.7%, 30.4%)	(7.4%, 18.7%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
	Positive	Day 29	245	Binding Antibody to Spike	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	66.0%	51.3%	66.0%
					(59.9%, 72.2%)	(44.8%, 57.8%)	(59.9%, 72.2%)
				PsV Neutralization 80% Titer	81.1%	69.1%	81.1%
					(76.0%, 86.2%)	(63.1%, 75.1%)	(76.0%, 86.2%)
				WT LV Neutralization 50% Titer	71.1%	53.0%	71.1%
					(65.2%, 77.0%)	(46.6%, 59.5%)	(65.2%, 77.0%)
		Day 57	465	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	95.9%	88.4%	95.9%
					(93.4%, 98.5%)	(84.3%, 92.6%)	(93.4%, 98.5%)
				PsV Neutralization 80% Titer	95.9%	94.2%	95.9%
					(93.3%, 98.5%)	(91.2%, 97.2%)	(93.3%, 98.5%)
				WT LV Neutralization 50% Titer	95.4%	92.2%	95.4%
					(92.7%, 98.1%)	(88.7%, 95.7%)	(92.7%, 98.1%)

Table 8e. Differences of responder rates between the vaccine arm and the placebo arm by Sex (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
				PsV Neutralization 50% Titer	28.3%	20.9%	28.3%
					(17.1%, 39.6%)	(8.6%, 33.2%)	(17.1%, 39.6%)
				PsV Neutralization 80% Titer	15.4%	14.0%	15.4%
					(5.9%, 25.0%)	(2.6%, 25.4%)	(5.9%, 25.0%)
				WT LV Neutralization 50% Titer	25.3%	27.0%	25.3%
					(13.9%, 36.7%)	(15.0%, 39.0%)	(13.9%, 36.7%)
		Day 57	245	Binding Antibody to RBD	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	9.1%	15.5%	9.1%
					(2.1%, 16.0%)	(7.3%, 23.6%)	(2.1%, 16.0%)
				PsV Neutralization 80% Titer	-1.4%	2.1%	-1.4%
					(-4.2%, 1.5%)	(-2.2%, 6.3%)	(-4.2%, 1.5%)
				WT LV Neutralization 50% Titer	9.0%	14.8%	9.0%
					(3.8%, 14.1%)	(7.6%, 22.0%)	(3.8%, 14.1%)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 8f. Differences of responder rates between the vaccine arm and the placebo arm by Age, sex

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Age < 65 Female	Negative	Day 29	291	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	61.0%	46.5%	61.0%
					(53.0%, 69.1%)	(38.2%, 54.7%)	(53.0%, 69.1%)
				PsV Neutralization 80% Titer	75.0%	65.2%	75.0%
					(67.9%, 82.2%)	(57.4%, 73.1%)	(67.9%, 82.2%)
				WT LV Neutralization 50% Titer	64.8%	50.8%	64.8%
					(56.9%, 72.7%)	(42.5%, 59.1%)	(56.9%, 72.7%)
		Day 57	291	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	94.5%	89.8%	94.5%
					(90.7%, 98.3%)	(84.8%, 94.8%)	(90.7%, 98.3%)
	Positive	Day 29	166	Binding Antibody to RBD	-0.0%	0.4%	-0.0%
					(-0.0%, 0.0%)	(-1.0%, 1.8%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	20.9%	19.4%	20.9%
					(6.0%, 35.7%)	(4.7%, 34.2%)	(6.0%, 35.7%)
				PsV Neutralization 80% Titer	-1.9%	10.0%	-1.9%
					(-13.8%, 10.1%)	(-4.7%, 24.6%)	(-13.8%, 10.1%)
				WT LV Neutralization 50% Titer	21.1%	32.2%	21.1%
					(6.7%, 35.6%)	(17.9%, 46.6%)	(6.7%, 35.6%)
	Day 57	166	Binding Antibody to RBD	-0.0%	-0.0%	-0.0%	
				(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)	

Table 8f. Differences of responder rates between the vaccine arm and the placebo arm by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Age < 65 Male	Negative	Day 29	222	Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	17.1%	21.1%	17.1%
					(7.4%, 26.9%)	(9.9%, 32.3%)	(7.4%, 26.9%)
				PsV Neutralization 80% Titer	3.9%	7.2%	3.9%
					(-0.9%, 8.7%)	(-0.1%, 14.6%)	(-0.9%, 8.7%)
				WT LV Neutralization 50% Titer	15.3%	26.2%	15.3%
					(7.1%, 23.5%)	(15.6%, 36.7%)	(7.1%, 23.5%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
	Positive	Day 29	128	Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	61.1%	45.4%	61.1%
					(51.8%, 70.4%)	(35.9%, 54.9%)	(51.8%, 70.4%)
				PsV Neutralization 80% Titer	78.9%	65.6%	78.9%
					(71.1%, 86.7%)	(56.5%, 74.6%)	(71.1%, 86.7%)
				WT LV Neutralization 50% Titer	68.7%	48.2%	68.7%
					(59.8%, 77.5%)	(38.6%, 57.7%)	(59.8%, 77.5%)
		Day 57	222	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	95.9%	86.7%	95.9%
					(92.1%, 99.7%)	(80.2%, 93.1%)	(92.1%, 99.7%)
				PsV Neutralization 80% Titer	95.1%	93.2%	95.1%
					(91.0%, 99.2%)	(88.4%, 98.0%)	(91.0%, 99.2%)
				WT LV Neutralization 50% Titer	94.8%	91.4%	94.8%
					(90.6%, 99.1%)	(86.1%, 96.8%)	(90.6%, 99.1%)

Table 8f. Differences of responder rates between the vaccine arm and the placebo arm by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Age >= 65 Female	Negative	Day 57	128	PsV Neutralization 50% Titer	33.7%	21.2%	33.7%
					(17.8%, 49.6%)	(4.3%, 38.0%)	(17.8%, 49.6%)
				PsV Neutralization 80% Titer	19.6%	16.9%	19.6%
					(5.7%, 33.5%)	(0.5%, 33.3%)	(5.7%, 33.5%)
				WT LV Neutralization 50% Titer	30.4%	30.4%	30.4%
					(14.3%, 46.5%)	(13.7%, 47.1%)	(14.3%, 46.5%)
				Binding Antibody to RBD	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	11.9%	19.7%	11.9%
					(1.5%, 22.3%)	(7.9%, 31.5%)	(1.5%, 22.3%)
				PsV Neutralization 80% Titer	-2.4%	1.1%	-2.4%
					(-6.4%, 1.6%)	(-4.8%, 6.9%)	(-6.4%, 1.6%)
				WT LV Neutralization 50% Titer	10.4%	17.8%	10.4%
					(3.2%, 17.6%)	(7.3%, 28.4%)	(3.2%, 17.6%)
	Negative	Day 29	306	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	82.4%	72.1%	82.4%
					(76.1%, 88.7%)	(64.7%, 79.5%)	(76.1%, 88.7%)
				PsV Neutralization 80% Titer	93.1%	79.8%	93.1%
					(89.0%, 97.3%)	(73.2%, 86.4%)	(89.0%, 97.3%)
				WT LV Neutralization 50% Titer	83.9%	68.7%	83.9%
					(77.8%, 90.0%)	(61.0%, 76.3%)	(77.8%, 90.0%)
		Day 57	306	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	96.9%	95.7%	96.9%
					(94.0%, 99.8%)	(92.4%, 99.1%)	(94.0%, 99.8%)

Table 8f. Differences of responder rates between the vaccine arm and the placebo arm by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Age >= 65 Male	Positive	Day 29	132	PsV Neutralization 80% Titer	98.9% (97.1%, 100.6%)	98.1% (95.8%, 100.4%)	98.9% (97.1%, 100.6%)
				WT LV Neutralization 50% Titer	96.6% (93.6%, 99.6%)	92.8% (88.5%, 97.0%)	96.6% (93.6%, 99.6%)
				Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	18.6% (5.7%, 31.5%)	24.4% (8.7%, 40.2%)	18.6% (5.7%, 31.5%)
				PsV Neutralization 80% Titer	17.5% (6.6%, 28.4%)	24.4% (12.3%, 36.6%)	17.5% (6.6%, 28.4%)
				WT LV Neutralization 50% Titer	26.4% (13.6%, 39.1%)	39.7% (24.9%, 54.5%)	26.4% (13.6%, 39.1%)
		Day 57	132	Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	3.6% (-2.3%, 9.5%)	6.9% (-0.1%, 14.0%)	3.6% (-2.3%, 9.5%)
				PsV Neutralization 80% Titer	3.3% (-0.8%, 7.5%)	3.3% (-0.8%, 7.5%)	3.3% (-0.8%, 7.5%)
				WT LV Neutralization 50% Titer	1.7% (-1.3%, 4.6%)	6.7% (0.9%, 12.5%)	1.7% (-1.3%, 4.6%)
	Negative	Day 29	243	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	84.3% (78.0%, 90.6%)	72.9% (65.3%, 80.6%)	84.3% (78.0%, 90.6%)
				PsV Neutralization 80% Titer	89.2% (83.9%, 94.6%)	82.4% (75.8%, 89.0%)	89.2% (83.9%, 94.6%)

Table 8f. Differences of responder rates between the vaccine arm and the placebo arm by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Positive		Day 57	243	WT LV Neutralization 50% Titer	80.0% (73.0%, 86.9%)	71.2% (63.3%, 79.0%)	80.0% (73.0%, 86.9%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	96.1% (92.7%, 99.4%)	95.1% (91.4%, 98.8%)	96.1% (92.7%, 99.4%)
				PsV Neutralization 80% Titer	99.0% (97.3%, 100.7%)	98.0% (95.6%, 100.4%)	99.0% (97.3%, 100.7%)
				WT LV Neutralization 50% Titer	97.6% (94.9%, 100.2%)	95.0% (91.3%, 98.8%)	97.6% (94.9%, 100.2%)
		Day 29	117	Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	14.2% (1.2%, 27.2%)	26.7% (10.5%, 42.9%)	14.2% (1.2%, 27.2%)
				PsV Neutralization 80% Titer	3.6% (-5.9%, 13.1%)	8.3% (-4.1%, 20.6%)	3.6% (-5.9%, 13.1%)
				WT LV Neutralization 50% Titer	11.3% (-2.8%, 25.4%)	19.0% (2.6%, 35.3%)	11.3% (-2.8%, 25.4%)
		Day 57	117	Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	0.6% (-4.7%, 5.9%)	2.0% (-7.0%, 10.9%)	0.6% (-4.7%, 5.9%)
				PsV Neutralization 80% Titer	2.4% (-1.6%, 6.5%)	5.7% (-0.4%, 11.9%)	2.4% (-1.6%, 6.5%)
				WT LV Neutralization 50% Titer	3.9% (-3.1%, 10.9%)	5.6% (-2.1%, 13.3%)	3.9% (-3.1%, 10.9%)

Table 8f. Differences of responder rates between the vaccine arm and the placebo arm by Age, sex (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
-------	----------	-------	---	----------	-------------	-------------	-----------

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 8g. Differences of responder rates between the vaccine arm and the placebo arm by Hispanic or Latino ethnicity

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Hispanic or Latino	Negative	Day 29	125	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	56.5% (44.6%, 68.5%)	44.5% (32.5%, 56.4%)	56.5% (44.6%, 68.5%)
				PsV Neutralization 80% Titer	80.4% (70.9%, 90.0%)	69.6% (58.5%, 80.7%)	80.4% (70.9%, 90.0%)
				WT LV Neutralization 50% Titer	66.4% (55.0%, 77.8%)	46.0% (34.0%, 58.0%)	66.4% (55.0%, 77.8%)
		Day 57	125	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	97.9% (94.4%, 101.3%)	90.5% (83.5%, 97.6%)	97.9% (94.4%, 101.3%)
				PsV Neutralization 80% Titer	92.2% (85.8%, 98.7%)	90.7% (83.7%, 97.7%)	92.2% (85.8%, 98.7%)
				WT LV Neutralization 50% Titer	95.8% (90.9%, 100.6%)	91.2% (84.4%, 98.0%)	95.8% (90.9%, 100.6%)
	Positive	Day 29	77	Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	34.8% (14.2%, 55.4%)	36.5% (15.5%, 57.5%)	34.8% (14.2%, 55.4%)
				PsV Neutralization 80% Titer	10.1% (-7.4%, 27.7%)	25.4% (4.3%, 46.5%)	10.1% (-7.4%, 27.7%)
				WT LV Neutralization 50% Titer	35.7% (15.4%, 56.0%)	39.9% (19.1%, 60.6%)	35.7% (15.4%, 56.0%)
		Day 57	77	Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)

Table 8g. Differences of responder rates between the vaccine arm and the placebo arm by Hispanic or Latino ethnicity (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Not Hispanic or Latino	Negative	Day 29	844	Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	10.8%	12.0%	10.8%
					(-3.0%, 24.7%)	(-2.1%, 26.2%)	(-3.0%, 24.7%)
				PsV Neutralization 80% Titer	-3.5%	1.7%	-3.5%
					(-12.0%, 5.0%)	(-9.3%, 12.7%)	(-12.0%, 5.0%)
				WT LV Neutralization 50% Titer	11.6%	18.0%	11.6%
					(1.3%, 21.9%)	(5.7%, 30.3%)	(1.3%, 21.9%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
	Positive	Day 29	406	Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	66.7%	51.4%	66.7%
					(62.1%, 71.4%)	(46.5%, 56.3%)	(62.1%, 71.4%)
				PsV Neutralization 80% Titer	80.2%	68.2%	80.2%
					(76.2%, 84.1%)	(63.6%, 72.8%)	(76.2%, 84.1%)
				WT LV Neutralization 50% Titer	70.0%	54.9%	70.0%
					(65.5%, 74.5%)	(50.0%, 59.8%)	(65.5%, 74.5%)
		Day 57	844	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	95.0%	89.7%	95.0%
					(92.8%, 97.1%)	(86.7%, 92.7%)	(92.8%, 97.1%)
				PsV Neutralization 80% Titer	97.7%	95.1%	97.7%
					(96.2%, 99.2%)	(93.0%, 97.2%)	(96.2%, 99.2%)
				WT LV Neutralization 50% Titer	94.8%	91.3%	94.8%
					(92.6%, 97.0%)	(88.5%, 94.1%)	(92.6%, 97.0%)
				Binding Antibody to RBD	0.0%	0.3%	0.0%
					(-0.0%, 0.0%)	(-0.4%, 1.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 8g. Differences of responder rates between the vaccine arm and the placebo arm by Hispanic or Latino ethnicity (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Not reported and unknown	Negative	Day 57	406	PsV Neutralization 50% Titer	23.5%	16.5%	23.5%
					(14.5%, 32.5%)	(6.9%, 26.1%)	(14.5%, 32.5%)
				PsV Neutralization 80% Titer	8.5%	14.1%	8.5%
					(0.8%, 16.1%)	(5.1%, 23.1%)	(0.8%, 16.1%)
				WT LV Neutralization 50% Titer	21.9%	29.5%	21.9%
					(12.9%, 30.8%)	(20.2%, 38.9%)	(12.9%, 30.8%)
				Binding Antibody to RBD	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	11.7%	15.5%	11.7%
					(6.4%, 16.9%)	(9.2%, 21.8%)	(6.4%, 16.9%)
				PsV Neutralization 80% Titer	1.7%	3.6%	1.7%
					(-0.4%, 3.7%)	(0.2%, 7.1%)	(-0.4%, 3.7%)
				WT LV Neutralization 50% Titer	10.2%	18.7%	10.2%
					(5.9%, 14.5%)	(12.5%, 24.8%)	(5.9%, 14.5%)
Not reported and unknown	Negative	Day 29	93	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	67.6%	62.3%	67.6%
					(55.0%, 80.3%)	(49.2%, 75.4%)	(55.0%, 80.3%)
				PsV Neutralization 80% Titer	76.2%	71.8%	76.2%
					(64.7%, 87.7%)	(59.7%, 83.9%)	(64.7%, 87.7%)
				WT LV Neutralization 50% Titer	72.2%	53.7%	72.2%
					(60.1%, 84.3%)	(40.3%, 67.2%)	(60.1%, 84.3%)
Not reported and unknown	Negative	Day 57	93	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
Not reported and unknown	Negative	Day 57	93	PsV Neutralization 50% Titer	96.6%	91.4%	96.6%
					(91.7%, 101.5%)	(83.9%, 99.0%)	(91.7%, 101.5%)

Table 8g. Differences of responder rates between the vaccine arm and the placebo arm by Hispanic or Latino ethnicity (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Positive		Day 29	60	PsV Neutralization 80% Titer	100.0% (100.0%, 100.0%)	93.4% (86.7%, 100.1%)	100.0% (100.0%, 100.0%)
				WT LV Neutralization 50% Titer	91.9% (84.5%, 99.3%)	91.9% (84.5%, 99.3%)	91.9% (84.5%, 99.3%)
				Binding Antibody to RBD	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
				PsV Neutralization 50% Titer	15.5% (-9.2%, 40.1%)	29.0% (5.1%, 53.0%)	15.5% (-9.2%, 40.1%)
				PsV Neutralization 80% Titer	-1.0% (-11.9%, 9.9%)	-7.5% (-27.3%, 12.3%)	-1.0% (-11.9%, 9.9%)
		Day 57	60	WT LV Neutralization 50% Titer	18.9% (-3.6%, 41.3%)	32.3% (8.0%, 56.5%)	18.9% (-3.6%, 41.3%)
				Binding Antibody to RBD	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
				PsV Neutralization 50% Titer	20.6% (1.4%, 39.9%)	40.2% (19.5%, 60.9%)	20.6% (1.4%, 39.9%)
				PsV Neutralization 80% Titer	9.0% (-1.3%, 19.3%)	17.2% (3.6%, 30.9%)	9.0% (-1.3%, 19.3%)
				WT LV Neutralization 50% Titer	19.2% (5.0%, 33.4%)	29.0% (12.6%, 45.4%)	19.2% (5.0%, 33.4%)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 8h. Differences of responder rates between the vaccine arm and the placebo arm by Race

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Not reported and unknown	Negative	Day 29	98	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	63.8% (50.3%, 77.2%)	50.6% (36.5%, 64.6%)	63.8% (50.3%, 77.2%)
				PsV Neutralization 80% Titer	78.0% (66.4%, 89.6%)	72.3% (59.8%, 84.8%)	78.0% (66.4%, 89.6%)
				WT LV Neutralization 50% Titer	66.6% (53.3%, 79.8%)	53.0% (39.0%, 67.0%)	66.6% (53.3%, 79.8%)
		Day 57	98	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	97.9% (93.9%, 101.9%)	94.0% (87.4%, 100.7%)	97.9% (93.9%, 101.9%)
				PsV Neutralization 80% Titer	99.1% (96.4%, 101.8%)	97.1% (92.4%, 101.8%)	99.1% (96.4%, 101.8%)
				WT LV Neutralization 50% Titer	98.2% (94.4%, 101.9%)	98.2% (94.4%, 101.9%)	98.2% (94.4%, 101.9%)
	Positive	Day 29	48	Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	38.0% (12.3%, 63.6%)	35.2% (8.2%, 62.3%)	38.0% (12.3%, 63.6%)
				PsV Neutralization 80% Titer	23.1% (1.8%, 44.4%)	26.8% (1.4%, 52.3%)	23.1% (1.8%, 44.4%)
				WT LV Neutralization 50% Titer	31.6% (5.1%, 58.0%)	34.7% (7.5%, 61.8%)	31.6% (5.1%, 58.0%)
		Day 57	48	Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)

Table 8h. Differences of responder rates between the vaccine arm and the placebo arm by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
American Indian or Alaska Native	Negative	Day 29	27	Binding Antibody to Spike	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	-4.6% (-13.5%, 4.3%)	6.9% (-8.6%, 22.3%)	-4.6% (-13.5%, 4.3%)
				PsV Neutralization 80% Titer	-0.0% (-0.0%, 0.0%)	23.0% (6.3%, 39.6%)	-0.0% (-0.0%, 0.0%)
				WT LV Neutralization 50% Titer	-0.0% (-0.0%, 0.0%)	25.7% (8.4%, 42.9%)	-0.0% (-0.0%, 0.0%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	62.7% (36.1%, 89.4%)	49.4% (21.8%, 76.9%)	62.7% (36.1%, 89.4%)
				PsV Neutralization 80% Titer	75.7% (52.1%, 99.4%)	51.5% (23.9%, 79.0%)	75.7% (52.1%, 99.4%)
				WT LV Neutralization 50% Titer	51.5% (23.9%, 79.0%)	34.9% (8.6%, 61.2%)	51.5% (23.9%, 79.0%)
		Day 57	27	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	98.2% (90.9%, 105.5%)	98.2% (90.9%, 105.5%)	98.2% (90.9%, 105.5%)
				PsV Neutralization 80% Titer	98.2% (90.9%, 105.5%)	98.2% (90.9%, 105.5%)	98.2% (90.9%, 105.5%)
				WT LV Neutralization 50% Titer	100.0% (100.0%, 100.0%)	99.7% (96.6%, 102.7%)	100.0% (100.0%, 100.0%)
				Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
	Positive	Day 29	17	Binding Antibody to Spike	-0.0%	-0.0%	-0.0%

Table 8h. Differences of responder rates between the vaccine arm and the placebo arm by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Asian	Negative	Day 57	17	PsV Neutralization 50% Titer	(-0.0%, 0.0%) 61.7%	(-0.0%, 0.0%) 23.3%	(-0.0%, 0.0%) 61.7%
				PsV Neutralization 80% Titer	(31.2%, 92.2%) 12.0%	(-28.2%, 74.7%) 28.4%	(31.2%, 92.2%) 12.0%
				WT LV Neutralization 50% Titer	(-18.9%, 42.9%) 17.5%	(-20.6%, 77.4%) 35.3%	(-18.9%, 42.9%) 17.5%
					(-6.3%, 41.4%)	(-13.2%, 83.9%)	(-6.3%, 41.4%)
				Binding Antibody to RBD	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	8.8%	8.8%	8.8%
					(-9.0%, 26.5%)	(-9.0%, 26.5%)	(-9.0%, 26.5%)
				PsV Neutralization 80% Titer	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				WT LV Neutralization 50% Titer	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
	Negative	Day 29	84	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	64.9%	45.3%	64.9%
					(48.9%, 80.9%)	(28.6%, 62.0%)	(48.9%, 80.9%)
				PsV Neutralization 80% Titer	89.2%	69.7%	89.2%
					(78.8%, 99.6%)	(54.2%, 85.1%)	(78.8%, 99.6%)
				WT LV Neutralization 50% Titer	66.9%	57.7%	66.9%
					(51.1%, 82.7%)	(41.1%, 74.2%)	(51.1%, 82.7%)
		Day 57	84	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	98.3%	92.1%	98.3%

Table 8h. Differences of responder rates between the vaccine arm and the placebo arm by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Black or African American	Positive	Day 29	46	PsV Neutralization 80% Titer	(93.9%, 102.6%) 98.4%	(83.1%, 101.2%) 95.9%	(93.9%, 102.6%) 98.4%
				WT LV Neutralization 50% Titer	(94.3%, 102.6%) 97.1%	(89.3%, 102.6%) 95.9%	(94.3%, 102.6%) 97.1%
					(91.4%, 102.7%)	(89.3%, 102.6%)	(91.4%, 102.7%)
				Binding Antibody to RBD	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
				PsV Neutralization 50% Titer	-23.2% (-51.9%, 5.5%)	17.0% (-10.8%, 44.8%)	-23.2% (-51.9%, 5.5%)
		Day 57	46	PsV Neutralization 80% Titer	-20.6% (-46.3%, 5.1%)	-32.0% (-59.6%, -4.5%)	-20.6% (-46.3%, 5.1%)
				WT LV Neutralization 50% Titer	-32.2% (-59.9%, -4.5%)	-2.4% (-31.9%, 27.1%)	-32.2% (-59.9%, -4.5%)
				Binding Antibody to RBD	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
				PsV Neutralization 50% Titer	15.2% (-6.0%, 36.4%)	14.9% (-7.6%, 37.3%)	15.2% (-6.0%, 36.4%)
				PsV Neutralization 80% Titer	-9.0% (-21.7%, 3.7%)	1.8% (-15.9%, 19.5%)	-9.0% (-21.7%, 3.7%)
	Negative	Day 29	216	WT LV Neutralization 50% Titer	26.3% (8.8%, 43.7%)	19.3% (-2.6%, 41.2%)	26.3% (8.8%, 43.7%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	63.9% (54.7%, 73.1%)	51.8% (42.2%, 61.4%)	63.9% (54.7%, 73.1%)
				PsV Neutralization 80% Titer	76.7%	63.1%	76.7%

Table 8h. Differences of responder rates between the vaccine arm and the placebo arm by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Positive	Day 57	216		WT LV Neutralization 50% Titer	(68.6%, 84.9%) 68.0% (59.0%, 77.0%)	(53.8%, 72.3%) 48.0% (38.3%, 57.6%)	(68.6%, 84.9%) 68.0% (59.0%, 77.0%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	89.6% (83.7%, 95.5%)	83.0% (75.8%, 90.2%)	89.6% (83.7%, 95.5%)
				PsV Neutralization 80% Titer	96.2% (92.5%, 99.9%)	92.8% (87.9%, 97.8%)	96.2% (92.5%, 99.9%)
				WT LV Neutralization 50% Titer	91.5% (86.1%, 96.8%)	88.5% (82.4%, 94.6%)	91.5% (86.1%, 96.8%)
		Day 29	91	Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	28.8% (8.9%, 48.8%)	9.5% (-11.0%, 30.0%)	28.8% (8.9%, 48.8%)
				PsV Neutralization 80% Titer	20.7% (4.9%, 36.6%)	19.7% (0.1%, 39.2%)	20.7% (4.9%, 36.6%)
				WT LV Neutralization 50% Titer	20.2% (1.0%, 39.4%)	28.5% (8.4%, 48.6%)	20.2% (1.0%, 39.4%)
				Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	8.8% (-1.6%, 19.2%)	18.0% (4.0%, 32.0%)	8.8% (-1.6%, 19.2%)
				PsV Neutralization 80% Titer	2.3% (-2.5%, 7.1%)	2.3% (-2.5%, 7.1%)	2.3% (-2.5%, 7.1%)
				WT LV Neutralization 50% Titer	6.8% (-2.5%, 7.1%)	24.2% (-2.5%, 7.1%)	6.8% (-2.5%, 7.1%)
	Day 57	91		Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	8.8% (-1.6%, 19.2%)	18.0% (4.0%, 32.0%)	8.8% (-1.6%, 19.2%)
				PsV Neutralization 80% Titer	2.3% (-2.5%, 7.1%)	2.3% (-2.5%, 7.1%)	2.3% (-2.5%, 7.1%)
				WT LV Neutralization 50% Titer	6.8% (-2.5%, 7.1%)	24.2% (-2.5%, 7.1%)	6.8% (-2.5%, 7.1%)
				Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)

Table 8h. Differences of responder rates between the vaccine arm and the placebo arm by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Multiracial	Negative	Day 29	62		(-1.2%, 14.8%)	(9.8%, 38.6%)	(-1.2%, 14.8%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	47.8%	33.7%	47.8%
		Day 57	62		(31.9%, 63.7%)	(18.6%, 48.8%)	(31.9%, 63.7%)
				PsV Neutralization 80% Titer	77.0%	67.1%	77.0%
					(63.6%, 90.4%)	(52.1%, 82.1%)	(63.6%, 90.4%)
				WT LV Neutralization 50% Titer	70.4%	47.7%	70.4%
					(55.8%, 84.9%)	(31.8%, 63.7%)	(55.8%, 84.9%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	100.0%	86.7%	100.0%
	Positive	Day 29	28		(100.0%, 100.0%)	(75.9%, 97.5%)	(100.0%, 100.0%)
				PsV Neutralization 80% Titer	100.0%	97.2%	100.0%
					(100.0%, 100.0%)	(91.9%, 102.5%)	(100.0%, 100.0%)
				WT LV Neutralization 50% Titer	93.9%	87.3%	93.9%
					(86.3%, 101.6%)	(76.7%, 97.9%)	(86.3%, 101.6%)
				Binding Antibody to RBD	-0.0%	-0.0%	-0.0%
		Day 57	28		(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	24.7%	33.9%	24.7%
					(-9.4%, 58.9%)	(-3.2%, 70.9%)	(-9.4%, 58.9%)
				PsV Neutralization 80% Titer	18.9%	49.2%	18.9%
					(-4.3%, 42.1%)	(16.8%, 81.5%)	(-4.3%, 42.1%)
				WT LV Neutralization 50% Titer	49.2%	54.9%	49.2%
					(16.8%, 81.5%)	(21.7%, 88.1%)	(16.8%, 81.5%)

Table 8h. Differences of responder rates between the vaccine arm and the placebo arm by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Native Hawaiian or Other Pacific Islander	Negative	Day 29	20		(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
				PsV Neutralization 50% Titer	(-0.0%, 0.0%) 35.8%	(-0.0%, 0.0%) 35.8%	(-0.0%, 0.0%) 35.8%
				PsV Neutralization 80% Titer	(12.1%, 59.5%) -0.0%	(12.1%, 59.5%) -0.0%	(12.1%, 59.5%) -0.0%
				WT LV Neutralization 50% Titer	(-0.0%, 0.0%) 22.1%	(-0.0%, 0.0%) 22.1%	(-0.0%, 0.0%) 22.1%
					(1.6%, 42.6%)	(1.6%, 42.6%)	(1.6%, 42.6%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
				PsV Neutralization 50% Titer	(100.0%, 100.0%) 69.0%	(100.0%, 100.0%) 63.2%	(100.0%, 100.0%) 69.0%
				PsV Neutralization 80% Titer	(32.5%, 105.6%) 92.6%	(25.0%, 101.3%) 90.5%	(32.5%, 105.6%) 92.6%
				WT LV Neutralization 50% Titer	(72.0%, 113.3%) 92.6%	(67.2%, 113.7%) 63.2%	(72.0%, 113.3%) 92.6%
					(72.0%, 113.3%)	(25.0%, 101.3%)	(72.0%, 113.3%)
	Positive	Day 57	20	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
				PsV Neutralization 50% Titer	(100.0%, 100.0%) 100.0%	(100.0%, 100.0%) 96.3%	(100.0%, 100.0%) 100.0%
				PsV Neutralization 80% Titer	(100.0%, 100.0%) 100.0%	(81.4%, 111.2%) 100.0%	(100.0%, 100.0%) 100.0%
				WT LV Neutralization 50% Titer	(100.0%, 100.0%) 97.8%	(100.0%, 100.0%) 97.8%	(100.0%, 100.0%) 97.8%
					(86.4%, 109.3%)	(86.4%, 109.3%)	(86.4%, 109.3%)
				Binding Antibody to RBD	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 8h. Differences of responder rates between the vaccine arm and the placebo arm by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Other	Negative	Day 57	7	Binding Antibody to Spike	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	11.6% (-43.7%, 66.8%)	88.4% (33.2%, 143.7%)	11.6% (-43.7%, 66.8%)
				PsV Neutralization 80% Titer	0.0% (-0.0%, 0.0%)	14.7% (-46.5%, 75.8%)	0.0% (-0.0%, 0.0%)
				WT LV Neutralization 50% Titer	26.2% (-49.8%, 102.3%)	26.2% (-49.8%, 102.3%)	26.2% (-49.8%, 102.3%)
				Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	14.7% (-46.5%, 75.8%)	14.7% (-46.5%, 75.8%)	14.7% (-46.5%, 75.8%)
				PsV Neutralization 80% Titer	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				WT LV Neutralization 50% Titer	0.0% (-0.0%, 0.0%)	14.7% (-46.5%, 75.8%)	0.0% (-0.0%, 0.0%)
	Negative	Day 29	28	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	74.3% (36.9%, 111.6%)	65.2% (24.6%, 105.9%)	74.3% (36.9%, 111.6%)
				PsV Neutralization 80% Titer	67.3% (27.3%, 107.4%)	64.1% (23.1%, 105.0%)	67.3% (27.3%, 107.4%)
				WT LV Neutralization 50% Titer	62.2% (20.7%, 103.6%)	46.2% (3.7%, 88.8%)	62.2% (20.7%, 103.6%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)

Table 8h. Differences of responder rates between the vaccine arm and the placebo arm by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
White	Positive	Day 29	24	PsV Neutralization 50% Titer	96.7%	96.7%	96.7%
					(81.5%, 111.9%)	(81.5%, 111.9%)	(81.5%, 111.9%)
				PsV Neutralization 80% Titer	84.6%	84.6%	84.6%
					(53.8%, 115.4%)	(53.8%, 115.4%)	(53.8%, 115.4%)
				WT LV Neutralization 50% Titer	98.1%	98.1%	98.1%
					(86.4%, 109.8%)	(86.4%, 109.8%)	(86.4%, 109.8%)
		Day 57	24	Binding Antibody to RBD	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	59.9%	56.4%	59.9%
					(26.8%, 93.0%)	(24.1%, 88.8%)	(26.8%, 93.0%)
	PsV Neutralization 80% Titer			4.0%	51.5%	4.0%	
				(-27.4%, 35.4%)	(16.1%, 86.8%)	(-27.4%, 35.4%)	
	WT LV Neutralization 50% Titer			72.6%	79.1%	72.6%	
				(43.8%, 101.3%)	(53.6%, 104.5%)	(43.8%, 101.3%)	
	Negative	Day 29	43	Binding Antibody to RBD	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	-11.5%	-7.9%	-11.5%
					(-35.7%, 12.6%)	(-34.2%, 18.5%)	(-35.7%, 12.6%)
				PsV Neutralization 80% Titer	-0.0%	15.5%	-0.0%
					(-0.0%, 0.0%)	(-5.5%, 36.6%)	(-0.0%, 0.0%)
				WT LV Neutralization 50% Titer	34.7%	19.5%	34.7%
					(7.0%, 62.3%)	(-15.6%, 54.6%)	(7.0%, 62.3%)
Binding Antibody to RBD				100.0%	100.0%	100.0%	
				(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)	
Binding Antibody to Spike				100.0%	100.0%	100.0%	
				(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)	
PsV Neutralization 50% Titer	74.8%	68.2%	74.8%				
				(56.5%, 93.0%)	(48.7%, 87.8%)	(56.5%, 93.0%)	

Table 8h. Differences of responder rates between the vaccine arm and the placebo arm by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Positive	Day 57	43		PsV Neutralization 80% Titer	82.4% (66.3%, 98.4%)	75.8% (57.9%, 93.8%)	82.4% (66.3%, 98.4%)
				WT LV Neutralization 50% Titer	69.2% (49.8%, 88.6%)	55.1% (34.2%, 76.0%)	69.2% (49.8%, 88.6%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	92.2% (80.9%, 103.5%)	84.6% (69.4%, 99.7%)	92.2% (80.9%, 103.5%)
				PsV Neutralization 80% Titer	100.0% (100.0%, 100.0%)	92.4% (81.2%, 103.5%)	100.0% (100.0%, 100.0%)
				WT LV Neutralization 50% Titer	89.1% (76.0%, 102.2%)	89.1% (76.0%, 102.2%)	89.1% (76.0%, 102.2%)
				Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	2.8% (-27.9%, 33.4%)	25.0% (-6.9%, 56.8%)	2.8% (-27.9%, 33.4%)
				PsV Neutralization 80% Titer	-0.8% (-13.4%, 11.7%)	1.6% (-22.9%, 26.0%)	-0.8% (-13.4%, 11.7%)
				WT LV Neutralization 50% Titer	42.3% (14.8%, 69.8%)	45.3% (15.9%, 74.6%)	42.3% (14.8%, 69.8%)
	Day 29	38		Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	22.4% (-3.6%, 48.5%)	39.2% (12.2%, 66.1%)	22.4% (-3.6%, 48.5%)
				PsV Neutralization 80% Titer	14.1% (-1.1%, 29.3%)	14.1% (-1.1%, 29.3%)	14.1% (-1.1%, 29.3%)
				Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	22.4% (-3.6%, 48.5%)	39.2% (12.2%, 66.1%)	22.4% (-3.6%, 48.5%)
				PsV Neutralization 80% Titer	14.1% (-1.1%, 29.3%)	14.1% (-1.1%, 29.3%)	14.1% (-1.1%, 29.3%)
	Day 57	38		Binding Antibody to RBD	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	22.4% (-3.6%, 48.5%)	39.2% (12.2%, 66.1%)	22.4% (-3.6%, 48.5%)
				PsV Neutralization 80% Titer	14.1% (-1.1%, 29.3%)	14.1% (-1.1%, 29.3%)	14.1% (-1.1%, 29.3%)

Table 8h. Differences of responder rates between the vaccine arm and the placebo arm by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
White Non-Hispanic	Negative	Day 29	456	WT LV Neutralization 50% Titer	17.4% (0.8%, 34.0%)	17.4% (0.8%, 34.0%)	17.4% (0.8%, 34.0%)
				Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	68.8% (62.6%, 75.0%)	52.8% (46.1%, 59.4%)	68.8% (62.6%, 75.0%)
				PsV Neutralization 80% Titer	80.6% (75.4%, 85.9%)	70.3% (64.2%, 76.4%)	80.6% (75.4%, 85.9%)
				WT LV Neutralization 50% Titer	72.5% (66.6%, 78.5%)	58.4% (51.9%, 65.0%)	72.5% (66.6%, 78.5%)
		Day 57	456	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	96.5% (94.0%, 98.9%)	92.3% (88.8%, 95.9%)	96.5% (94.0%, 98.9%)
				PsV Neutralization 80% Titer	98.2% (96.4%, 99.9%)	95.2% (92.4%, 98.1%)	98.2% (96.4%, 99.9%)
				WT LV Neutralization 50% Titer	94.7% (91.7%, 97.7%)	89.8% (85.8%, 93.9%)	94.7% (91.7%, 97.7%)
	Positive	Day 29	224	Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	0.5% (-0.8%, 1.8%)	-0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	23.5% (11.3%, 35.6%)	11.1% (-1.9%, 24.2%)	23.5% (11.3%, 35.6%)
				PsV Neutralization 80% Titer	7.4% (-3.1%, 17.9%)	12.3% (0.3%, 24.3%)	7.4% (-3.1%, 17.9%)
				WT LV Neutralization 50% Titer	27.3% (15.4%, 39.2%)	30.9% (18.4%, 43.4%)	27.3% (15.4%, 39.2%)

Table 8h. Differences of responder rates between the vaccine arm and the placebo arm by Race (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
		Day 57	224	Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	14.7% (7.7%, 21.6%)	17.3% (8.7%, 25.9%)	14.7% (7.7%, 21.6%)
				PsV Neutralization 80% Titer	2.5% (-1.0%, 6.1%)	1.6% (-3.3%, 6.6%)	2.5% (-1.0%, 6.1%)
				WT LV Neutralization 50% Titer	9.6% (3.6%, 15.6%)	20.2% (12.4%, 27.9%)	9.6% (3.6%, 15.6%)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 8i. Differences of responder rates between the vaccine arm and the placebo arm by Race and ethnic group

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
White Non-Hispanic	Negative	Day 29	456	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	68.8% (62.6%, 75.0%)	52.8% (46.1%, 59.4%)	68.8% (62.6%, 75.0%)
				PsV Neutralization 80% Titer	80.6% (75.4%, 85.9%)	70.3% (64.2%, 76.4%)	80.6% (75.4%, 85.9%)
				WT LV Neutralization 50% Titer	72.5% (66.6%, 78.5%)	58.4% (51.9%, 65.0%)	72.5% (66.6%, 78.5%)
		Day 57	456	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	96.5% (94.0%, 98.9%)	92.3% (88.8%, 95.9%)	96.5% (94.0%, 98.9%)
				PsV Neutralization 80% Titer	98.2% (96.4%, 99.9%)	95.2% (92.4%, 98.1%)	98.2% (96.4%, 99.9%)
				WT LV Neutralization 50% Titer	94.7% (91.7%, 97.7%)	89.8% (85.8%, 93.9%)	94.7% (91.7%, 97.7%)
	Positive	Day 29	224	Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	0.5% (-0.8%, 1.8%)	-0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	23.5% (11.3%, 35.6%)	11.1% (-1.9%, 24.2%)	23.5% (11.3%, 35.6%)
				PsV Neutralization 80% Titer	7.4% (-3.1%, 17.9%)	12.3% (0.3%, 24.3%)	7.4% (-3.1%, 17.9%)
				WT LV Neutralization 50% Titer	27.3% (15.4%, 39.2%)	30.9% (18.4%, 43.4%)	27.3% (15.4%, 39.2%)
		Day 57	224	Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)

Table 8i. Differences of responder rates between the vaccine arm and the placebo arm by Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Communities of Color	Negative	Day 29	535	Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	14.7%	17.3%	14.7%
					(7.7%, 21.6%)	(8.7%, 25.9%)	(7.7%, 21.6%)
				PsV Neutralization 80% Titer	2.5%	1.6%	2.5%
					(-1.0%, 6.1%)	(-3.3%, 6.6%)	(-1.0%, 6.1%)
				WT LV Neutralization 50% Titer	9.6%	20.2%	9.6%
					(3.6%, 15.6%)	(12.4%, 27.9%)	(3.6%, 15.6%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	62.9%	49.5%	62.9%
					(57.1%, 68.8%)	(43.5%, 55.6%)	(57.1%, 68.8%)
				PsV Neutralization 80% Titer	79.1%	66.7%	79.1%
					(74.2%, 84.1%)	(61.0%, 72.5%)	(74.2%, 84.1%)
				WT LV Neutralization 50% Titer	67.8%	50.2%	67.8%
					(62.1%, 73.4%)	(44.2%, 56.3%)	(62.1%, 73.4%)
	Positive	Day 29	261	Binding Antibody to RBD	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 8i. Differences of responder rates between the vaccine arm and the placebo arm by Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
				PsV Neutralization 50% Titer	26.0%	25.8%	26.0%
					(14.6%, 37.4%)	(14.2%, 37.4%)	(14.6%, 37.4%)
				PsV Neutralization 80% Titer	10.3%	18.0%	10.3%
					(1.0%, 19.6%)	(6.6%, 29.5%)	(1.0%, 19.6%)
				WT LV Neutralization 50% Titer	21.7%	31.7%	21.7%
					(10.4%, 33.1%)	(20.2%, 43.3%)	(10.4%, 33.1%)
		Day 57	261	Binding Antibody to RBD	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	8.1%	13.9%	8.1%
					(1.3%, 14.9%)	(6.0%, 21.8%)	(1.3%, 14.9%)
				PsV Neutralization 80% Titer	-0.9%	6.2%	-0.9%
					(-3.7%, 1.9%)	(1.1%, 11.4%)	(-3.7%, 1.9%)
				WT LV Neutralization 50% Titer	13.1%	21.3%	13.1%
					(7.4%, 18.9%)	(13.1%, 29.5%)	(7.4%, 18.9%)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

Table 8j. Differences of responder rates between the vaccine arm and the placebo arm by Age, Race and ethnic group

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Age < 65 Communities of Color	Negative	Day 29	253	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	57.6%	43.4%	57.6%
					(48.9%, 66.4%)	(34.7%, 52.2%)	(48.9%, 66.4%)
				PsV Neutralization 80% Titer	75.3%	62.9%	75.3%
					(67.6%, 82.9%)	(54.3%, 71.5%)	(67.6%, 82.9%)
				WT LV Neutralization 50% Titer	62.9%	44.2%	62.9%
					(54.3%, 71.5%)	(35.4%, 53.0%)	(54.3%, 71.5%)
		Day 57	253	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	94.1%	87.0%	94.1%
					(90.0%, 98.3%)	(81.0%, 93.0%)	(90.0%, 98.3%)
	Positive	Day 29	148	Binding Antibody to RBD	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	28.2%	27.0%	28.2%
					(12.8%, 43.7%)	(12.2%, 41.8%)	(12.8%, 43.7%)
				PsV Neutralization 80% Titer	11.5%	19.1%	11.5%
					(-1.6%, 24.5%)	(3.5%, 34.7%)	(-1.6%, 24.5%)
				WT LV Neutralization 50% Titer	24.0%	33.1%	24.0%
					(8.6%, 39.4%)	(17.8%, 48.3%)	(8.6%, 39.4%)
	Day 57	148	Binding Antibody to RBD	-0.0%	-0.0%	-0.0%	
				(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)	

Table 8j. Differences of responder rates between the vaccine arm and the placebo arm by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Age < 65 White Non-Hispanic	Negative	Day 29	227	Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	10.2%	16.6%	10.2%
					(0.4%, 19.9%)	(5.4%, 27.8%)	(0.4%, 19.9%)
				PsV Neutralization 80% Titer	-1.6%	7.1%	-1.6%
					(-5.4%, 2.1%)	(-0.3%, 14.4%)	(-5.4%, 2.1%)
				WT LV Neutralization 50% Titer	15.1%	24.8%	15.1%
					(7.0%, 23.2%)	(13.3%, 36.3%)	(7.0%, 23.2%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
	Positive	Day 29	117	Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	64.6%	47.3%	64.6%
					(55.6%, 73.7%)	(37.9%, 56.8%)	(55.6%, 73.7%)
				PsV Neutralization 80% Titer	78.4%	67.4%	78.4%
					(70.6%, 86.2%)	(58.5%, 76.3%)	(70.6%, 86.2%)
				WT LV Neutralization 50% Titer	70.7%	56.0%	70.7%
					(62.1%, 79.3%)	(46.6%, 65.4%)	(62.1%, 79.3%)
		Day 57	227	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	96.6%	91.4%	96.6%
					(93.2%, 100.0%)	(86.1%, 96.7%)	(93.2%, 100.0%)
				PsV Neutralization 80% Titer	97.7%	94.0%	97.7%
					(94.8%, 100.5%)	(89.5%, 98.5%)	(94.8%, 100.5%)
				WT LV Neutralization 50% Titer	94.4%	89.2%	94.4%
					(90.0%, 98.7%)	(83.3%, 95.1%)	(90.0%, 98.7%)
				Binding Antibody to RBD	0.0%	0.7%	0.0%
					(-0.0%, 0.0%)	(-1.4%, 2.7%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 8j. Differences of responder rates between the vaccine arm and the placebo arm by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Age >= 65 Communities of Color	Negative	Day 57	117	PsV Neutralization 50% Titer	25.5%	8.3%	25.5%
					(8.3%, 42.7%)	(-9.8%, 26.4%)	(8.3%, 42.7%)
				PsV Neutralization 80% Titer	3.8%	8.7%	3.8%
					(-11.3%, 18.8%)	(-8.4%, 25.9%)	(-11.3%, 18.8%)
				WT LV Neutralization 50% Titer	28.3%	31.0%	28.3%
					(11.5%, 45.2%)	(13.7%, 48.3%)	(11.5%, 45.2%)
				Binding Antibody to RBD	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				PsV Neutralization 50% Titer	18.0%	21.2%	18.0%
					(7.7%, 28.3%)	(8.8%, 33.7%)	(7.7%, 28.3%)
				PsV Neutralization 80% Titer	2.7%	0.5%	2.7%
					(-2.5%, 7.9%)	(-6.6%, 7.5%)	(-2.5%, 7.9%)
				WT LV Neutralization 50% Titer	11.6%	23.4%	11.6%
					(2.8%, 20.3%)	(12.1%, 34.7%)	(2.8%, 20.3%)
		Day 29	282	Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	81.7%	71.2%	81.7%
					(75.3%, 88.1%)	(63.7%, 78.7%)	(75.3%, 88.1%)
				PsV Neutralization 80% Titer	92.9%	80.5%	92.9%
					(88.7%, 97.2%)	(73.9%, 87.0%)	(88.7%, 97.2%)
		Day 57	282	WT LV Neutralization 50% Titer	85.0%	71.7%	85.0%
					(79.1%, 90.9%)	(64.3%, 79.2%)	(79.1%, 90.9%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				Binding Antibody to Spike	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	97.1%	95.0%	97.1%

Table 8j. Differences of responder rates between the vaccine arm and the placebo arm by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Age >= 65 White Non-Hispanic	Positive	Day 29	113	PsV Neutralization 80% Titer	(94.3%, 99.9%) 97.9%	(91.4%, 98.6%) 96.3%	(94.3%, 99.9%) 97.9%
				WT LV Neutralization 50% Titer	(95.6%, 100.3%) 98.3%	(93.1%, 99.4%) 95.4%	(95.6%, 100.3%) 98.3%
					(96.2%, 100.5%)	(91.9%, 98.8%)	(96.2%, 100.5%)
				Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	17.6% (5.4%, 29.9%)	22.8% (7.2%, 38.3%)	17.6% (5.4%, 29.9%)
		Day 57	113	PsV Neutralization 80% Titer	6.1% (-1.8%, 14.0%)	14.9% (3.5%, 26.3%)	6.1% (-1.8%, 14.0%)
				WT LV Neutralization 50% Titer	13.1% (-0.2%, 26.3%)	27.1% (11.2%, 43.1%)	13.1% (-0.2%, 26.3%)
				Binding Antibody to RBD	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
				PsV Neutralization 50% Titer	-1.0% (-5.2%, 3.2%)	2.6% (-3.9%, 9.0%)	-1.0% (-5.2%, 3.2%)
				PsV Neutralization 80% Titer	2.6% (-1.6%, 6.8%)	2.6% (-1.6%, 6.8%)	2.6% (-1.6%, 6.8%)
				WT LV Neutralization 50% Titer	4.4% (-1.0%, 9.8%)	6.1% (-0.2%, 12.5%)	4.4% (-1.0%, 9.8%)
	Negative	Day 29	229	Binding Antibody to RBD	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				Binding Antibody to Spike	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
				PsV Neutralization 50% Titer	85.2% (78.5%, 91.9%)	74.1% (65.8%, 82.3%)	85.2% (78.5%, 91.9%)
				PsV Neutralization 80% Titer	89.4%	81.8%	89.4%

Table 8j. Differences of responder rates between the vaccine arm and the placebo arm by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
Positive	Day 57	229		WT LV Neutralization 50% Titer	(83.6%, 95.2%)	(74.5%, 89.0%)	(83.6%, 95.2%)
					79.6%	68.0%	79.6%
					(72.1%, 87.2%)	(59.2%, 76.8%)	(72.1%, 87.2%)
				Binding Antibody to RBD	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
				Binding Antibody to Spike	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
				PsV Neutralization 50% Titer	95.9%	95.9%	95.9%
					(92.2%, 99.7%)	(92.2%, 99.7%)	(92.2%, 99.7%)
					100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
	Day 29	107		WT LV Neutralization 50% Titer	95.9%	92.4%	95.9%
					(92.2%, 99.7%)	(87.4%, 97.4%)	(92.2%, 99.7%)
					-0.0%	-0.0%	-0.0%
				Binding Antibody to RBD	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					-0.0%	-0.0%	-0.0%
				PsV Neutralization 50% Titer	15.0%	20.3%	15.0%
					(0.0%, 29.9%)	(2.3%, 38.3%)	(0.0%, 29.9%)
					20.1%	24.4%	20.1%
					(7.0%, 33.2%)	(9.6%, 39.2%)	(7.0%, 33.2%)
	Day 57	107		WT LV Neutralization 50% Titer	22.6%	29.6%	22.6%
					(7.5%, 37.7%)	(12.1%, 47.0%)	(7.5%, 37.7%)
					-0.0%	-0.0%	-0.0%
				Binding Antibody to RBD	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
				Binding Antibody to Spike	-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					-0.0%	-0.0%	-0.0%
				PsV Neutralization 50% Titer	2.1%	2.5%	2.1%
					(-4.2%, 8.4%)	(-7.0%, 11.9%)	(-4.2%, 8.4%)
					2.0%	5.9%	2.0%
					(-1.7%, 5.6%)	(-0.3%, 12.1%)	(-1.7%, 5.6%)
				PsV Neutralization 80% Titer	2.1%	8.0%	2.1%

Table 8j. Differences of responder rates between the vaccine arm and the placebo arm by Age, Race and ethnic group (*continued*)

Group	Baseline	Visit	N	Endpoint	2-Fold Rise	4-Fold Rise	Responder
					(-4.2%, 8.4%)	(-0.7%, 16.7%)	(-4.2%, 8.4%)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.